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Abstract 
Human cardiovascular diseases (CVDs) are leading causes of human death globally and 
cause huge social and economic impacts. Similarly, bovine mastitis is the most 
economically important disease of dairy cattle world-wide. The pathogenesis of both 
diseases involves an inflammatory process. Biomarkers are measurable substances, 
which may be used to detect the presence of specific diseases. Cardiac troponin T 
(cTnT) is recommended as a potential biomarker for cardiovascular disease (CVD) 
detection due to its high specificity and sensitivity. In addition, elevation in L-lactate 
dehydrogenase (LDH) levels in mastitic milk suggests that it may have potential as a 
biomarker for the detection of sub-clinical mastitis.  
 
Classical CVD biomarkers, including cardiac myoglobin and creatine kinase-MB, have 
been extensively studied but are lacking in specificity and early–stage sensitivity. 
Troponin T was recommended as a potential ‘gold standard’ for CVD detection, and, 
therefore, a key aim of this project was to generate recombinant antibody fragments 
against cTnT and, ultimately, to develop a sensitive immunoassay for early-stage CVD 
diagnosis. Recombinant antibody fragments, including scFvs and Fabs, have excellent 
antigen recognition specificity but have additional benefits compared to standard 
antibodies. Current immunoassays for cTnT detection use monoclonal antibodies and 
the generation and application of recombinant antibodies and a novel assay platform 
may introduce significant improvements in cTnT assay development. 
 
A recombinant avian anti-cTnT scFv antibody was generated and the antigen binding 
capacity of the antibody was improved using chain-shuffling. The chain-shuffled 
antibody, with sub-nanomolar affinity, was subsequently incorporated into an ELISA 
inhibition assay for the detection of cTnT. 
 
Bovine mastitis is an inflammation of the mammary gland caused by invasion of 
pathogens. Its early detection is of paramount importance in controlling bovine health. 
Current diagnostic tests for mastitis have drawbacks such as high costs, lack of 
suitability for ‘on-site’ testing as well as poor specificity and sensitivity. Lactate 
dehydrogenase (LDH) was evaluated as a potential biomarker for the detection of sub-
xiv 
 
clinical mastitis in this research, LDH levels in milk samples were determined using a 
reliable and reproducible fluorescence-based assay, and the potential of LDH as a 
marker of subclinical mastitis was determined. It was found that LDH levels had a good 
correlation with somatic cell count, the gold standard mastitis marker. Moreover, it was 
shown that a number of factors including lactation stage and storage conditions affected 
LDH levels in milk samples.  These factors must be taken into account when using LDH 
as biomarker for sub-clinical mastitis detection. 
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1 Introduction 
1.1 Cardiovascular diseases  
1.1.1 Background to cardiovascular diseases 
Cardiovascular diseases (CVDs) refer to a range of disorders and conditions that affect 
heart and blood vessels. Types of CVDs include atherosclerosis, angina, 
cerebrovascular accident (stroke), myocardial infarction (heart attack), coronary artery 
disease, heart valve disease, arrhythmia, aortic aneurysm, heart failure, hypertension, 
orthostatic hypotension, shock, endocarditis, ischemic myocardial necrosis, peripheral 
vascular disease and congenital heart disease (Table 1.1).  
 
CVDs kill more people each year than any others types of diseases. More than 17.5 
million people worldwide die from CVDs every year as reported by the Health Europe 
in 2010. It is estimated that approximately 23.6 million people will die annually from 
CVDs by 2030. Due to the high death rate, CVDs have consequently become a threat to 
social and economic stability. Huge expenditure on clinical care and treatment for 
CVDs has lead to significant reductions of resources available for general medical care. 
In addition, CVDs affect both the elderly and the working-age population. 
Consequently, the productive years of working-age patients are reduced due to CVDs. 
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Table 1.1. List of cardiovascular diseases and their characteristics 
Types of cardiovascular diseases and their characteristics   
Atherosclerosis  
 Major form of heart diseases  
 Hardening, thickening or furring of the walls of the arteries 
 Caused by fatty deposits on the inner lining of arteries, calcification of the wall of the arteries, or thickening of the muscular wall of the 
arteries from chronic hypertension 
Angina  
 Most common form of coronary heart disease 
 Heaviness or tightness of the chest caused when there is a decreased blood oxygen supply to an area of the heart muscle  
 The lack of blood supply is due to a narrowing of the coronary arteries as a result of atherosclerosis 
Coronary artery disease (CAD)  
 Begins when plaques are deposited within a coronary artery. The plaques in the coronary arteries can cause a tiny clot to form which can 
obstruct the flow of blood to the heart muscle 
 Leads to chest pain (angina pectoris) and heart attack (acute myocardial infarction) from the sudden total blockage of a coronary artery or 
sudden death, due to a fatal disturbance of heart rhythm 
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Ischemic myocardial necrosis  
 Death of myocardial cells and tissue 
 Caused by the interruption of the blood supply through the coronary arteries 
High blood pressure/ hypertension 
 Elevation of systemic blood pressure in the arteries  
 Risk factor for stroke, myocardial infarction, heart failure and arterial aneurysm 
Orthostatic hypertension 
 Sudden decrease in blood pressure when one stretches or stands up 
 Arteries and veins that are able to constrict or squeeze   
 May be caused by atherosclerosis 
Heart attack / Acute myocardial infarction (AMI) 
 Interruption of blood supply to a part of the heart 
 Causing the death of heart cells 
 Caused by blockage of a coronary artery following the rupture of a vulnerable atherosclerotic plaque, which is an unstable collection of lipids 
(fatty acids) and white blood cells (especially macrophages) in the wall of an artery 
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Cerebrovascular accident/stroke 
 Damage to the brain because of impaired blood supply  
 Causes a sudden malfunction of the brain 
Arrhythmia/ dysrhythmia 
 Refers to an irregular heartbeat; it may occur with slow, normal and rapid heart rate. 
 Caused by changes in heart muscle, injury from a heart attack or at the healing process after heart surgery 
 Can also occur in healthy hearts 
Heart valve disease 
 Occurs when the heart's valves are narrowed or do not have enough of a supply of blood  
 Caused by valvular stenosis and valvular insufficience 
 Leads to heart failure or aortic stenosis 
Heart failure (often called congestive heart failure) 
 Refers to weak pumping power of the heart 
 Caused by coronary artery disease, heart attack or cardiomyopathy 
 Symptoms including shortness of breath, leg swelling and exercise intolerance 
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Cardiomyopathy 
 Damage to the heart muscle from causes other than artery or blood flow problems 
 Causes include infections, alcohol or drug abuse 
Cardiogenic shock 
 Occurs when the heart is damaged and unable to supply sufficient blood to the body 
 May be caused by heart attack or congestive heart failure 
Rheumatic heart disease 
 One of the most serious forms of heart disease of childhood and adolescence  
 Causes damage to the entire heart and its membranes  
 Usually followed attacks of rheumatic fever 
Myocarditis 
 Refers to the inflammation or degeneration of heart muscle 
 May appear as the primary disease in adults or as a degenerative disease of old age 
 May be related to dilation (enlargement due to weakness of the heart muscle) or hypertrophy (overgrowth of the muscle tissue) 
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Endocarditis 
 Caused by growth of bacteria on the heart valves leading to heart infection 
 The infection may be introduced during brief periods when bacteria are present in the bloodstream, such as after dental work, colonoscopy, 
or other similar procedures 
Peripheral vascular disease 
 Refers to the narrowing and hardening of the arteries that supply the legs and feet 
 The narrowing of the blood vessels can lead to decreased blood flow which can injure nerves and other tissues 
 May be caused by atheriosclerosis 
Congenital heart disease 
 Refers to malformations of the heart or heart blood vessels which are present since birth  
 The most frequent form of major birth defects in newborns affecting close to 1% of newborn babies  
Aortic aneurysm 
 Describes a localized, blood-filled balloon-like bulge in the wall of a blood vessel 
 Occurs in the main artery carrying blood from the left ventricle of the heart 
 The increased size of an aneurysm may lead to a significant risk of rupture, resulting in severe hemorrhage, other complications or death  
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 Can be hereditary or caused by disease 
(Based on references: Phillips et al., 2000; Davies, 2005; Gaziano, 2005; Jokni and Curzen, 2010; Butcher et al., 2011; Daidoji et al., 
2011) 
9 
 
In most developed countries, CVDs account for the largest share of mortality and 
morbidity (WHO, 2005; Vasan, 2006). In the EU, Nearly half of all deaths (42%) are 
caused by CVDs each year. In Ireland, CVD is the leading killer disease which accounts 
for 36% of all deaths. The UK has one of the highest rates of death from CVDs. In the 
US, more than one third of American adults have one or more types of CVD. In 
developing countries, CVDs are increasing in epidemic proportions (Reddy, 2002). 
They already account for almost 10% of the developing world’s burden of disease and 
are likely to become the leading cause of death. In 2001, CVDs accounted for 
approximately 31% of all death in Latin American and the Caribbean, and it is 
estimated the figure will increase to 38% by 2020 (Murray and Lopes, 1996). In Middle 
East and North Africa, CVDs are the leading cause of death which account for 25 to 
45% of total death (Jamison et al., 2006). The China Multicenter Collaborative Study of 
Cardiovascular Epidemiology indicated that cardiovascular disease was the major cause 
of death for both men and women, with stroke accounting for over 40% of deaths (Liu, 
2007). According to the statistic at the 7th China Heart Congress in 2011, it was 
estimated that 230 million people in China suffer from CVDs, and six people die from 
CVDs per minute. In India, CVDs caused a loss of 9.2 million productive years of life 
in 2000. 
 
CVDs also have a huge impact on the global economy. In 2003, the EU spent €169 
billion on CVDs and it is estimated that annual losses due to CVDs in the EU is €192 
billion (Allender et al., 2008). The American Heart Association estimated that $503.2 
billion were spent on direct or indirect costs associated with CVDs in 2010. Direct costs 
refer to direct medical costs, such as ambulance transportation, diagnostic tests, 
medication and surgery; while indirect costs involve the loss of productivity and the loss 
of income from patients. In most developing countries, there is a continually increasing 
economic burden caused by cardiovascular diseases (Neal et al., 2002). Four percent of 
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the gross national income of the Chinese economy, estimated as €30.76 billion, is spent 
on cardiovascular diseases and its related factors. In South Africa, 25% of the total 
health care expenditure is spent on CVDs. 
 
Due to the huge social and economic impact of CVDs, their prevention and accurate 
diagnosis has become one of the main priorities of public health-care (WHO, 2005; 
Schwappach et al., 2007). CVD risk factors are the variables associated with an 
increased risk of CVD development. It was stated that approx. 75% of CVDs can be 
attributed to conventional risk factors. Risk factors are grouped into two categories, 
non-modifiable and modifiable. Non-modifiable factors are factors that cannot be 
altered or controlled, such as age, genetics, race and gender. Modifiable factors can be 
prevented and controlled by altering the lifestyle behaviors or getting medical treatment. 
People are exposed to more risk factors have the higher risk of developing CVDs. Lack 
of prevention of risk factors can consequently lead to the initiation of CVDs 
pathogenesis (Table 1.2). 
  
Table 1.2. Modifiable risk factors and primary pathophysiological effects of CVDs 
Modifiable risk factors Initial pathogenesis effects References 
Poor dietary habits diet 
(high fat and cholesterol) 
High levels of cholesterol Sacks and Katan., 2002 
Physical inactivity Poor perfusion, 
adverse lipid profile 
Ignarro, 2006 
Obesity Metabolic syndrome of  
insulin resistance 
Grundy, 2004 
Tobacco taking Oxidative stress Pasupathi et al., 2009 
Dyslipidaemia Oxidative stress Rizzo et al., 2009 
Hypertension  
(high blood pressure) 
Oxidative stress,  
enhanced vasoconstriction 
Harrison and Gongora, 2009 
Infection Inflammation Lowe, 2001 
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1.1.2 Inflammation process of atherosclerosis 
Atherosclerosis, the major cause of CVDs, refers to a chronic inflammation process 
affecting medium and large sized arteries, subsequently restricting blood flow by the 
formation of blood clots inside arteries. The development of atherosclerosis in humans 
starts as early as twenty years of age and progresses slowly over many years. The 
adhesion of endothelial cells (ECs) from the inner surface of the artery wall with 
leukocytes initiates the process of inflammation (Libby et al., 2006). Healthy ECs lack 
the ability to adhere to leukocytes. However, common risk factors, physical damage and 
infection of the arteries trigger the interaction of the endothelium with monocytes and T 
lymphocytes, which are two types of leukocytes involved in the early stage of 
atherosclerosis. This causes the penetration of monocytes and T lymphocytes into the 
intima, which is an inner layer of the vessel wall. Monocytes express the scavenger 
receptors CD36 and SR-A, leading to their transformation into highly activated 
macrophages which take up low-density lipoproteins (LDL). These macrophages, which 
also called foam cells, combine with T cells in the intima to form the fatty streak.   
 
The migration of smooth muscle cells to the site of inflammation is stimulated by 
cytokines and growth factors secreted by macrophages and T cells. Within the intima, 
macrophages also secrete inflammatory cytokines including tumour necrosis factor α 
(TNF α), interleukins and metalloproteinases. Collagen, synthesised by smooth muscle 
cells, becomes the predominant connective tissue of these inflammatory areas. The 
connective tissue deposits over the foam cells and macrophages, thus forming a fibrous 
cap. The foam cells and macrophages subsequently undergo apoptosis and the cell 
debris generated from apoptosis forms a ‘lipid-rich’ necrotic core. The fibrous cap 
containing the necrotic core finally develops into an atherosclerotic plaque. At the 
shoulder of the plaque, i.e. the junction of the fibrous cap with the endothelium, 
leukocytes continually transform into foam cells and deposit at the bottom of the 
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necrotic core, which results in the enlargement of the plaque. Meanwhile, T cells secrete 
cytokines such as interferon γ (IFN-γ), which restricts the production of collagen by 
smooth muscle cells. Macrophages also produce enzymes which digest the collagen and 
the prothrombotic substances within the plaque. These reactions lead to the activation of 
platelets, and cause the fibrous cap to reduce its strength. The fibrous cap undergoes 
thrombosis and ruptures in the blood vessel. The blood flow is interrupted by the 
contents released when the plaques rupture, finally leading to necrosis and acute 
myocardial infarction (AMI).  
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Figure 1.1. The process of atherosclerosis development. Low-density lipoprotein 
(LDL) undergoes chemical changes and activates the endothelial cells to adhere with the 
immune cells. These immune cells penetrate the intima and trigger the inflammation 
process, which encourage the transformation of macrophage into foam cells. Foam cells 
secrete a variety of cytokines and then undergo apoptosis. The fatty streak is 
subsequently formed due to the deposition of foam cells and their debris, and the fatty 
streak finally transforms into a fibrous cap. Substances released from foam cells 
destabilize the fibrous cap and cause rupturing of the fatty plaque (Based on references: 
Libby 2006; Full et al., 2009).   
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1.2 Biomarkers for cardiovascular diseases 
1.2.1 Current biomarkers for cardiovascular diseases 
A biomarker is a measurable and evaluable substance which can indicate a specific 
biological state, including healthy and pathological biological processes and 
pharmacologic responses to a therapeutic intervention. Biomarkers can be used to 
identify risk stratification of diseases, to make a diagnosis, to assess the evolution of a 
disease and to detect a response to the toxicity of a disease treatment (Frank and 
Hargreaves, 2003; Phillips et al., 2006; Christ-Crain and Opal, 2010). 
 
Cardiac biomarkers are a class of biological analytes that are detectable in the 
bloodstream at elevated levels during the continuum of CVD. Current available CVD 
biomarkers for AMI detection have been extensively studied (Galvani et al., 2001; 
Daniels et al., 2009; McDonnell et al., 2009). In general, each CVD biomarker is 
associated with types and stages of cardiac disease development (Fig 1.2). For instance, 
markers of inflammation are related to cardiac plaque formation and rupture. 
Coagulation factors and proteins are associated with intracoronary thrombus formation. 
Perfusion and functional imaging can detect reduced blood flow. Early ischemic 
biomarkers and classical CVD biomarkers indicate myocardial ischemia and necrosis. 
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Figure 1.2. Biomarkers associated with stages of cardiovascular disease 
development. The arrow represents the progression of CVD from early stage (plaque 
formation) to late stage (necrosis). Biomarkers of inflammation indicate the stage of 
plaque formation and plaque rupture. Coagulation factors and proteins are biomarkers 
for thrombosis. Reduced blood flow can be detected by perfusion or functional imaging. 
Myocardial ischemia and necrosis can be diagnosed with early ischemic biomarkers and 
classical CVD biomarkers, respectively (Vasan, 2006).   
 
Lactate dehydrogenase (LDH), Creatine Kinase (CK) and their isoenzymes and 
myoglobin are the classical biomarkers for CVD (O’Brien, 2006). LDH can be found in 
most tissues such as cardiac muscle, skeletal muscle, liver, lungs and brain. LDH has 
five isoforms, which are LDH-1, LDH-2, LDH-3, LDH-4 and LDH-5. Each isoform is 
comprised of combinations of two different subunits, which are M and H (Bansal et al., 
2005; Babaei et al., 2007). LDH-1, mainly present in cardiac muscle, contains 4 H 
subunits. LDH-2, the predominant form in serum, contains 3 H subunits and 1 M 
subunit. The ratio of LDH-1 and LDH-2 levels can be used an indicator for CVD 
diagnosis (Chu et al., 2002). Generally, LDH levels start to increase twelve to 
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twenty-four hours after myocardial infarction and reach a peak at forty-eight to 
seventy-two hours. The levels return to normal within 10 days. However, in most cases, 
skeletal muscle damage can also lead to the elevation of LDH levels. LDH, therefore, 
has low specificity for the CVD diagnosis.  
 
In the second section of this thesis LDH is evaluated as a potential marker of mastitis. 
This links both sections of the thesis as the overall focus of the research was the 
evaluation of potential biomarkers related to inflammation for their applicability for 
early disease detection with relatively high specificity. 
 
Myoglobin is a low molecular weight oxygen binging protein and it is also an early 
stage biomarker for myocardial infarction. Myoglobin levels are detectable as early as 
two hours after cardiac injury. Myoglobin is present in both skeletal and cardiac muscle 
and its levels increase with both skeletal and cardiac injury (O’Brien, 2008). Myoglobin, 
therefore, has to be used in conjunction with other serum markers to obtain accurate 
CVD diagnosis.  
 
Creatine Kinase (CK) is one of the early used biomarkers for myocardial infarction. 
However, it also has low specificity due to its presence in slow-twitch muscle tissue. In 
comparison to CK, Creatine Kinase-MB (CK-MB), a derivative form of CK, is a more 
specific biomarker (Jaffe et al., 2006). The CK-MB can be detected in the serum four to 
six hours after the onset of ischemia and its levels reach a peak at twelve to twenty-four 
hours. The levels return to normal within three days (Jaffe, 2005; Jaffe et al., 2006). 
CK-MB levels can be elevated in a number of non-cardiac conditions such as pregnancy 
and parturition. It, therefore, cannot be used as a ‘gold-standard’ for AMI detection 
(Jaffe, 2005; Jaffe et al., 2006).  
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Currently, cardiac troponins, either troponin T or troponin I, are the biomarkers of 
choice for the detection of cardiac injury (O’Brien, 2008; Conroy et al., 2009). Cardiac 
troponin T levels increase in the immediate aftermath of myocardial damage. The 
elevation of cTnT levels can be monitored within minutes after myocardial injury and 
the peak occurs as early as two to six hours (O’Brien, 2008). Similarly, Lim and 
co-workers also reported cTnT level increased and showed a peak three to four hours 
after the occurrence of cardiac symptoms in patients with acute myocardial infarction 
action (AMI) (Lim et al., 2005). Moreover, Inbar and Shoenfeld reported that cardiac 
troponins were detected in patients’ serum within six hours after the initiation of CVD 
(Inbar and Shoenfeld, 2009). Due to the high cardiac sensitivity and specificity of 
troponin, the European Society of Cardiology and the American College of Cardiology 
(ESC/ACG) have recommended cardiac troponins as the preferred biomarkers since 
2000. The diagnosis of acute myocardial infarction was redefined by ESC/ACG. It was 
recommended that the 99th percentile of a reference control population (normal value) 
should be the ‘cut-off’ for the diagnosis of AMI as well as at least one of the these 
criteria: symptoms of ischaemia; ECG changes indicative of new ischaemia (e.g. new 
ST-segment depression or a new complete left bundle branch block); development of 
pathological Q-waves in the ECG and demonstration of a new area of infarction or 
disturbance of regional wall motility by imaging (Morrow, 2006; Giannitsis and Katus, 
2010). From clinical studies, patients with an elevated cTnT level greater than 0.01 μg/L 
are considered as sub-clinical AMI (Morrow, 2001).  
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Table 1.3. Overview of serological markers used for myocardial necrosis detection  
(Based on references: Horak, 1999; Kemp et al., 2004; Bunk and Welch, 2006; Vasan, 2006; McDonnell et al., 2009)
Biomarkers 
MW 
(kDa) 
Initial 
elevation 
Peak 
level 
Return to 
normal 
Advantages Disadvantages 
Creatine kinase  
- MB (CK-MB) 
85 3 to 12 h 12-24 h 2 to 3 days More specific than CK alone; early detection 
marker; used for diagnosis of reinfarction 
Low cumulative specificity; present in skeletal 
tissue; low discriminative value in coronary 
reperfusion  
Lactate dehydrogenase 
(LDH)  
35 12 to 24 h 48 to 72 h 10 days High sensitivity when detected with isoforms 
ratios of LDH-1:LDH-2 
Low specificity; present in most tissues; 
Myoglobin 
(Myo) 
17 2 h 6 to 12 h 1 to 2 days Peaks rapidly; very early detection marker; high 
sensitivity; can determine the size of infarction 
Low specificity; exists in skeletal tissue; returns to 
normal quickly 
Heart Fatty acid 
binding protein (HFBP)  
14.5 2 to 3 h 8-10 h 18-30 h Early marker; estimate of infarction size; detects 
the re-perfusion of MI  
Low specificity; present in muscle, brain and 
kidney 
Troponin T  
(TnT) 
35 4 to 6 h 12-24h 7 to 10 days High sensitivity; high specificity, significant 
prognostic potential 
Limited in detection of reinfarction; associated 
with end-stage renal disease 
Troponin I 
(TnI) 
23.5 4 to 6 h 12-24 h 6 to 8 days High sensitivity and specificity; significant 
prognostic potential 
Limited in detection of reinfarction; no accepted 
reference standards thus affecting assay reliability  
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1.2.2 The biology of cardiac troponins 
In 1963, Ebashi isolated a protein complex called ‘natural tropomyosin’ from rabbit 
skeletal muscle (Perry, 1998). The biological properties of the protein complex are 
similar to tropomyosin, therefore, the complex was named ‘troponin’ after tropomyosin 
(Tm) by Ebasi and Enda in 1968 (Ebashi and Endo, 1968). A number of groups 
performed the subsequent fractionation of the troponin complex and in 1972 the three 
components of troponin complex were separated and were named as troponin C (TnC), 
troponin I (TnI) and troponin T (TnT) (Fig. 1.3)(Greaser et al., 1972). 
 
Figure 1.3. Structure of the human cardiac complex.  The blue ribbon represents 
troponin C (TnC), the green ribbon represents troponin I (TnI), and the magenta ribbon 
represents troponin T (TnT). 
  
The troponin complex plays a critical role in the regulation of striated muscle 
contraction. Striated muscle filaments consist of thick myosin filaments and thin actin 
filaments. The tropnin complex (Fig. 1.4) is attached to the tropomyosin protein 
forming the troponin/tropomyosin complex and is located within the groove of the thin 
actin filaments (Parmacek and Solaro, 2004; Ohtsuki and Morimoto, 2008). Typically, 
muscle contraction is accomplished by the sliding motion of the thick myosin filaments 
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along the thin actin filaments. In relaxed muscle, the heads of myosin filaments are 
attached to the actin molecules thus forming cross-bridges. When ATP interacts with a 
myosin head, it causes the detachment of the myosin head from the actin molecule. ATP 
then undergoes degradation and breakdown into ADP and inorganic phosphate. Calcium 
ions (Ca2+) are stored in the sarcoplasmic reticulum of striated muscle. When the muscle 
contraction process initiates, Ca2+ ions are released from the reticulum and migrate to 
the sarcoplasm around the muscle filaments. After myosin detaches from the actin 
molecule, Ca2+ binds to troponin C which is located on the actin filaments thus leading 
to the shift of the tropomyosin-troponin complex (Fig.1.4). The shift of the complex 
allows the exposure of new myosin binding sites. The myosin head moves along the 
actin filaments and subsequently binds to a new actin molecules. This movement results 
in shortening of the muscle fiber thus causing muscle contraction (Szent-Gyorgyi, 1975; 
Krans, 2010).  
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Figure 1.4. (A) Components of the troponin complex. Three troponin subunits, 
Troponin I (TnI), troponin C (TnC), and troponin T (TnT) interact with tropomyosin 
located along the actin filaments on the striated muscle. (B) Cross-sectional view of 
the interaction between the striated muscle and calcium ions. The interaction 
between myosin to actin is prevented by the tropomyosin-troponin complex when Ca2+ 
is absent. The binding of Ca2+ ions to TnC causes the movement of 
tropomyosin-troponin complex, thus initiating the interaction of myosin to actin and 
subsequently causing muscle contraction. 
 
The TnC subunit, of approximately 18 kD molecular weight, consists of two globular 
domains and a central α-helix connecting the domains. The Ca2+ binding sites are 
located on both the N terminal and C terminal regions of the globular domains. 
Ca2+-saturated TnC causes position shifting of the Tn–Tm complex, thus allowing the 
binding of actin with myosin. The Tn-Tm complex stimulates ATPase activity thus 
producing muscle contraction (Flicker et al., 1982; Filatov et al., 1999).  
 
TnI, is a polar protein with positively charged residues that is responsible for inhibition 
of the actomyosin ATPase activity (Filatov et al., 1999). In the presence of 
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Ca2+-saturated TnC, the two peptide inhibition sites on cTnI interact with TnC instead 
of actin, resulting in the release of the actomyosin ATPase activity. TnT interacts with 
tropomyosin in the muscle contraction process thus regulating actomyosin ATPase 
activity. The binding of TnT with TnI and TnC in the presence of Ca2+ causes less 
inhibition of ATPase activity than in the absence of the Ca2+ and, therefore, assisting in 
muscular contraction (Filatov et al., 1999). 
 
Troponin T is an asymmetric ‘comma’-shaped polypeptide. It has a globular domain at 
the C-terminus and an extended N-terminal end as the tail of the comma (Flicker et al., 
1982). Three homologous genes encode the three muscle-specific types of TnT: slow 
skeletal troponin T (ssTnT), fast skeletal troponin T (fsTnT) and cardiac muscle 
troponin T (cTnT) (Burlina et al., 1994; Babuin and Jaffe, 2005). Each of the genes 
undergoes alternative mRNA splicing during development, resulting in different 
isoform expression at the N-terminus (Burlina et al., 1994; Sumandea et al., 2009). The 
gene fragment which encodes the N-terminus of the cTnT molecule is highly variable 
due to the alternative splicing of short exons 4 and 5 on mRNA. The variations of the 
genotype can lead to the variations of phenotype in the N-terminus (residue 1-70) 
(Ohtsuki, 1979; Filatov et al., 1999). Troponin T has a molecular weight in the 31-36 
kDa range and consists of about 250 to 300 amino acids. Four troponin T isoforms 
(cTnT1 to cTnT4) can be found in human cardiac muscle. All four isoforms are 
expressed in fetal cardiac muscle, and only one isoforms (cTnT2) predominantly exists 
in adult cardiac muscle (Anderson et al., 1991). Snyder and co-worker found that rabbit 
cardiac TnT had a longer N-terminal region than its skeletal counterpart and was 20% 
more helical (Snyder et al., 1996). Similarly, Townsend and co-workers compared the 
alignments of the TnT isoform from adult humans with other animal species and 
significant sequence variations were found between species in 67 residues at the 
N-terminal end (Townsend et al., 1994). In addition, Dhoot and co-workers also 
23 
 
reported that the major isoforms of TnT in fast skeletal, slow skeletal and cardiac 
muscles are immunochemically distinct proteins (Dhoot et al., 1979).  
 
1.2.3 Immunoassay for Troponin T  
Currently the Roche Elecsys® cTnT assay (Roche Diagnostics) is the only commercially 
available assay. This first generation of the Roche Elecsys® cTnT assay is based on a 
sandwich format using two monoclonal antibodies, with a detection capacity for cTnT 
of 0.1 µg/L (Katus et al., 1991). However, the lack of cardiac specificity of the 
HRP-labeled 2nd monoclonal antibody caused 12% cross-reactivity with skeletal 
isoform of TnT, therefore, yielding false-positive diagnosis for patients with skeletal 
muscle injury (Wu et al., 1994; Muller-Bardorff et al., 1997; Hallermayer et al., 1999). 
Katus and colleagues improved the assay by substituting the non-specific monoclonal 
antibody with a high-affinity cardiac antibody (Muller-Bardorff et al., 1997). The new 
version of troponin T assay showed no binding against skeletal TnT and increased 
sensitivity with the detection level at 0.0123 µg/L. Both the first and second generation 
troponin T assays were compromised due to the use of recombinant cTnT purified from 
bovine sources as standard material (Hallermayer et al., 1999). The recombinant bovine 
cTnT was found to be problematic for generating a linear calibration curve and thus the 
assays were not reliable. In the third generation cTnT assay, the bovine cTnT was 
replaced by recombinant human cardiac TnT (recHcTnT). The recHcTnT brings several 
advantages. Firstly, it can generate a high linear calibration curve which eliminates the 
non-linear dilution behavior caused by the use of bovine cTnT. Secondly, it has higher 
binding affinity to the monoclonal antibody. The fourth generation troponin assay uses 
the Fab fragments of two cardiac-specific monoclonal antibodies. A highly sensitive 
cardiac troponin T (hs-cTnT) was further developed by replacing the mouse constant C1 
region with a human IgG C1 region, thus producinging to a mouse-human chimeric 
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detection antibody. This replacement can reduce the susceptibility to interferences by 
heterophilic antibodies (HAMAs) (Katus, 2008).  
 
Using the Fab fragments, the sensitivities of the TnT assays have rapidly improved. The 
European Society of Cardiology and the American College of cardiology (ESC/ACG) 
have recommended the 99th percentile of the reference population as a ‘cut-off’ value 
for AMI diagnosis. Moreover, a 10% coefficient of variation (CV) is the level of 
precision. For clinical validation of the hs-cTnT assay, Koerbin and co-workers 
determined cTnT concentration of 104 samples from a cardio-healthy population using 
the hs-cTnT assay. Results showed that the hs-cTnT assay met the recommended 
criteria of a 10% CV at the 99th percentile of the population studied (Koerbin et al., 
2010). However, Tate (2008) reported that the fourth generation cTnT assay have a 20% 
CV at the 99th percentile in clinical validation. Thus, its imprecision has failed to meet 
the recommended level (Tate, 2008). Panteghini and co-workers also reported that the 
current troponin assay had not achieved the 10% CV at the 99th percentile by testing 
with eight serum pools (Panteghini, 2004). The development of new cTnT assays 
remains as a great challenge due to the limited number of available formats and their 
failure to meet recommended standards. Hence, it was hoped that the use of 
recombinant antibodies and a novel assay platform may introduce significant 
improvements for cTnT assay development. 
 
1.3 Recombinant antibody technology 
1.3.1 The immune system and antibodies 
The immune system is the body's defence against infectious organisms and other 
foreign particles. It protects the body by using a network of cells, proteins, tissues and 
organs. Two fluid systems of the body, the blood system and lymph system, transport 
the agents of the immune system to various locations of the body. The blood system is 
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composed of liquid plasma and blood cells. These include erythrocytes (red blood cell), 
leukocytes (white blood cells) and thrombocytes (platelets). A subdivision of 
leukocytes, lymophocytes, consists of B and T cells. These cells circulate in both the 
blood and lymph system and generally are located in the lymphoid organs. The 
bean-shaped lymph nodes are often the location where the antigens are recognised by 
the immune system. Lymph organs include bone marrow, the thymus gland, adenoids, 
tonsils, spleen, lymph nodes and the appendix. The primary lymph organs, bone marrow 
and the thymus gland, are responsible to a large degree for the production of 
lymphocytes. Mature lymphocytes circulate in both the blood and lymph systems. 
Secondary lymph organs maintain mature naive lymphocytes and initiate an adaptive 
immune response allowing the activation of lymphocytes when foreign pathogens are 
encountered.   
 
The classification of immune responses is based on their characteristics. For example, 
whether they are innate or acquired, have self or non-self recognition, are specific or 
general, cell mediated or humoral, primary or secondary. The innate and the acquired 
systems are two major divisions of the immune system although in reality they are very 
closely connected. 
 
The innate immune system is a non-specific genetically derived system passed on from 
mother to offspring, which consists of physical barriers, mucous membranes, and 
internal mechanisms. Skin, as primary physical barrier, prevents the penetration of 
various micro-organisms by its physical presence, its acidic environment and secretions 
from hair follicles. Innate immunity involves a collection of immune cells including 
macrophages, neutrophils, eosinophils, natural killer cells, and dendritic cells. Each of 
these cells binds to antigens using pattern-recognition factors which results in the basic 
defence mechanisms of the innate response including phagocytosis and inflammation. 
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Phagocytosis is a process that involves engulfment and destruction of infectious 
organisms and other foreign particles by phagocytes. In cell-mediated immunity, 
phagocytes, such as macrophages, secrete lymphokines that encourage cytotoxic T cells 
and B cells to grow and divide. Lymphokines also attract neutrophils and increase the 
capacity of macrophages to engulf and destroy infectious organisms.  
 
Acquired immunity is a specific immune response stimulated by a foreign substance. It 
is subdivided into cell-mediated immunity and humoral immunity. T lymphocyte 
precursors are produced in the bone marrow but mature in the thymus and constitute the 
basis of cell-mediated immunity. Cytotoxic T cells lyse antigens by secreting 
lymphotoxins and other factors or by inducing apoptosis. B lymphocytes are derived 
from the stem cells of the bone marrow and are selected for immune tolerance by clonal 
selection before maturing in the plasma. The mature plasma B cells can produce highly 
specific antibodies at a rate of 2000 molecules per second for four to five days.  
 
Antibodies, also known as immunoglobins (Ig), are soluble glycoproteins, produced by 
the plasma B cells, to identify and inactive foreign substances, such as bacteria and 
viruses. Antibodies may inactivate antigens generally through four types of biochemical 
processes, i.e. complement fixation; neutralization; clumping of antigens by 
agglutination or in activation/removal by precipitation.  
 
An immunoglobin monomer is the basic functional unit of each antibody. It is a ‘Y’ 
shaped molecule consisting of two identical heavy chains (VH ~ 50 kD) and two 
identical light chains (VL ~ 25 kD) linked by disulfide bonds and non-covalent 
interactions (Fig. 1.5). The heavy chains have one variable domain and three constant 
domains. The light chains consist of one variable domain and one constant domain. 
Antibodies of the same isotype have the same constant domain. Antibodies produced by 
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different B cells have different variable domains. The variable domain of each heavy 
chain consists of approximately 110 amino acids. The light chain consists of one 
variable domain and one constant domain. The variability of the antigen binding site is 
located in the complementary-determining regions (CDRs), subdivided into CDR-1, 
CDR-2, and CDR-3 (Janeway et al., 2001).  
 
 
 
Figure 1.5. Structure of Immunoglobulin G (IgG). IgG (150 kD) consists of two 
heavy chains (50 kD) and two light chains (25 kD) which are linked by disulphide 
bonds. The light chain consists of a variable domain (VL) and a constant domain (CL). 
The heavy chain consists of a variable chain (VH) and three constant chains (CH1, CH2 
and CH3). The two heavy chains are linked by disulfide bonds in the hinge region. The 
antigen binding sites are located on the VL and VH domains (Gabrielli et al., 2009). 
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Antibodies are divided into five groups based on the number of Y units and the type of 
heavy chain. The five groups are IgG, IgA, IgM, IgD and IgE (Table 1.4). IgG is a 150 
kD monomer and it is the most common type of antibody in the blood. It constitutes 
approximately 75% of the total serum Ig and its relative abundance and excellent 
specificity toward the antigen has made it the principal antibody used in immunological 
research and clinical diagnosis. Human IgG consists of four subclasses, named IgG1, 
IgG2, IgG3 and IgG4. The four subclasses have 90% to 95% similarity with each other 
in the constant region. IgM is a 950 kD pentameric antibody and appears in the primary 
response after immunisation. It is the most effective ‘complement-fixing’ 
immunoglobin and comprises approximately 10% of normal human serum Ig content. 
IgA, comprising approximately 13% of the total serum Ig, can be monomeric or dimeric 
and is found in saliva, tears, nasal mucosa, prostatic fluid and many other bodily fluids. 
IgD is monomeric antibody and is found on the surface of B cells. IgE is 200 kD 
antibody in the monomeric form and triggers allergic reactions. Antibodies can be 
classified into subclasses based on the minor differences in the heavy chain type of each 
Ig class, in addition to the major antibodies classes (Alberts et al., 2002). 
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Table 1.4. Antibody classification and characterisation 
 Structure Size Constitution in 
serum 
Subclasses 
(Isotopes) 
Function 
IgG Monomer 150 kD 75% (12.5 mg/mL) IgG1, IgG2, 
IgG3, IgG4 
Entering tissue spaces and primarily 
binding antigens 
IgA Dimer 160 kD 13% (2.1 mg/mL) ----- Concentrating in body fluids to guard 
the entrances of the body 
IgM Pentamer 950 kD 10% (1.25 mg/mL) IgA1, IgA2 First appears during an immune 
response and first formed by 
developing foetus 
IgD Monomer 175 kD < 1% (40 μg/mL) ----- Regulating B cell’s activities 
IgE Monomer 190 kD < 0.003 % 
(0.4 μg/mL) 
  ----- Fc parts binds to mast cells and 
basophils and trigger allergic 
reactions; protection against parasitic 
worms 
 
Both the light and heavy chains of an immunoglobin are encoded by multigene families 
located on the different chromosomes. The light chain family contains L (leader), V 
(variable), J (junctional) and C (constant) regions. The heavy chain family contains the 
same regions with an additional D (diversity) region. Antibody diversity is generated by 
the rearrangement of these segments in the developing B cells. There are slight 
differences of sequence rearrangements between light and heavy chains. In the light 
chains, the V and J segments are initially combined together, then preceded by an L 
segment and followed by an intron sequence and a C segment. However, in heavy 
chains, the D segment is combined with the J segment initially, and then this DJ 
segment is combined with the V segment to form the complete heavy chain VDJ 
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domain. The VDJ is finally joined to the C segment by RNA splicing after transcription 
(Fig. 1.6).   
 
V D J CV VV D D D J J J
V DV VV D CJ
JD D J J
V DV VV D CJ
V V D CJ
V V D
V V D CJ
Genes in heavy chain locus 
Removal of unwanted D 
and J gene segment
D and J exon
recombination
Removal of unwanted 
V and D gene segment
V, D and J exon
recombination  
 
Figure 1.6. Recombinational arrangement of the DNA encoding variable (V), 
diversity (D), junction (J) and constant (C) regions of an immunoglobulin heavy 
chain. The rearranged chain is transcribed into messager RNA and translated into the 
heavy chain. (Based on references: Abbas and Lichtman, 2003; Costanzo et al., 2009) 
 
1.3.2 Polyclonal antibody generation 
Antibodies have become vitally important as research tools for a range of applications 
due to their ability to bind, recognise and determine a range of different antigens 
including many biomarkers. Polyclonal and monoclonal antibodies are the basic forms 
of antibodies commonly used in analysis.   
 
Polyclonal antibodies are generally purified direct from serum collected from animal 
hosts immunised with the desired antigens. The heterogeneous immunological response 
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elicited from an antigen produces different cell lines of B-lymphocytes which originated 
from common stem cells. Polyclonal antibodies produced by these different 
B-lymphocytes recognise different epitopes on an antigen. A number of different animal 
species can be used as hosts for polyclonal antibody production, such as rabbits, 
chicken, rats, goats, sheep, horses and guinea pigs. (Stills, 1994). For laboratory use, 
rabbits are excellent due to their capacity for producing sufficient antibody in a relative 
short period of time as well as the size which facilitates handing. Goats are also 
excellent hosts due to the large volume of serum generated as well as the ease and 
relatively low cost of maintaining goat herds for long periods of time. Chickens are 
suitable hosts owing to their phylogenetic distance from mammals, which may be 
beneficial for the production of antibodies to certain mammalian proteins. Chicken egg 
yolk contains large quantities of antibodies up to 60 mg per egg (Pauly et al., 2011). 
Therefore, harvesting antibodies from eggs eliminates the need for invasive bleeding. 
The procedure for polyclonal antibody production is outlined in Figure 1.7. Polyclonal 
antibody preparations are used in a range of applications especially when labeled with 
an enzyme or chromophore (Waggoner, 2006).  
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Immunisation of
animal host 
with antigen of interest
Serum collection 
when sufficient 
titre obtained
Specific antibodies are 
retained in the column
Whole serum is added to the affinity column
Specific antibodies are 
eluted off the column and 
collected
 
Figure 1.7. Polyclonal antibody generation and purification. Polyclonal antibody 
production requires the immunisation of animal hosts with the antigen of interest. Once 
a sufficient antibody immune response titre is obtained, serum containing polyclonal 
antibodies is collected. Polyclonal antibodies may be purified using affinity column 
chromatography. 
 
1.3.3 Monoclonal antibody generation  
Monoclonal antibodies are produced by an individual B-lymphocyte clone. They have a 
single defined specificity as they recognise and bind to the same unique epitope on the 
antigen. Cells from the spleen and lymph nodes from immunised animals are the 
sources used to isolate B-lymphocytes. The isolated B-lymphocytes are fused with 
myeloma cells creating a monoclonal hybrid cell line or hybridoma (Fig. 1.8). The 
production of antibodies using a monoclonal hybrid cell line ensures that the antibodies 
bind to the same epitope on antigens. In addition, the hybridoma is a constant and 
renewable antibody source so that antibodies produced from every batch are identical. 
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However, it is an expensive and time-consuming process, and the antibodies generated 
sometimes show cross-reactivity with unrelated antigens (Sun et al., 2001).    
 
Immunisation of a mouse 
with antigen of interest 
Collection of B-cells and 
growth of myeloma cells
Fusion of B-cells 
with myeloma cells  
Selection of 
specific clones
Purification of specific antibodies 
using an affinity column
Purified monoclonal antibodies
specific to the immunogen of interest
 
Figure 1.8. Monoclonal antibody generation using hybridoma technology. The 
production of monoclonal antibodies starts with the immunisation of mice with an 
antigen of interest. Antibody response is monitored throughout the immunisation 
process. B-lymphocytes are isolated when a sufficient serum antibody response is 
obtained. Addition of polyethylene glycol facilitates the fusion of B-lymphocytes with 
myeloma cells. Fused cells are grown in a selective media, selected and cloned out and 
monoclonal antibodies produced by selected fused cells can be purified using affinity 
chromatography with protein A or G. 
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1.3.4 Recombinant antibody generation 
Recombinant antibodies are derived from the mRNA of B-lymphocytes, generating 
antibodies to immunised antigens, or from antibody libraries, using molecular biological 
techniques. They can be the whole IgG antibodies or fragments of antibodies. 
Nowadays, recombinant antibodies have become extremely important tools in various 
biomedical research applications. The antigen recognition binding sites are located in 
the complementary-determining regions (CDRs) on the variable regions of antibodies. 
By reformatting the heavy and light chain fragments of antibodies, recombinant 
antibodies with improved antigen-binding capacities can be constructed. Recombinant 
antibodies retain the recognition capacities of their parental antibody. Furthermore, due 
to the smaller molecular size, antibody fragments can often localise antigens more 
precisely than intact IgG. Antibody fragments are, therefore, widely used for both 
diagnosis and therapeutic purposes. Two commonly chosen formats of recombinant 
antibodies are the single chain fragment variable (scFv) and antigen binding fragment 
(Fab) (Fig. 1.9) (Hudson, 1998). 
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scFv 
(~ 25 kDa)
Fab
(~ 50 kDa)
VH
VL
CH
CL
- variable heavy chain
- variable light chain
- constant heavy chain
- constant light chain
- glycine-serine linker
 
Figure 1.9 Commonly used recombinant antibody fragments. A scFv contains a VH 
domain and a VL domain linked by a peptide linker. The Fab contains a VH domain and 
a fragment of the constant domain (CHI) paired with VL and the light chain constant 
domain (CL). 
 
Generation of recombinant antibodies requires the construction of antibody libraries and 
the selection of specific antibodies from those libraries. In general, three types of 
antibody libraries can be constructed: naive libraries, synthetic libraries and immune 
libraries. Naive libraries are produced from non-immunised animals. Theoretically, they 
can be used for the selection of antibodies against an unlimited range of antigens. 
However, a very large library size is required to obtain antibodies with high affinities 
(Carmen and Jermytus, 2002). Synthetic libraries are constructed by in vitro assembly 
of VL and VH genes thus introducing artificial CDR domains by altering the loop 
lengths using PCR and randomising oligonucleotide primers. Antibodies with moderate 
affinities are normally selected from synthetic libraries and a very large library size is 
also beneficial to enhance the likelihood for the selection of antibody with the required 
sensitivity and specificity (Hong and Kim, 2002). In contrast to non-immunised 
libraries, immune libraries require the immunisation of the target antigen into animal 
hosts. This approach is designed to increase the capacity of the libraries to possess high 
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affinity antibodies with the desired sensitivity for the target antigens (Carmen and 
Jermutus, 2002). An immune library should have at least 108 individual 
antibody-containing clones thus giving the possibility of selection of antibodies of the 
desired specificity. Phage display will subsequently allow selection of high affinity 
antibodies from millions of antibody variants (Fig. 1.10) (Okamoto et al., 2004). 
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Phagemid vector
Extraction of RNA
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and bone marrow
Reverse transcription
of mRNA to cDNA
Chain combination
by SOE PCR
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product into phagemid vector 
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Plasmid vector into E. coli cells 
Infection of E. coli cells 
with phage particles
Amplification antibody 
chains using PCR
Antibodies are displayed 
on  the phage particles
Serum collection when 
sufficient titre obtained
Immunisation of animal 
host with antigen of interest
 
 
Figure 1.10. Construction of immune recombinant antibody library and selection 
of recombinant antibody by phage display. The production of recombinant antibodies 
starts with the immunisation of an animal host with the antigen of interest. Antibody 
responses are monitored throughout the immunisation process. Total RNA is extracted 
from the animal spleen and bone marrow once a sufficient antibody response is 
obtained. cDNA, which encodes antibody genes, are produced by reverse transcript of 
mRNA. Antibody chain genes are subsequently amplified using PCR followed by 
ligation into phagemid vectors. The ligation product is transformed into E.coli cells and 
phage particles are subsequently infected into the E. coli cells. Antibody fragments can 
be expressed and displayed on the surface protein of the phage particles (e.g. PIII) and 
specific antibody fragments can ultimately be selected by the biopanning process.   
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1.3.5 Phage display technology 
Phage display is an extremely powerful tool for selecting peptides, proteins and 
antibodies with specific binding affinities from a large number of variants. This 
technique, first introduced by Smith in 1985, allows display of polypeptides on the 
surface of filamentous phage by fusing a foreign gene fragment on to gene III of 
filamentous phage (Smith, 1985; Winter et al., 1994). Phage display provides a direct 
linkage between genotype and phenotype. While fusing a foreign DNA fragment with 
phage genome, the coat proteins of a phage particle must tolerate this foreign fusion 
without changing their properties. The foreign protein can thus be displayed on the 
phage particle with the aid of the coat proteins (Kay and Hoess, 1996; Bradbury and 
Marks, 2004). Phage displays allow the generation of vast numbers of variants. 
Typically, the infected phages number can reach to 1011 to 1012 per ml after continuous 
generations. This feature enables the construction of large antibody libraries with the 
required diversity, and an antibody with the required affinity can consequently be 
selected using biopanning.     
     
1.3.5.1 Phage particles 
Bacteriophages, first reported by Frederick in 1915 and Felix d’Herelle in 1917, are a 
class of viruses that contain a circular single-stranded DNA genome encased in a long 
protein capsid cylinder (Fig. 1.11). The Ff class phage (f1, fd and M13) is 
approximately 6.5 nm in diameter and 930 nm in length, containing a single-stranded 
DNA molecule of approximately 6400 nucleotides base pairs in length. The capsid 
cylinder contains about 2700 molecules of the geneVIII protein (pVIII). Other coat 
proteins such as gene VII (pVII) , gene IX (pIX), gene III (pIII) and gene VI (pVI) are 
present at the end of the phage particle. They use the tip of the F conjugative pilus as a 
receptor. Therefore, they are specific for E. coli containing the F pilus (Grossman et al., 
1990). 
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Figure 1.11. Structure of a filamentous phage particle. A filamentous phage particle 
contains a single strand DNA (gene III) encapsulated in major coat protein pVIII and 
manor coat proteins pIII, pVI, pVII and pIX. Antibody gene segments (VH and VL) are 
fused with gene III and antibodies can subsequently be expressed and displayed on the 
pIII coat protein.  
 
pIII protein contains two N-terminal domains (N1 and N2) and one C-terminal domain 
(CT). N1 interacts with the TolA protein of the TolQRA complex located at the 
periplasmic space between the inner and outer E. coli membranes. The TolQRA 
complex is responsible for the phage infection and the translocation of single strand 
phage DNA into the cytoplasm. The infection of phage into bacteria cells is initiated by 
the binding of the tip of the F pilus to the N2 domain of the phage protein. Once the F 
pilus binds to the N2, N1 is isolated from N2 and interacts with the co-receptor for 
phage binding domain 3 of TolA (TolA-D3). Soluble TolA-D3 which is presented in the 
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periplasm inhibits the phage infection process. Due to the single strand phage DNA is 
translocated into the cytoplasm, other proteins, including the major capsid pVIII protein 
and minor proteins pVII and pIX, are subsequently disassembled into the cytoplasmic 
membrane. The complementary DNA strand of the phage DNA is synthesised and the 
phage DNA is subsequently converted into a supercoiled, double-stranded DNA. The 
double-stranded DNA serves as a template for phage gene expression. After protein 
synthesis and assembly processes, the coat proteins including the major capsid protein 
pVIII (as well as pVII and pIX) are fused with antibody light and heavy variable regions 
resulting in their display on the surface of phage particles. Consequently, biopanning 
allows the selection of phage particles with specific antibody fragments displayed on 
their surfaces through their binding with the immobilised target antigen (Gaskin et al., 
2001). 
 
1.3.5.2 Phage vector systems 
Phage vectors and phagemid vectors are two different systems which have been 
developed for the expression of gene III and antibody fusion proteins. The differences 
between the two vector systems include the types of coat protein used for protein 
display, the fractions of the protein to be displayed and the location where recombinant 
fusion occurs (Paschke, 2006). Phage vectors are directly derived from the phage 
genome encoding all proteins required for the replication and assembly of the phage 
particles. Using these vectors, libraries are cloned as a fusion with the coat protein 
originally present in the phage genome (Scott and Smith, 1990; Kay et al., 1993) or 
inserted as fusion gene cassette with an additional copy of the coat protein. M13KE is a 
wild-type phage genome with a slight modification on the coat protein PIII, so that it 
can carry restriction sites to facilitate gene cloning (Zacher et al., 1980). Phagemid 
vectors contain both phage and plasmid origins of DNA replication. The fusion protein 
expression is independent of the phage genome. They replicate as plasmids in E. coli, and 
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they can also be packaged as phage particles in the presence of helper phage. Helper phage 
provides the necessary structural proteins that encapsulate both the help-phage and 
phagemid genomes. The phagemid carries an expression cassette that encodes the 
fusion-coat protein to be displayed.  
 
1.3.5.3 Biopanning process 
In general, an antibody library contains millions of different antibodies. The selection 
against the desired target molecules is achieved by iterative cycles of biopanning (Fig 
1.12). Biopanning is typically performed by re-amplifying a phage library by growing it 
in an appropriate media. The phage library, containing phage-displayed antibodies, is 
incubated with the target molecule of interest, which is immobilised on either a 
polystyrene plate or on paramagnetic beads. The phage-displayed antibodies are 
allowed to bind to the immobilised target. The unbound phage are washed away and the 
bound phage are eluted with an appropriate solution. The eluted phage are then 
re-amplified and subjected to next round of biopanning. A few additional cycles of 
binding and amplification are performed to enrich for higher affinity clones which have 
the ability to bind to the desired target. Typically, it takes from two to four rounds of 
biopanning to obtain a target with the desired affinity (Yuan et al., 2006). 
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1) Incubate  phage antibody library 
with antigen of interest. Specific phage 
are bound to antigens
2) Wash to remove
unbound phage. Bound 
phage are retained
3) Elute the antigen-
bound phage   
4) Propagate the eluted 
phage by infecting into 
E. coli
Discard the 
unbound phage
Analyse the 
eluted phage 
Phage particle
Antigen of interest 
 
Figure 1.12 Biopanning cycle. Four steps are commonly involved in a biopanning 
cycle, labeled 1 to 4 in the Figure. In step 1, the phage library is incubated with the 
target antigen to allow binding of specific antibodies. In step 2, bound phage are 
retained and unbound phage particles are removed by washing. In step 3, antigen-bound 
phage particles are eluted and analysed. In step 4, eluted phage particles are infected 
into E. coli cells for propagation. Typically, four to six rounds of panning are required 
to obtain antigen-specific antibodies.    
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1.4  Mastitis 
1.4.1 Introduction to mastitis 
The second disease involved in this study is mastitis. Mastitis is an inflammation of the 
mammary gland and is the major disease affecting dairy cattle worldwide. This 
inflammation can be caused by microbial organisms or non-infectious sources such as 
physical injury. Organisms such as bacteria, viruses, fungi, mycoplasma and chlamydia 
have been found to be the causative agents (Watts, 1988; Radostits et al., 1994). Over 
159 different types of microbial species have been identified as pathogens for mastitis 
(Kuang et al., 2009) and the majority are bacteria. The major infectious bacterial strains 
are Streptococcus agalactiae, Staphylococcus aureus and Escherichia coli. Fungi, 
viruses and yeast are also frequently found in infected udders (Wellenberg, 2002; 
Vimalraj et al., 2006; Marques et al., 2008). Although intensive studies have been 
performed on mastitis aetiology, up to 20 to 35% mastitis-causing pathogens have not 
yet been identified (Miltenburg et al., 1996; Wedderkopp, 1997; Viguier et al., 2009). 
 
Mastitis affects approximately 30% of dairy cows worldwide annually. In addition, 
mastitis cost the EU dairy industry approximately €1.55 billion in 2005 (Hillerton and 
Berry, 2005). In the US, annual expenditure on mastitis is over $1.5 billion. In the UK, 
it was estimated that the average cost of a case of clinical mastitis dairy industry was 
£175 (Kossaibati, 2000). In Ireland, mastitis affects approximately 25% of Irish cows 
every year. Each mastitis incidence costs approximately €72 per cow (Berry and Amer, 
2005). Mastitis is also the leading cause of death in adult dairy cows (Esslemont and 
Kossaibati, 1997). Bradley and Green reported that in the UK 0.6% of lactating cows 
died from mastitis (Bradley and Green, 2001a). In addition to the high economic losses 
and cow mortality, mastitis also lead to reduced productive-lives of cows, reduced milk 
yield, and altered milk composition which affects the quality of milk and its 
by-products.    
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1.4.2 Pathogenesis of mastitis 
Mastitis starts when bacteria enter the mammary gland through the teat canal. Bacteria 
propagate in the udder and secrete toxins which can cause damage within the udder and 
leukocytes are then produced. These cause a change in milk composition and also affect 
milk quality and production.  
 
Generally, the teat canal acts as the primary defence-line for mastitis infection. The teat 
is surrounded by a sphincter of smooth muscle which keeps the teat canal tightly closed 
and forms a physical barrier preventing bacterial invasion (Murphy et al., 1988). Inside 
the teat canal, keratin also prevents the invasion of pathogens.   
  
Once bacteria enter the teat canal, they start growing and multiplying. A number of 
enzymes are released by the bacterial cells and these enzymes cause leukocytes and 
epithelial cells to release factors, such as tumor necrosis factor-α, interleukin 8, 
interleukin 1, eicosanoids, oxygen radicals and acute phase proteins (Dohoo and Leslie, 
1991). These chemoattactants then stimulate polymorphonuclear neutrophils (PMNs), 
attracting them to migrate to the sites of infection. At the sites of infection, PMNs 
release hydroxyl and oxygen radicals thus destroying the bacteria and some of the 
epithelial cells. Enzymes such as LDH and NAGase are also released by leukocytes and 
epithelial cells during this process (Viguier et al., 2009). 
 
1.4.3 Types of mastitis  
Mastitis generally can be classified into two major groups: contagious mastitis and 
environmental mastitis. Contagious mastitis is the major type, which is caused by the 
infection by bacteria near the teat canal or inside the canal. This type of infection can be 
transmitted between cows during milking. In contrast, environmental mastitis is caused 
by pathogens from a contaminated environment, for example, from bedding or feeding 
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materials. This is a minor source of infection and it is only accounts for around 10% of 
the total incidence of mastitis.    
 
Contagious mastitis can be subdivided into three groups: clinical mastitis, sub-clinical 
mastitis and chronic mastitis (Table 1.5). For clinical mastitis, visible indications can be 
observed from either the infected grand, the milk or from systemic symptoms 
(temperature, lost of weight), whereas, no obvious changes can be observed for 
sub-clinical mastitis and chronic mastitis. Clinical mastitis is further divided into 
pre-acute, acute and sub-acute mastitis based on the visible indications.      
Table 1.5. Classification and characterisation of contagious mastitis 
       Contagious mastitis       Characterisation 
Clinical mastitis 
  
 
- Pre-acute mastitis  
 Can be identified by the appearance of 
inflammation in the udder, such as 
redness and swelling 
 Changes in milk appearance (watery, 
flaky, clotting) 
 Symptoms of cows: fever, low appetite, 
lost of weight 
- Acute mastitis  Still have visible signs of udder  
inflammation and alternations in milk 
appearance 
 Have less symptoms  
- Sub-acute mastitis  Have minimum inflammation of udder 
 Have no visible symptoms 
Sub-clinical mastitis  Have no visible signs of udder 
inflammation  
 Have no visible systemic symptoms 
Chronic mastitis  Long-term infection process may last for 
months 
 No visible signs of udder inflammation, 
milk appearance and symptoms  
(Based on references: Erskine et al., 1988; Hogeveen, 2005; Abdel-Rady and Sayed, 
2009) 
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1.4.4 Current detection approaches for sub-clinical mastitis  
A number of approaches have been developed for the detection of sub-clinical mastitis 
and the majority of the approaches are based on the measurement of the number of 
somatic cells. Somatic cells, also termed white blood cells or leucocytes, play an 
important role in the immune response to infection with mastitis. Somatic cells can 
minimise bacterial infection and eventually eliminate the infection by phagocytosis. 
Somatic cell count (SCC) represents the number of somatic cells in milk samples, and it 
is reported as cells per ml of milk. SCC levels in milk can be used for detecting 
sub-clinical mastitis in cows (Fosmire and Timasheff, 1972). It is suggested that if the 
SCC exceeds 200,000 cells/mL in a milk sample, the udder quarter is likely to be 
infected by mastitis-causing pathogens (Fox and Kelly, 2006). Currently, a number of 
tests, base on SCC levels, are widely used for the diagnosis sub-clinical mastitic udders. 
These include, for example, the Portacheck® milk test, the FossomaticTM SCC test and 
the California Mastitis Test (CMT).  
 
The Portacheck® milk test is a portable assay kit. It contains the PortaSCC® digital reader 
that can be used to conduct a ‘cow-side’ determination of SCC within 45 minutes. In 
this test, enzymes found in the somatic cells can react with a dye on the test strip 
provided in the kit. The reaction turns the test strip from pink to blue; the darker the 
blue colour, the higher the SCC levels. The darkness of colour can then be determined 
using the PortaSCC® digital reader. The digital reader correlates the darkness of the colour 
to SCC and the reader output shows the SCC levels in milk samples. The Portacheck® 
milk test is widely used for the determination of SCC due to its low cost. However, it 
has limited sensitivity when SCC levels are low (Viguier et al., 2009). 
  
In comparison to Portacheck® milk test, the FossomaticTM SCC has higher sensitivity. It 
is based on the measurement of optical fluorescence levels which are generated from the 
47 
 
interaction between ethidium bromide and nuclear DNA of somatic cells (Gonzalo et al, 
2003). The detection is rapid and automated, however, the device is expensive and it is 
limited in relation to ‘on-site’ diagnosis.  
 
The California Mastitis Test (CMT) is also based on the detection of SCC. The test 
reagents in CMT are bromocresol purple-containing detergents. They can disrupt the 
cell membrane of somatic cells, and subsequently interact with the DNA of somatic 
cells thus forming a ‘gel-like’ matrix. The size of the gel is proportion to the quantity of 
somatic cell present (Schalm and Noorlander, 1957). Although the gel-forming reaction 
only takes 10 seconds, the gel matrix disappears within 20 seconds. Therefore, the 
output data needs to be recorded immediately. This test is simple, inexpensive, rapid 
and is capable of being used ‘on-site’. However, repeated tests may be required to 
obtain accurate data. 
       
1.4.5 Enzymatic biomarkers for mastitis 
Currently available assays for the detection of sub-clinical mastitis usually involve the 
determination of SCC as described in section 1.4.4. Compared to the SCC-based tests, 
antibody-based diagnostic approaches offer a number of distinct advantages. Antibodies 
involved in an immunoassay are developed against a specific antigen and, therefore, the 
assay is generally highly specific. Furthermore, a wide range of detection methods can 
be applied in the immunoassay, including enzymatic, radioactive-labeling, fluorescence, 
luminescence and electrochemical approaches. The antibody-antigen interactions can 
also be incorporated into different assay platforms such as lateral flow strips, ELISA, 
BiacoreTM chips or immuno-PCR. N-acetyl-β-D-glucosaminidase (NAGase) and Lactate 
dehydrogenase (LDH) are enzymes released by damaged epithelial cells and leukocytes 
from the mammary gland. Both the LDH and NAGase may have potential as 
biomarkers for detection of sub-clinical mastitis (Zank and Schlatter, 1998).  
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NAGase hydrolyses N-acetyl-β-D-glucosamine residues from 
N-acetyl-β-D-glucosaminides, including glycoproteins and fragments of chitin. NAGase 
has two isoforms Hex A and Hex B. Hex A has a molecular weight 118 kDa and Hex B 
has a molecular weight 234 kDa (Friggens et al., 2007). NAGase activity in milk was 
determined using a fluorometric assay (Guilbault, 1975; Kitchen et al., 1984). However, 
Chagunda and co-workers (2006) found that NAGase may be less reliable than LDH as 
a marker of mastitis (Chagunda et al., 2006).  
 
1.4.6 Lactate dehydrogenase (LDH)  
LDH is a ubiquitous enzyme which can be found in the cytoplasm of all cells and 
tissues in animals, as well as in yeasts and bacteria. It has five isoforms (LDH-1 to 
LDH-5) which are composed of combinations of two different subunits (Babaei et al., 
2007), each with a molecular weight of 35 kDa (Bakuev et al., 1972, Huston et al., 
1972). The two forms of subunits of LDH are M and H (Bansal et al., 2005). They are 
encoded by two different genes. Gene LDHA located on chromosome 11p15.4 encodes 
subunit M. Gene LDHB located on chromosome 12p12.2-p12.1, encodes subunit H. 
LDH-1 contains 4H subunits and is found in the heart. LDH-2 contains 3H subunits and 
1M subunit and is the predominant form in serum. LDH-3 contains 2H subunits and 2M 
subunits and is found in the lungs. LDH-4 consists of 1H and 3M subunits and is found 
in the kidneys and LDH-5 consists of 4M subunits and is found in the liver. The 
isoforms differ in catalytic, physical and immunological properties (Chagunda et al., 
2005).  
 
In living cells, LDH catalyses the reversible conversion of pyruvate to lactic acid in the 
absence of oxygen using nicotinamide-adenine dinucleotide (NADH) as a co-substrate. 
The equilibrium of this reaction strongly favours the reduction reaction, where pyruvate 
is converted to lactate (Drent et al., 1996)  
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Normally, damage of body tissues can cause the increase of LDH levels in serum. LDH 
and its isoforms have been used as biomarkers for the detection of a number of diseases, 
such as cardiac necrosis (section 1.2.1) and lung inflammation (Drent et al., 1996).  
 
The stability of LDH in serum was studied by Jacobs and co-workers (Jacobs et al., 
1986). They found LDH-1 was stable at 25°C, 4°C and −20°C with less than 10% loss 
of activity. In contrast, LDH isoforms, -2 to 5, were stable at 4°C. Interestingly, they 
also reported that LDH-containing serum should be stored either frozen or at room 
temperature but not in a refrigerator (Jacobs et al., 1986). Milk is a different matrix to 
serum, so the effects of storage temperature and storage time period on LDH stability in 
milk samples were investigated in this study.  
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1.5 Research aims 
The first aim of the project was to generate and characterise recombinant antibodies 
against cardiac troponin T. Chickens were selected as the host for immunisation due to 
their phylogenetic distance from humans in order to generate a diverse anti-troponin T 
antibody library. Both phage display selection and automated high throughput screening 
technologies were used for the selection of specific antibodies and their characterisation. 
Affinity maturation of selected antibodies by heterogeneous chain shuffling yielded 
novel panels of recombined fragments with improved binding characteristics that were 
analysed by biomolecular interaction analysis technology. Antibodies produced in this 
project will eventually be integrated, with other anti-CVD biomarker antibodies, for the 
development of a multi-analyte CVD point-of-care device (e.g. an array or biochip).  
 
The standard method for diagnosis of mastitis is to measure the somatic cell count in 
milk. However, this technique is limited in detection sensitivity for routine use in herds. 
In recent decades, indigenous L-lactate dehydrogenase (LDH) in milk has attracted 
much attention as a potential indicator of mastitis. The second aim of this project was to 
identify the effectiveness of LDH as a mastitis biomarker by measuring its levels in 
both healthy and mastitic milk samples using a standardized fluorescence-based assay. 
The correlation of LDH levels with other markers of mastitis (SCC and NAGase) in 
milk samples was also to be analysed. Moreover, the effect of storage and handling on 
LDH activity in milk samples was also investigated.  
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Chapter 2 
Materials and Methods  
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2.1 Materials  
The materials section consists of reagents, consumable labware, commercial kits, 
culture compositions, buffer compositions and bacterial strains.  
 
2.1.1 Reagents 
All reagents were of analytical grade and purchased from Sigma-Aldrich Ireland Ltd. 
(Dublin, Ireland). Reagents were purchased from other suppliers are listed in Table 2.1.  
Table 2.1. Reagents used and their suppliers  
Reagents Suppliers 
Human cardiac troponin T  
Human skeletal troponin T   
Human cardiac troponin I   
Human skeletal troponin I                                 
Life Diagnostics, Inc.,                                                                              
West Chester PA 19380,                                                                             
USA. 
Mouse anti-cTnT  
monoclonal antibody     
HyTest Ltd., 
Joukahaisenkatu 6, 
20520, Turku, Finland. 
Mouse anti-M13 monoclonal 
antibody, HRP conjugated 
GE Healthcare Bio-Sciences AB, 
SE-751 84 Uppsala,  
Sweden. 
Mouse anti-HA monoclonal 
antibody, HRP conjugated 
Roche Diagnostics Ltd., 
Grenzacherstrasse 124, 
Basel 4070, Switzerland. 
Rabbit anti-HA epitope tag  
polyclonal antibody 
Thermo Fisher Scientific, 
25/28 North Wall Quay, 
Dublin 1, Ireland.  
Bacteriological agar 
Yeast extract 
Cruinn Diagnostics Ltd.,  
Hume Center, Parkwest Business Park,  
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Typtone Nangor Road, Dublin 12, Ireland.  
Chicken PCR primers Eurofins MWG Operon, 318 Worple Road, 
Raynes Park, London,  
SW 20, 8QU, UK.  
T4 DNA ligase 
M13KO7 Helper phage 
AluI/SfiI restriction enzymes 
ISIS Ltd., Unit 1 & 2, Ballywaltrim Business 
Centre, Boghall Road, Bray, 
Co. Wicklow, Ireland. 
Deoxynucleotide Triphosphates (dNTP) 
Go Taq
®
 DNA polymerase 
Fusion Taq
®
 DNA polymerase 
Medical Supply Company Ltd., 
Damastown, Mulhuddart, 
Dublin 15, Ireland. 
RNaseZAP
®  
solution 
Sodium acetate (3M, pH 5.2) 
 
Applied Biosystems/Ambion. Inc., 
Lingley House, 
120 Birchwood Boulevard, Warrington,  
WA3 &QH, UK 
Pellet paint
®
 NF co-precipitant Merck Millpore Ltd.,  
4045 Kingswood Road, 
Citywest Business Campus, 
Dublin 24, Ireland. 
Industrial methylated spirits (IMS) Lennox Laboratory Supplies Ltd.,  
John F. Kennedy Drive,  
Naas Road, Dublin 12, Ireland. 
PageRuler
TM 
Plus Prestained  
Protein ladder 
VWR International Ltd., 
Orion Business Campus,  
Northwest Business Park, Ballycoolin, 
Dublin 15, Ireland. 
Platinum HIFI
TM 
Taq DNA polymerase 
TRIzol
®
 reagent 
Bio-sciences,  
Crofton, Dun Laoghaire, 
Co. Dublin, Ireland. 
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Ni-NTA agarose resin Qiagen, 
28159 Avenue Stanford, 
Valencia, CA 91355, USA. 
      
2.1.2 Consumables  
Consumables section describes disposable labware and the supplier information.  
Table 2.2. Laboratory consumables and suppliers  
Consumables Suppliers 
Plastic labware,  
(Eppendorf tubes, PCR tubes,  
Sterile polypropylene centrifuge  
tubes, Pipette tips, Petri dishes)                                                                     
Sarstedt, 
Sinnottstown, Drinagh, 
Co. Wexford. 
‘RNase-free’ Oakridge tubes  Applied Biosystems/Ambion. Inc., 
Lingley House, 
120 Birchwood Boulevard, Warrington,  
WA3 &QH, UK. 
Immuno 96 MicroWell
TM 
 
solid plates                                     
Nunc, 
Kamstrup DK, Roskilde, 
Denmark. 
F96 MicroWell
TM
 polystyrene  
black plates  
Bio-Sciences Ltd.,  
Dun Laoghaire,  
Co. Dublin, Ireland. 
Biacore
TM
 CM5 sensor chips,   
Vivaspin™ concentrators                                
GE Healthcare Bio-Sciences AB, 
SE-751 84 Uppsala, 
Sweden.  
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2.1.3 Commercial kits  
Various commercial kits used for recombinant antibody library generation and their 
suppliers are listed in Table 2.3. 
Table 2.3. Commercial kits and suppliers  
Commercial kits Suppliers 
Superscript™ III reverse transcriptase kit Invitrogen Corporation, 
5791 Van Allen Way, 
Carlsbad, CA 92008, USA . 
Perfectprep Gel Cleanup Kit Eppendorf AG, 
Barkhausenweg 1, 
Hamburg 22339, 
Germany. 
Wizard Plus SV Miniprep™ kit 
Wizard™ PCR clean-up kit 
Promega, 
2800 Woods Hollow Road, 
Madison, WI 53711, 
USA. 
QIAquick™ gel extraction Kit 
 
Qiagen, 
28159 Avenue Stanford, 
Valencia, CA 91355,  
USA. 
Amine coupling kit GE Healthcare Bio-Sciences AB, 
SE-751 84 Uppsala, 
Sweden.  
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2.1.4 Composition of culture media 
Culture media and their components are listed in Table 2.4. 
Table 2.4. Components of culture media  
Super Broth (SB) Media                 Mops                              10 g/L 
 Yeast Extract                30 g/L 
 Tryptone                  20 g/L 
           
Terrific Broth (TB) Media           Tryptone                        12 g/L 
 Yeast Extract                24 g/L 
 Glycerol                   4 mL 
The constituents were dissolved in 900 mL of molecular grade water and autoclaved. The 
final volume was adjusted to 1 L with 100 mL of a sterile filtered solution of 0.17 M 
KH2PO4 and 0.72 M K2HPO4.    
 
 
2 x Tryptone-Yeast Extract (TYE) Media           Tryptone                        16 g/L 
 Yeast Extract                10 g/L 
 NaCl                  5 g/L 
 
100 x 5O5 media           Glycerol                       50% (v/v) 
 Glucose             5% (w/v) 
SOC Media           Tryptone                        20 g/L 
 Yeast Extract                  5 g/L 
 NaCl                   0.5 g/L 
 KCl                              2.5 mM 
 MgCl2                                        20 mM 
 Glucose                         20 mM 
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2.1.5 Composition of buffers 
This section describes the constituents of various buffers used in this study. 
Table 2.5. Components of buffers  
Phosphate buffered saline (PBS)            NaCl                                8 g/L 
The pH of the solution was adjusted to 7.4  Na2HPO4                     1.44 g/L 
with 1M HCl, and it with then filtered and 
degassed prior to use 
KH2PO4  
KCl                     
0.24 g/L 
0.2 g/L 
                             
Phosphate buffered saline Tween (PBST)            NaCl                                8 g/L 
 Na2HPO4                     1.44 g/L 
The pH of the solution was adjusted to 7.4 KH2PO4                      0.24 g/L 
with 1M HCl, and it then filtered and 
degassed prior to use 
KCl  
Tween 20                               
0.2 g/L 
0.05% (v/v) 
 
Hepes buffered saline (HBS) HEPES                         2.38 g/L 
The pH of the solution was adjusted to 7.4 NaCl                             8.77 g/L 
with 1M HCl, and it was then filtered and 
degassed followed by addition of Tween 20 
EDTA  
Tween 20                          
1.27 g/L 
0.5 mL 
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Table 2.6. Components of buffers for SDS-PAGE and Western blotting 
1M Tris-HCl solution            Trizma base                             121.14 g /L 
 Molecular grade water to 1L 
Trizma base was dissolved in 1 L of molecular grade water and it was aliquoted into three 
clean bottles. The pH of each solution was adjusted to 6.8, 8.3 or 8.8, and they were then 
filtered and degassed prior to use 
 
0.5 M Tris-HCl solution            Trizma base                             60.57 g /L 
 Molecular grade water   to 1L 
Trizma base was dissolved in 1 L of molecular grade water. The pH was adjusted to 6.8 with 
1M HCl , and it was then filtered and degassed prior to use 
 
12.5% (v/v) Separation gel 1 M TrisHCl (pH 8.8)   1.5 mL 
 30% (w/v) acrylamide (Acrylagel)  2.5 mL 
 2% (w/v) methylamine bisacrylamide                                            1.0 mL
 10% (w/v) sodium dodecyl sulfate (SDS)      30 μL 
 10% (w/v) ammonium persulphate (APS) 30 μL 
 TEMED       6 μL 
 Molecular grade water                934 μL 
 
5% (v/v) Stacking gel  1 M TrisHCl (pH 6.8)    250 μL 
 30% (w/v) acrylamide (Acrylagel)  375 μL 
 2% (w/v) methylamine bisacrylamide  150 μL 
 10% (w/v) sodium dodecyl sulfate        25 μL 
 10% (w/v) ammonium persulphate (APS) 25 μL 
 TEMED    5 μL 
 Molecular grade water                1.67 mL 
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SDS - PAGE gel loading buffer (4 x) 10 mL 
0.5M Tris HCl (pH 6.8) 2.5 mL 
20% (v/v) glycerol  2.0 mL 
5% (v/v) 2-mercaptoethanol 0.5 mL 
20% SDS (w/v) 2.5 mL 
Bromophenol blue 20 ppm 
Molecular grade water  2.5 mL 
 
     
 
 
  
10 x electrophoresis buffer         1M Tris HCl (pH 8.3)                              30 g/L 
 Glycine                                               144 g/L
 SDS                                                      10 g/L 
 Molecular grade water  to 1L 
Transfer buffer         1M Tris HCl (pH 8.3)                           30 g/L 
 Glycine                                               144 g/L
 SDS                                                      10 g/L
 20% (v/v) methanol 200mL 
 Molecular grade water  to 1L 
Coomassie stain dye 500 mL 
Coomassie blue R-250                                                 1 g 
45% (v/v) methanol 225 mL 
Acetic acid (17.46 M, 1.05g/mL)                50 mL 
Molecular grade water  225 mL 
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Table 2.7. Components of buffers used for immobilised metal ion affinity 
chromatography (IMAC) 
100mM Sodium Hydroxide (NaOH)            NaOH                                4 g/L 
NaOH (0.4 g) was dissolved in 10 mL of molecular grade water and the solution was filtered 
and degassed prior to use 
 
100mM Sodium Acetate (pH 4.4)          CH3COONa                                8.2 g/L 
Sodium Acetate (0.82 g) was dissolved in 100 mL of molecular grade water. The pH was 
adjusted to 4.4 with 1 M HCl, and it was filtered and degassed prior to use 
 
 
 
Coomassie destain 1 L 
Acetic acid (17.46 M, 1.05g/mL)                                     250 mL 
20% (v/v) methanol 250 mL 
Molecular grade water  500 mL 
Sonication buffer   100 mL 
150 mM PBS                                       100 mL 
NaCl (0.03g/mL) 2.92 g 
Imidazole (1.36g/L) 0.136 g 
Running buffer   100 mL 
150 mM PBS                                       99 mL 
NaCl (0.03g/mL) 2.92 g 
Imidazole (1.36g/L) 0.136 g 
1% (v/v) Tween-20 1 mL 
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2.1.6 Bacterial strains 
This section describes two bacterial strains used for cloning and expression. Both strains 
were purchased from Stratagene, La Jolla, California, USA (Table 2.8). 
Table 2.8. E.coli strains used for antibody cloning and expression 
E.  coli XL1-Blue strain: recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F′ proAB 
lacI
qZ∆M15 Tn10 (TetR)]. 
E.  coli TOP10 F strain: {lacIq, Tn10(TetR)} mcrA ara-leu)7697 galU galK rpsL (StrR) endA1 nupG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Elution buffer   1 mL 
100 mM NaOH                                      500 μL 
10 x PBS (pH 7.4) 500 μL 
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2.2 Equipment 
The standard equipment used in this study and supplier information are listed in Table 
2.9.  
Table 2.9. Laboratory equipment and the suppliers 
Equipment Supplier 
Balances (Chyo JK-180, Mettler PJ300) Medical Supply Company Ltd.,  
Damastown, Mulhuddart, 
Dublin 15, Ireland. 
Biacore
 TM
 3000 
Biacore
 TM
 4000 
GE Healthcare Bio-Sciences AB, 
SE-751 84 Uppsala,  
Sweden. 
Biometra TGRADIENT PCR machine, 
Sanyo Gallenkamp orbital shaker 
(D070022)  
 
ABG Scientific Ltd., 
Orion Business Campus,  
Northwest Business Park, Ballycoolin, 
Dublin 15, Ireland. 
DNA gel electrophoresis apparatus  Alpha Technologies,  
The Leinster Technology Centre,  
Blessington Industrial Estate, 
Co. Wicklow, Ireland. 
Gene Pulser Xcell ™ electroporation system Alpha Technologies,  
The Leinster Technology Centre,  
Blessington Industrial Estate, 
Co. Wicklow, Ireland. 
Nanodrop™ ND-1000 NanoDrop Technologies, Inc., 
3411 Silverside Rd 100BC,  
Wilmington,  
DE19810-4803, USA. 
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PortaSCC
®
 digital reader PortaCheck Inc., 
1 Whittendale Drive, Suite E Moorestown, 
NJ 08057, USA. 
PX2 thermal cycler Thermo Electron Corporation,  
81 Wyman Street, Waltham,  
Massachusetts (MA), 02454, USA. 
Roller mixer SRT1 Sciencelab, Inc., 
14025 Smith Road, 
Houston, Texas 77396, USA. 
Safire2
TM
 microplate reader Tecan Group Ltd.,  
Seestrasse 103, 
CH-8708 Männedorf, Switzerland. 
SDS Bio Rad min-Protean
® 
3 cell, 
Trans-Blot
®
 SD Semi-Dry Transfer, 
Bio-Rad Powerpac
TM 
(Basic) 
Alpha Technologies,  
The Leinster Technology Centre,  
Blessington Industrial Estate, 
Co. Wicklow, Ireland. 
Vibra Cell™ sonicator (VC50) Sonics and Materials Inc., 
53 Church Hill Road, 
Newtown, 
CT 06470-1614, USA. 
Eppendorf benchtop centrifuge (5810R), 
Eppendorf microcentrifuge (5417R) 
 
VWR International Ltd., 
Orion Business Campus,  
Northwest Business Park, Ballycoolin, 
Dublin 15, Ireland. 
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2.3 Methods 
2.3.1 Generation of avian anti-cTnT scFv antibody fragments 
2.3.1.1 SDS-PAGE analysis of commercial cTnT antigen 
SDS-PAGE gel analysis was used to detect the purity of commercial preparations of 
cTnT antigen. Human cTnT (1.92 mg/mL) was purchased from Life Diagnostics Inc. 
(USA). The cTnT antigen was diluted 1 in 10, 1 in 20 or 1 in 40 with 1 x PBS (pH 7.4). 
SDS-PAGE gel loading buffer was added to the cTnT samples followed by boiling at 
95oC for 5 minutes. The samples were then analysed on a 12.5% (v/v) SDS-PAGE gel. 
The remaining cTnT was aliquoted into sterile PCR tubes and stored at -80oC.    
 
2.3.1.2 Immunisation of chicken with cTnT antigen 
The animal handing procedure was approved by the Ethics Committee at Dublin City 
University (Dublin, Ireland) and licensed by the Irish Department of Health and 
Children (Dublin, Ireland). All experiments were performed ensuring that the animals 
suffered minimum stress.  
 
A white male Leghorn chicken, aged 4-5 weeks, was injected with cTnT antigen over a 
period of two months. A pre-bleed was collected 7 days prior to the immunisations. The 
chicken was initially injected with a final concentration of 200 µg/mL cTnT, mixed in a 
1:1 ratio with Freund’s complete adjuvant. The immunogen was vigorously shaken to 
ensure the formation of a completely homogenous emulsion. Subsequent immunisations 
with 100 µg/mL cTnT mixed with equal volume of Freund’s incomplete adjuvant were 
given at two weeks intervals. A bleed was taken from the chicken 7 days after the fourth 
boost and the serum anti-cTnT titre was determined by ELISA. The chicken was given 
the final boost when the titre reached a sufficient level; it was sacrificed 7 days after the 
last immunisation. 
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2.3.1.3 Determination of the serum anti-cTnT antibody titres  
The avian polyclonal serum was analysed using a direct ELISA to determine its titre 
against cTnT antigen. An immuno 96 MicroWellTM solid plate (Nunc, Denmark) was 
coated with 1µg/mL cTnT for 1 hour at 37oC. The plate was blocked with 5% (w/v) 
Milk Marvel in 1 x PBS (pH 7.4) for 1 hour at 37oC. The plate was washed once with 1 
x PBST (pH 7.4) and once with 1 x PBS (pH 7.4). A series of chicken serum dilutions 
from neat to 1 in 1,000,000 was prepared in 1xPBST (pH 7.4). Each dilution (100 µL) 
were added to the ELISA plate in triplicate and incubated for 1 hour at 37oC. The plate 
was washed twice with 1 x PBST (pH 7.4) followed by twice with 1 x PBS (pH 7.4). 
Rabbit anti-chicken IgY conjugated to horseradish peroxidase (HRP) was diluted 1 in 
2000 with 1 x PBS and 100µL of the dilution was added to the plate. After a 1 hour 
incubation at 37oC, the plate was washed 3 times with 1 x PBST (pH 7.4) and 1 x PBS 
(pH 7.4). HRP TMB substrate (100 L) was added to each well and the plate was 
incubated for 10 minutes at 37oC. The reaction was stopped by the addition of 100 µL 
of 10% (v/v) HCl. The absorbance levels of the wells were determined at 450 nm using 
a Safire2TM microplate reader (Tecan, Switzerland). 
 
2.3.1.4 Extraction of total RNA from the immunised chicken 
A Laminar flow hood (Gelaire BSB 4) was thoroughly cleaned with 70% (v/v) 
industrial methylated spirits (IMS, Lennox, Ireland) and RNaseZAP® (Ambion, UK) to 
create an ‘RNA-free’ environment. Surgical tools and a homogeniser (Ultra-Turrax, 
model TP 18/10, IKA® Werke GmbH & Co. KG, Germany) were autoclaved and baked 
overnight at 180oC to ensure sterility. The immunised chicken was sacrificed by 
cervical dislocation. The spleen was transferred into 10 mL pre-chilled TRIzol® reagent 
(Invitrogen, USA) and thoroughly homogenised at 50% power output for 1 minute. The 
bone marrow from the chicken was washed out with 10 mL of chilled TRIzol® reagent 
using a sterile needle and syringe. Both samples were incubated at room temperature for 
5 minutes followed by centrifugation (Eppendorf benchtop centrifuge 5810R, VWR, 
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Ireland) at 5,500 g for 10 minutes at 4oC in a pre-chilled rotor. The supernatants were 
carefully transferred to ‘RNase-free’ Oakridge tubes (Ambion, UK) and 3 mL of 
chloroform was added into each tube. Both samples were mixed vigorously and 
incubated at room temperature for 15 minutes followed by centrifugation (Eppendorf 
microcentrifuge 5417R, VWR, Ireland) at 19,500 g at 4°C for 15 minutes. The samples 
were separated into a lower phenol/chloroform phase, an interphase containing DNA 
and protein and an upper aqueous phase containing RNA. The upper aqueous phase was 
carefully transferred to a fresh ‘RNase-free’ Oakridge tube and 15 mL of propan-2-ol 
was added into each sample. The tubes were shaken vigorously for 15 seconds and 
incubated at room temperature for 10 minutes for RNA precipitation. Samples were 
centrifuged at 19,500 g at 4°C for 30 minutes, resulting in a white ‘gel-like’ RNA pellet. 
The pellet was washed with 30 mL of 75% (v/v) ethanol and centrifuged at 19,500 g at 
4°C for 10 minutes in a pre-chilled rotor. The supernatant was carefully removed and 
the RNA pellet was air-dried for 5 minutes in a laminar hood. The pellet was finally 
resuspended in 250 μL of ‘RNase-free’ water. RNA concentrations were measured by 
spectrophotometric measurement at 260 nm with a NanoDropTM spectrophotometer 
ND-1000 (Thermo Fisher Scientific, USA). 
 
2.3.1.5 Reverse transcription of total RNA to cDNA 
A fresh aliquot of the total RNA was immediately reverse transcribed into cDNA using 
an oligo-(dT) primer and a SuperScriptTM III First-Strand Synthesis System (Invitrogen, 
USA). All components were kept on ice throughout the experiments. A 10 x master 
mixture 1 was prepared with the components listed below (Table 2.10). Mixture 1 (25 
μL) was aliquoted into 8 ‘RNAase-free’ PCR tubes followed by incubation at 65°C for 
5 minutes (Biometra TGRADIENT PCR machine, Labrepco, USA). The mixture was then 
incubated on ice for 1 minute.  Mixture 2 (25 µL) (Table 2.11) was added to the 8 
tubes containing mixture 1 and then incubated at 50°C for 50 minutes, followed by 
85°C for 5 minutes. RNase H (5 μL) was then added to each tube. The tubes were 
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incubated at 37°C for 20 minutes. The cDNA was aliquoted into sterile tubes and stored 
at −20°C. 
 
Table 2.10. Composition of mixture 1 for reverse transcription reaction 
 
Table 2.11. Composition of mixture 2 for reverse transcription reaction 
 
2.3.1.6 PCR primers for the generation of avian scFv antibodies 
The sets of primer sequences listed in Table 2.12 were used to generate a chicken scFv 
library with a 15 amino acid residue (Gly4Ser)3 linker. All primers were purchased from 
Eurofins MWG Operon (London, UK) and were immediately aliquoted into sterile 
tubes after delivery and subsequently stored at -20oC. 
 
Mixture 1 - components Stock concentration Volume per reaction 
RNA 15.5 μg/μL 0.32 μL (to give 5 μg) 
Oligo-dt 50 μM 1 μL 
dNTPs 10 mM 1 μL 
Sterile H2O ------ 7.68 μL 
Total Volume  10 μL 
Mixture 2 - components Stock concentration Volume per reaction 
RT buffer 10 x 2 μL 
MgCl2 25 mM 4 μL 
DTT 10 mM 2 μL 
RNase OUT 40 U/μL 1 μL 
Superscript™ III RT 200 U/μL 1 μL 
Total Volume  10 μL 
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Table 2.12. Primer sequences for the amplification of avian scFv gene fragments 
 
2.3.1.7 Amplification of variable chains for the generation of avian anti-cTnT scFv 
antibodies 
The PCR components of the VH and VL amplification listed in Table 2.13. The volume 
of one reaction was 50 µL. Four amplification reactions were performed to ensure 
sufficient VH and VL genes for the SOE-PCR (section 2.3.1.9). 
 
 
 
 
Variable heavy chain (VH) primers 
CSCHo-F (sense), long 
Linker 
5′ GGT CAG TCC TCT AGA TCT TCC GCC GTG AC GTT GGA 
CGA G 3′ 
CSCG-B (reverse)   5′ CTG GCC GGC CTG GCC ACT AGT GGA GGA GAC GAT 
GAC TTC GGT CC 3′ 
Variable light chain (VL) primers 
CSCVK (sense)  5′ GTG GCC CAG GCG GCC CTG ACT CAG CCG TCC TCG 
GTG TC 3′ 
CKJo-B (reverse)   5′ GGA AGA TCT AGA GGA CTG ACC TAG GAC GGT CAG G 
3′ 
Overlap extension primers 
CSC-F (sense) 5′ GAG GAG GAG GAG GAG GAG GTG GCC CAG GCG GCC 
CTG ACT CAG 3′ 
CSC-B (reverse)   5′ GAG GAG GAG GAG GAG GAG GAG CTG GCC GGC CTG 
GCC ACT AGT GGA GG 3′ 
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Table 2.13. Composition of PCR reaction mixture used for the amplification of the 
variable domains 
PCR component Concentration in  
50 µL reaction 
Volume of  
each component 
cDNA template  1µL 
5 x Go Taq
®
 buffer 1x 5µL 
VL/VH sense primer 60pM 0.6µL 
VH/VL reverse Primer 60pM 0.6µL 
dNTP (10 mM) 0.2mM 1µL 
Go Taq
®
 Polymerase 1U/µL 0.25µL 
MgCl2 (25 mM) 2mM 4µL 
H2O ------ 37.55µL 
Total volume  50µL 
 
The amplification of the VH and VL domains was performed in a Biometra TGRADIENT 
PCR machine under the following conditions: 
Stage Cycle Temperature
 
(
o
C) Time (sec) 
1) Initial denaturation 1 94oC 300 
2) Denaturation 30 94oC 15 
   Annealing  56oC 90 
   Extension  72oC 90 
3) Final extension 1 72oC 600 
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2.3.1.8 Isolation of the variable heavy and variable light gene fragments  
The amplified PCR products were evaluated on a 1% (w/v) agarose gel and extracted 
with the QIAquick™ gel extraction Kit (Qiagen, USA) and Wizard® PCR ‘clean-up’ system 
kit (Promega, USA). The gel fragments of VH (~ 400 bp product) and VL (~ 350 bp 
product) were carefully separated using sterile scalpels and weighed in 1.5 mL 
eppendorf tubes.  
 
Three volumes of binding buffer were added to 1 volume of gel fragment and the gel 
slices were fully dissolved in the binding buffer by incubating at 50°C for 10 to 20 
minutes. The guanidine isothiocyanate contained in the buffer enhances DNA binding 
to the silica membrane columns. The mixture (700 µL) was transferred to a collection 
column and centrifuged (Eppendorf microcentrifuge 5417R, VWR, Ireland) at 19,500 g 
for 1 minute to remove any residual buffer. After the removal of ‘flow-through’, wash 
buffer (750 µL) was added onto the membrane of the QIAquick™ spin column and 
centrifuged at 19,500 g for 1 minute. The washing step was repeated once to ensure the 
maximum removal of salts and other buffer residuals. The DNA was eluted with 30 µL 
molecular grade water by centrifuging at 19,500 g for 1 min. The purified DNA 
concentration was measured at 260 nM using the Nanodrop™ ND-1000 
 
2.3.1.9 Splice by Overlap Extension (SOE) PCR for the construction of anti-cTnT scFv 
gene fragments 
Splice by overlap extension (SOE) primers listed in Table 2.12 were used to link the 
purified VH and VL fragments with a glycine-serine linker (Gly4Ser)3. The fragment was 
analysed on a 1% (w/v) agarose gel and purified as described in section 2.3.1.8. 
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Table 2.14. Components of SOE-PCR reaction mixture used for the amplification 
of scFv fragments 
PCR component Concentration in  
50 µL reaction 
Volume of  
each component 
5 x Go Taq
®
 buffer 1x 5 µL 
VL gene 100 pM 1µL 
VH gene 100 pM 1µL 
MgCl2 (25mM) 3 mM 6 µL 
dNTP (10mM)  0.2 mM 1µL 
CSC-F Primer 60 pM 0.6 µL 
CSC-B Primer 60 pM 0.6 µL 
Go Taq
® 
Polymerase 1U/µL 2 µL 
H2O   ------ 32.8 µL 
Total volume    50 µL 
 
The SOE-PCR was performed in a Biometra TGRADIENT PCR machine under the 
following conditions: 
Stage Cycle Temperature
 
(
o
C) Time (sec) 
1) Initial denaturation 1 94oC 240 
2) Denaturation 24 94oC 30 
   Annealing  56oC 45 
   Extension  72oC 120 
3) Final extension 1 72oC 600 
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2.3.1.10 SOE-PCR restriction digestion and ligation into pComb3XSS vector  
The cloning vector pComb3XSS and the puried scFv fragment were quantified using 
the NanoDropTM ND1000 spectrophotometer with UV absorbance at 260 nM. The SfiΙ 
restriction enzyme was used to digest both the cloning vector pComb3XSS and the 
puried scFv fragment. It recognises the nucleotide sequence 5′ggccnnnn ^ nggcc3′. The 
restriction digestion site within the nucleotides is indicated by the ‘^’symbol. The 
reactions (Table 2.15) were incubated at 50oC for 5 hours. 
 
Table 2.15. Reaction mixture for restriction digestion of pComb vector and 
SOE-PCR product  
   
 
 
 
 
 
 
 
 
 
 
 
The digested pComb3XSS vector (~ 3400 bp) and the scFv fragment (~ 750 bp) were 
evaluated on a 1% (w/v) agarose gel and purified, as described in section 2.3.1.8. DNA 
concentrations of both samples were determined using the NanoDropTM ND1000 
spectrophotometer by measuring O.D. at 260 nm. The scFv fragment was ligated into 
the pComb3XSS vector with a mass ratio of 2:1. The reaction (Table 2.16) was 
incubated overnight at room temperature.  
SOE-PCR product     SfiΙ digest 
Component Volume 
SOE-PCR product         116 µL 
10 x Buffer 2 20 µL 
10 x BSA 20 µL 
SfiΙ 23.4 µL 
H2O 20.6 µL 
Total volume 200 µL 
pComb vector       SfiΙ digest 
Component Volume 
pComb vector 4 µL 
10 x Buffer 2 20 µL 
10 x BSA 20 µL 
SfiΙ 1.2 µL 
H2O 154.8 µL 
Total volume 200 µL 
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Table 2.16. Reaction mixture for ligation of SOE-PCR product into pComb vector  
 
The ligation mixture was precipitated by adding 20 µL sodium acetate (pH 5.2), 400 µL 
100% ethanol and 2 µL of pellet paint® NF co-precipitant. After overnight precipitation 
at -20oC, the solution was centrifuged (Eppendorf microcentrifuge 5417R, VWR, 
Ireland) at 19,500 g for 20 minutes in a pre-chilled rotor. The supernatant was discarded 
and the pellet was washed with 70% (v/v) pre-chilled ethanol. The sample was 
centrifuged at 19,500 g for 10 minutes at 4°C and the pellet was resuspended in 10 µL 
of molecular grade water. The ligation product was stored at 4oC. 
 
2.3.1.11 Electroporation of XL-1 blue E. coli cells with a scFv-containing plasmid 
The scFv-containing pComb3XSS plamid was electro-transformed into 
electrocompetent XL-1 blue E. coli cells (Stratagene, USA) using a Gene Pulser Xcell 
electroporation system (Alpha Technologies, Ireland). The apparatus was set at 25 µF, 
1.25 kV and the Pulse Controller at 200 Ω. Electrocompetent E. coli cells (50 µL) were 
slowly thawed in ice. The ligated product (2 µL) was carefully added to the E. coli cells. 
The mixture was incubated on ice for 1 minute and then immediately transferred to a 
pre-chilled electroporation cuvette (Alpha Technologies, Ireland). The cuvette was then 
Digest component Concentration in 
200 µL volume 
Volume of  
each component 
Digested  
pComb3XSS vector 
1.4 µg/rxn 34.7 µL 
Digested scFv gene 0.7 µg/rxn 4.4 µL 
5 x Ligase buffer                                     1 x 40 µL 
T4 DNA Ligase 400 U/µL 10 µL 
H2O ------ 110.9 µL 
Total volume                                                                                                      200 µL 
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securely placed in the ShockPod. One pulse was passed through the mixture in the 
cuvette chamber and the mixture was immediately flushed with 1 mL of pre-warmed 
SOC medium. The time before addition of SOC medium to the cells was kept to a 
minimum, as a delay of 1 minute can result in a 3-fold decrease in transformation 
efficiency. The mixture was transferred to a 20 mL sterile tube containing 2 mL of 
pre-warmed SOC media and incubated (Sanyo orbital incubator D070022, ABG, 
Ireland) for 1 hour at 37oC while shaking at 220 rpm. The pComb3XSS transformants 
were spread on TYE plates which were supplemented with 100µg/ml carbenicillin and 
1% (v/v) glucose. Commercial XL-1 blue E. coli cells with no transformants were 
plated out in parallel on agar plates containing 100 µg/mL carbenicillin and 1% (v/v) 
glucose as negative controls. The plates were incubated overnight at 37oC. The 
pComb3XSS transformant colonies were scraped off the plates and amplified in super 
broth media. The amplified library was then subjected to the selection of specific 
anti-cTnT antibody through biopanning.  
 
2.3.1.12 Rescue of anti-cTnT scFv-displaying phage 
In the phage rescue process, all glassware and centrifuge tubes were autoclaved and 
baked overnight at 60oC to ensure all containers were completely sterile and dry. A total 
of 200 µL of the potential anti-cTnT scFv library suspension was immediately 
inoculated into two conical flasks after being scraped from overnight plates. Each 
conical flask contained 100 mL pre-warmed sterile Super Broth (SB) media with 100 
µg/mL carbenicillin. These library-containing cultures were incubated at 200 rpm and 
37oC until mid-exponential phase of growth (O.D. ~ 0.400 at 600 nm) was reached. The 
M13KO7 helper phage was then added to the culture to a final concentration of 1 x 1011 
plaque-forming units (pfu)/mL. The cultures were incubated at 37oC for 30 minutes 
while stationary followed by incubation at 200 rpm and 37oC for 2 hours. Subsequently, 
kanamycin (50 µg/mL) was added and the cultures were grown overnight at 30oC while 
shaking at 200 rpm. The culture was transferred into sterile sorval tubes and centrifuged 
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(Eppendorf benchtop centrifuge 5810R, VWR, Ireland) at 5,500 g (4oC) for 15 minutes 
and the bacterial pellet was discarded. For phage propagation, the supernatant was 
transferred into ‘RNase-free’ Oakridge tubes and the phage particles precipitated by the 
addition of 4% (w/v) polyethylene glycol (PEG) 8,000 and 3% (w/v) NaCl. The mixture 
was shaken at 200 rpm for 10 minutes at 37oC to allow the PEG/NaCl to completely 
dissolve. The mixture was precipitated on ice for 1 hour in the cold room (4oC) and 
centrifuged (Eppendorf microcentrifuge 5417R, VWR, Ireland) at 14,000 g for 20 
minutes in a pre-chilled rotor with an extended break for 15 minutes. The 
phage-containing bacterial pellet was resuspended in 2 mL of 1% (w/v) BSA in 1 x PBS 
(pH 7.4) solution and then centrifuged at 19,500 g for 10 minutes at 4oC to remove cell 
debris. Sodium azide (0.05%, w/v) was added to the supernatant as preservative to 
prevent antibody degradation. Sodium azide is a toxic material and hence the handing of 
the sodium azide solution was performed in the fumehood throughout this study. The 
antibody-containing supernatant was stored at 4oC. 
 
2.3.1.13 Selection of avian scFv phage library via biopanning against immobilised 
cTnT 
Eight wells of an immuno 96 MicroWellTM solid plate (Nunc, Demark) were coated 
overnight at 4oC with 100 µL of 50 µg/mL cTnT in 1 x PBS (pH 7.4). The plate was 
blocked with 200 µL of 5% (w/v) Marvel in 1x PBS (pH 7.4) for 1 hour at 37 oC and the 
plate was washed once with 1 x PBST (pH 7.4) and once with 1 x PBS (pH 7.4). 
Rescued phage (100 µL) were added into each well and incubated at 220 rpm for 2 
hours at room temperature. Non-bound phage were washed away with 3 times 1x PBST 
(pH 7.4) and 3 times 1 x PBS (pH 7.4) for round one panning. The numbers of washing 
steps were increased for the following 4 rounds of panning to increase the stringency of 
phage-infected antibody selection. For antigen-binding phage elution, a total of 100 µL 
of 10 mg/mL type II porcine trypsin in 1x PBS (pH 7.4) solution was added into the 
plate and incubated at 37oC for 30 minutes. Sodium azide (2%, w/v) was added into 400 
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µL of the eluted phage as preservative and stored at 4oC. The remaining 400 µL of 
phage were infected into 2 mL of mid-exponential phase XL-1 blue E. coli cells 
(O.D.600 nm ~ 0.4). The cells were incubated for 30 minutes at 37oC without shaking. 
A serial dilution of the phage infected cells ranged from 10-1-10-10 was prepared in 
sterile 2xTY media and spread on 2xTY agar plates, containing 100 µg/mL 
carbenicillin, and incubated overnight at 37oC. The remaining culture was further 
propagated at 200 rpm for 1 h at 37oC. Cells were harvested by centrifugation 
(Eppendorf benchtop centrifuge 5810R, VWR, Ireland) at 5,500 g for 10 minutes at 
4oC. Antibody library were prepared by resuspending the cell pellet in 400 µL of fresh 
2xTY media. The mixture was then spread on TYE plates containing 1% (w/v) glucose 
and 100 µg/mL carbenicillin. Plates were incubated overnight at 37 oC. Input titres were 
determined by infecting mid-exponential growth phase XL-1 blue E. coli cells (180 µL) 
with 20 µL of precipitated phage (stored at 4oC) for 15 minutes at 37oC. Serial dilutions 
were performed (10-1-10-12) and spread on TYE agar plates containing 100 µg/mL 
carbenicillin and incubated overnight at 37oC. 
  
In the subsequent rounds of biopanning (rounds 2-5), growth media (100 mL) was used 
for cell propagation. The concentrations of immobilised antigen on the Immuno 96 
MicroWellTM solid plate surface were reduced. The number of washing steps by 1 x 
PBST (pH 7.4) and 1 x PBS (pH 7.4) were increased. These strategies were employed 
to select specific antigen-binding clones. For the generation of soluble scFv antibodies, 
scFv-phage particles from round four were infected to E. coli Top10-F cells. Volume of 
media for phage propagation, antigen coating concentrations and the number of washing 
steps are shown in Table 2.17. 
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Table 2.17. Biopanning conditions for the selection of anti-cTnT scFvs  
 
Biopanning 
round 
Volume of 
media (mL) 
Immobilised 
antigen (µg/mL) 
No. of wash 
steps 
Infected cell strains 
1 200 50 
3 x PBST, 
3 x PBS 
E. coli XL1-blue 
2 100 25 
5 x PBST, 
3 x PBS 
E. coli XL1-blue 
3 100 10 
5 x PBST, 
5 x PBS 
E. coli XL1-blue 
4 100 5 
7 x PBST, 
5 x PBS 
E. coli XL1- blue 
5 100 2 
7 x PBST, 
7 x PBS 
E. coli Top10-F 
 
2.3.1.14 Soluble expression of anti-cTnT scFv antibodies using a simple ‘on-plate’ 
screening method  
Output phage, from the 5th round of biopanning, were infected into E. coli Top 10F’ 
cells. The cells were then diluted in media and spreaded on agar plates supplemented 
with 50g/mL carbenicillin. After 20 hours incubation at 37oC, a total of 96 single 
colonies from the output titer plates were inoculated into microtitre plate wells 
containing 200 µL of SB broth (10 g/L MOPS, 30 g/L Tryptone and 20 g/L yeast 
extract) supplemented with 50 µg/mL carbenicillin and 10 µg/mL tetracycline and 
grown while shaking at 37oC for 6-8 hours. The culture from each well (20 µL) was 
removed as a master stock and 20 µL of 10 mM IPTG added to the remaining 180 µL of 
culture. The induced culture was immediately transferred to an ELISA plate (Immuno 
96 MicroWellTM solid plate) previously coated with 100 µL/well of a 1 µg/mL cTnT 
solution for 1 h at 37oC and blocked with 3% (w/v) BSA for 1 h at 37oC. The 
culture-containing ELISA plate was incubated overnight at 30oC with agitation. 
Following overnight ‘on-plate’ expression, the cells and culture media were removed by 
washing with PBST (pH 7.4). For the detection of bound antibody, HRP-labelled mouse 
anti-HA monoclonal antibody (Roche) of a concentration of 25 ng/mL (100 µL) was 
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added to each well for 1 h at 37oC and the wells were washed five times with PBST 
prior to the addition of the HRP TMB substrate. This method was published in Journal 
of Immunological Methods (Guo et al., 2010) (see Appendix I). 
 
2.3.1.15 Analysis of anti-cTnT scFv antibodies using direct and inhibition ELISAs 
A direct ELISA was performed to determine the titre of anti-cTnT scFv antibodies 
against cTnT antigen. It was carried out by coating an immuno 96 MicroWellTM solid 
plate overnight at 4oC with 100 L of 1 g/ml cTnT and blocked with 200 L 5% (w/v) 
Marvel in 1 x PBS (pH 7.4) for 1 hour at 37oC. The plate was washed once with 1 x 
PBST (pH 7.4) and once with 1 x PBS. A series of dilutions of crude lysate extracted 
from antibodies (neat, 1 in 5, 1 in 10, 1 in 20, 1 in 16, 1 in 32, 1 in 64, 1 in 128, 1 in 256 
and 1 in 5,120) were prepared in 1 x PBS (pH 7.4) and 100 L of each was added into 
wells in duplicate. The plate was incubated at 37oC for 1 hour. The plate was washed 
twice with 1 x PBST (pH 7.4) and twice with 1 x PBS (pH 7.4). HRP-labelled mouse 
anti-HA monoclonal antibody (25 g/mL) were diluted in 1 x PBS (pH 7.4) and added 
into the plate for 1 hour at 37oC. HRP TMB substrate (100 L) was added to each well 
and the plate was incubated for 10 minutes at 37oC. The absorbance reading was 
determined at 450 nm using a Safire2TM microplate reader. 
 
Inhibition ELISA was performed by coating an immuno 96 MicroWellTM solid plate 
overnight at 4oC with 100 L of 1 g/mL cTnT and blocked with 200 L 5% (w/v) 
Marvel in 1 x PBS (pH 7.4) for 1 hour at 37oC. Various concentrations of cTnT (1 
g/mL, 500 ng/mL, 250 ng/mL, 125 ng/mL, 62.5 ng/mL, 31.25 ng/mL, 15.63 ng/mL 
and 7.81 ng/mL) were prepared in 1 x PBS (pH 7.4) and incubated with a fixed dilution 
of scFv clone for 1 hour at 37oC. HRP-labelled mouse anti-HA monoclonal antibody 
was diluted 1 in 2000 in 1 x PBS (pH 7.4) and added to the plate for 1 hour at 37oC. 
HRP TMB substrate (100 L) was added to each well and the plate was incubated for 
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10 minutes at 37oC. The absorbance values were determined at 450 nm with a Safire2TM 
microplate reader. 
 
2.3.1.16 Purification of anti-cTnT scFv fragments using immobilised metal affinity 
chromatography (IMAC) 
An overnight culture containing scFv (300 mL) was centrifuged (Eppendorf benchtop 
centrifuge 5810R, VWR, Ireland) at 5,500 g for 20 minutes. The cell pellet was 
resuspended in 10 mL of sonication buffer. The mixture was then sonicated at 40% 
amplitude with 6 seconds pulse for 2 minutes and then centrifuged at 19,500 g at 4oC to 
remove cell debris. The clear lysate was filtered with a 2 μm filter consists of 
nitrocellulose membrane (Merck Millipore, Ireland). A 2 mL aliquot of Ni-NTA 
agarose resin (Qiagen, USA) was added to a 20 mL column and equilibrated with 20 
mL running buffer. The filtered lysate was then applied to the equilibrated column and 
the ‘flow-through’ collected in a 50 mL tube. The column was then washed with 30 mL 
of running buffer to remove any loosely bound non-specific proteins and once again the 
‘flow-through’ was collected in a 50 mL tube. The scFv fragment was eluted using 8 
mL of 100 mM NaAc, pH 4.4, and collected in a 50 mL tube containing 2 mL of 100 
mM NaOH and 2 mL of 10 x PBS (pH 7.4). The 12 mL scFv-containing elution 
fragment was then thoroughly buffer exchanged against filtered 1 x PBS (pH 7.4) using 
a 5 kDa cut-off Vivaspin™ concentrators column (GE healthcare, Sweden). The 
buffer-exchanged scFv was then quantified using the Nanodrop™ ND-1000 at 280 nm 
and aliquoted into clean PCR tubes and stored at -20°C. 
 
2.3.1.17 Preconcentration analysis of rabbit anti-HA polyclonal antibody on a 
Biacore
TM
 CM5 sensor chip 
Preconcentration studies was performed to indentify the optimal pH value of sodium 
acetate allowing the maximum immobilisation level of rabbit anti-HA epitope tag 
polyclonal antibody (Thermo Fisher, Ireland) to the carboxy-methylated dextran CM5 
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sensor chip surface (GE healthcare, Sweden). A total of six different sodium acetate 
buffer (10 mM) solutions (pH 5.0, pH 4.8, pH 4.6, pH 4.4, pH 4.2 and pH 4.0) were 
mixed with anti-HA polyclonal antibody for a final antibody concentration of 12.5 
μg/mL. A CM5 sensor chip was activated by passing over a mixture of 400 mM 
1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) (GE Healthcare, 
Sweden) and 100 mM N-hydroxysuccinimide (NHS) (GE Healthcare, Sweden). The 
diluted antibodies were subsequently passed over the surface at a flow rate of 10 
µL/min for 30 seconds.  
 
2.3.1.18 Immobilisation of rabbit anti-HA polyclonal antibody on a Biacore
TM
 
CM5 sensor chip 
A BiacoreTM CM5 sensor chip surface was immobilized with rabbit anti-HA epitope tag 
polyclonal antibody (Thermo Fisher, Ireland) using amine coupling reagents. Hepes 
buffered saline buffer (HBS, pH 7.4) was used as the running buffer throughout the 
experiment. HBS was filtered and degassed before running through the BiacoreTM. The 
dextran surface with initially activated by an injection of the fresh prepared mixture of 
EDC (0.4 M) and NHS (0.1 M), at 1:1 ratio, for 10 minutes. Anti-HA antibody was 
prepared in sodium acetate buffer (pH 4.0) to a final concentration of 25 µg/mL and 
injected over flow cells 1, 2, 4, 5 for 10 minutes at a flow rate of 10 µL/min. Flow cell 3 
was left unmodified as a reference. The residual reactive sites (unbound material) were 
then deactived by injection of 1 M ethanolamine hydrochloride (GE Healthcare, 
Sweden), pH 8.5. The chip surface was regenerated by five injections of 20 mM NaOH. 
 
2.3.1.19 SPR-based kinetic studies of anti-cTnT scFv antibodies 
The kinetic studies were performed on anti-cTnT scFv to assess its antigen binding 
affinity. Anti-HA antibody was diluted in sodium acetate buffer (pH 4.0) and 
immobilised on a BiacoreTM CM5 sensor chip surface (section 2.3.1.18). Anti-cTnT 
scFv antibodies were diluted in 1x HBS and then passed over the chip surface at a rate 
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of 10 µL/min for 2 minutes. CTnT, at a series of concentrations (50 nM, 25 nM, 12.5 
nM, 6.25 nM, 3.125 nM and1.56 nM), was subsequently injected over the chip surface. 
The association phase was processed for 2 minutes and the dissociation phase was 
processed for 10 minutes. The 12.5 nM concentration was run in duplicate. All 
sensorgrams were subjected to fit globally to a 1:1 binding model. The assay format is 
illustrated in Fig.2.1. 
 
1        2        3        4        5
Blank
reference
Active 
Capture
spot
Active 
capture
spot
Capturing 
reference
Capturing 
reference
Flow cell
• cTnT antigen
• mouse anti-HA mAb
• anti-cTnT lysates
 
Figure 2.1. Assay format used for the characterisation of anti-cTnT scFv antibody. 
The five gold circles represent five flow cells (1-5). Flow cells 1, 2, 4, 5 were 
immobilised with anti-HA antibody. The active binding sites of flow cells 2 and 4 were 
deactived using ethanolamine hydrochloride; they are used as capturing references. 
Antibody-containing lysate was passed over flow cells 1 and 5 followed by injecting 
with cTnT antigen. Flow cell 3 was used as blank reference. 
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2.3.2   Affinity maturation of avian anti-cTnT scFv clones by chain-shuffling 
2.3.2.1 Amplification of variable domains of plamids extracted from anti-cTnT 
scFv libraries 
The primers used for the construction of light chain-shuffled antibody library are listed 
in Table 2.18. The variable light (VL) chains were amplified using the plasmid pooled 
from the unpanned library; and variable heavy (VH) genes were amplified using the 
plasmid pooled from the 5th biopanning round. The variable heavy (VH) chains were 
amplified using the plasmid extracted from the unpanned library and variable light (VL) 
genes were amplified using the plasmid pooled from 5th biopanning round. The PCR 
components for VH and VL amplification are described in Tables 2.18 and 2.19, 
respectively.  
 
Table 2.18. Composition of PCR reaction mixture used for the amplification of the 
VH domain 
PCR component Concentration in  
50 µL reaction 
Volume of  
each component  
Plasmid DNA 50 ng 1 µL 
5 x Go Taq
®
 buffer 1 x 5 µL 
VH sense primer 60 pM 0.6 µL 
VH reverse primer 60 pM 0.6 µL 
dNTP (10 mM) 0.2 mM 1 µL 
Go Taq
® 
Polymerase      5U/µL 0.25 µL 
MgCl2 (25 mM) 0.75mM 1.5 µL 
H2O ------ 40.05 µL 
Total volume  50 µL 
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The amplification of the VH gene was performed in a Biometra TGRADIENT PCR machine 
under the following conditions: 
 
Table 2.19. Composition of PCR reaction mixture used for the amplification of the 
VL domain 
 
 
 
 
Stage Cycle Temperature
 
(
o
C) Time (sec) 
1) Initial denaturation 1 94oC 300 
2) Denaturation 30 94oC 15 
   Annealing  58oC 15 
   Extension  72oC 90 
3) Final extension 1 72oC 600 
PCR component Concentration in  
50 µL reaction 
Volume of  
each component 
Plasmid DNA 50 ng 1 µL 
10 x HIFI buffer  1 x 5 µL 
VL sense primer 60 pM 0.6 µL 
VL reverse Primer 60 pM 0.6 µL 
dNTP (10 mM) 0.2 mM 1 µL 
Platinum HIFI ™ Taq 5 U/µL 0.2 µL 
MgCl2 (25 mM) 4 mM 8 µL 
H2O ------ 33.6 µL 
Total volume  50 µL 
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The amplification of the VL gene was performed in a Biometra TGRADIENT PCR machine 
under the following conditions: 
 
2.3.2.2 Splice by Overlap Extension (SOE) PCR for the construction of chain-shuffled 
anti-cTnT scFv gene fragments 
Splice overlapping extension (SOE) primers listed in section 2.3.1.6 were used to link 
the purified VH and VL fragments with a long glycine-serine linker (Gly4Ser)3. The light 
chain-shuffled SOE was generated by linking VL amplified from an unpanned library 
with VH amplified from the 5
th biopanning round. The heavy chain-shuffled SOE was 
generated by linking VL amplified from pan 5 library with VH amplified from an 
unpanned library. The PCR components are presented in Tables 2.20 and 2.21. 
 
 
 
 
 
 
 
 
 
Stage Cycle Temperature
 
(
o
C) Time (sec) 
1) Initial denaturation 1 94oC 300 
2) Denaturation 30 94oC 15 
   Annealing  57oC 15 
   Extension  72oC 90 
3) Final extension 1 72oC 600 
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Table 2.20. Composition of SOE-PCR reaction mixture used for the amplification 
of the heavy chain-shuffled scFv fragments 
PCR component Concentration in  
50 µL reaction 
Volume of  
each component 
VH (unpanned) 100 ng 2.5 µL 
VL (5
th
 round ) 100 ng 2.5 µL 
SOE sense primer 60 pM 0.6 µL 
SOE reverse primer 60 pM 0.6 µL 
5 x Go Taq
®
 buffer 1 x 10 µL 
dNTP (10 mM) 0.2 mM 1 µL 
Go Taq
®
 Polymerase 5 U/µL 0.25 µL 
MgCl2 (25 mM) 3 mM 6 µL 
H2O ------ 26.55 µL 
Total volume  50µL 
 
The SOE-PCR for heavy chain-shuffling was performed in a Biometra TGRADIENT PCR 
machine under the following conditions: 
Stage Cycle Temperature
 
(
o
C) Time (sec) 
1) Initial denaturation 1 94oC 300 
2) Denaturation 30 94oC 15 
   Annealing  58oC 15 
   Extension  72oC 90 
3) Final extension 1 72oC 600 
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Table 2.21. Composition of SOE-PCR reaction mixture used for the amplification 
of the light chain-shuffled scFv fragments 
PCR component Concentration in  
50 µL reaction 
Volume of  
each component 
VL (unpanned) 102 ng 0.6 µL 
VH (5
th
 round) 100 ng 2.5 µL 
SOE sense primer 60 pM 0.6 µL 
SOE reverse primer 60 pM 0.6 µL 
5 x Go Taq
®
 buffer 1 x 10 
dNTP (10 mM) 0.2 mM 1 µL 
Go Taq
®
 Polymerase 5 U/µL 0.25 µL 
MgCl2 (25 mM) 3 mM 6 µL 
H2O ------ 28.45 µL 
Total volume  50µL 
 
The SOE-PCR for light chain-shuffling was performed in a Biometra TGRADIENT PCR 
machine under the following conditions: 
 
 
 
Stage Cycle Temperature
 
(
o
C) Time (sec) 
1) Initial denaturation 1 94oC 300 
2) Denaturation 30 94oC 15 
   Annealing  58oC 15 
   Extension  72oC 90 
3) Final extension 1 72oC 600 
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2.3.2.3 Construction of chain-shuffled anti-cTnT scFv libraries and rescue of 
anti-cTnT scFv-displaying phage  
The purified SOE products were digested by the SfiI restriction enzyme and then ligated 
into the pComb3XSS vector followed by transforming into E. coli XL1-blue cells for 
library construction, using the protocol described in section 2.3.1.11. Digestion and 
ligation conditions are given in Tables 2.22 and 2.23. 
 
Table 2.22. Reaction mixture for restriction digestion of pComb vector and the 
SOE-PCR product  
 
 
 
 
 
 
 
 
 
 
 
.    
 
 
 
 
 
 
SOE-PCR product     SfiΙ digest 
Component Volume 
SOE-PCR product 102 µL 
10 x Buffer 2 20 µL 
10 x BSA 20 µL 
SfiΙ 23.4 µL 
H2O 34.6 µL 
Total volume 200 µL 
pComb vector        SfiΙ digest 
Component Volume 
pComb vector 5 µL 
10 x Buffer 2 20 µL 
10 x BSA 20 µL 
SfiΙ 1.2 µL 
H2O 153.8 µL 
Total volume 200 µL 
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Table 2.23. Reaction mixture for ligation of the heavy chain-shuffled SOE-PCR 
product into pComb vector  
Digest component  Concentration in 
200 µL volume 
Volume of  
each component 
Digested  
pComb3XSS vector 
1.4 µg/rxn 81.36 µL 
Digested scFv gene 0.7 µg/rxn 61 µL 
5 x Ligase buffer                                      1 x 20µL 
T4 DNA Ligase 400 U/µL 10 µL 
H2O ------ 27.64 µL  
Total volume                      200 µL 
 
Table 2.24. Reaction mixture for ligation of pComb vector and the light 
chain-shuffled SOE-PCR product 
Digest component  Concentration in 
200 µL volume 
Volume of  
each component 
Digested  
pComb3XSS vector 
1.4 µg/rxn 81.36 µL 
Digested scFv gene 0.7 µg/rxn 75 µL 
5 x Ligase buffer                                      1 x 20µL 
T4 DNA Ligase 400 U/µL 10 µL 
H2O ------ 13.64µL 
Total volume                      200 µL 
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The biopanning process for selection of chain-shuffled antibodies was described in 
section 2.3.1.12. More stringent panning conditions were used, including a decrease in 
antigen coating concentration and an increase in the number of washing steps (Table 
2.25).  
Table 2.25. Biopanning conditions for the selection of chain-shuffled anti-cTnT 
scFv antibodies  
 
2.3.2.4 DNA fingerprinting of anti-cTnT scFv antibodies 
DNA fingerprinting was performed to analyse antibody diversity. Anti-cTnT scFv 
clones were grown in 5 mL SB media overnight at 37oC.  The overnight culture was 
subjected to plasmid purification using a Wizard Plus SV Miniprep™ kit (Promega, 
USA). The cell culture was harvested by centrifugation (Eppendorf benchtop centrifuge 
5810R, VWR, Ireland) at 3,200 g for 20 minutes. The supernatant was discarded and 
the pellet was resuspended in 250 µL cell resuspension buffer. Cell lysis buffer was then 
added to lyse the cells and release periplasm proteins. The mixture was then incubated 
at room temperature for 5 minutes followed by addition of 300 µL of neutralisation 
solution. Cell debris were then pelleted by centrafugation at 22,000 g for 10 minutes. 
The supernatant, which contained the plasmid DNA, was transferred to a spin column 
allowing the plasmid DNA to bind to the spin column. Wash buffer (700 µL) was then 
Biopanning 
round 
Volume of 
media (mL) 
Immobilised 
antigen (µg/mL) 
No. of 
wash steps 
Infected 
cell strains 
1 200 20 
3 x PBST, 
3 x PBS 
E. coli XL1-blue 
2 100 10 
5 x PBST, 
3 x PBS 
E. coli XL1-blue 
3 100 5 
5 x PBST, 
5 x PBS 
E. coli XL1-blue 
4 100 2 
7 x PBST, 
7 x PBS 
E. coli XL1-blue 
5 100 1 
9 x PBST, 
9 x PBS 
E. coli 
Top10-F 
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added to the spin column and centrifuged at 19,500 g for 1 minute. The washing step 
was repeated once to resure the maximum removal of salts and other buffer residuals. 
The plasmid DNA was eluted with 50 µL of molecular grade water. The scFv gene 
fragments were then amplied from the DNA plasmid. The PCR components are listed in 
Table 2.26.  
Table 2.26. Composition of PCR reaction mixture for the amplification of scFv 
plasmid DNA  
PCR component Concentration in  
50 µL reaction 
Volume of  
each component 
Plasmid DNA 100 ng 1 µL 
SOE sense primer 60 pM 0.6 µL 
SOE reverse primer 60 pM 0.6 µL 
5 x Go Taq
®
 buffer 1 x 10 
dNTP (10 mM) 0.2 mM 1 µL 
Go Taq
®
 Polymerase 5 U/µL 0.25 µL 
MgCl2 (25 mM) 3 mM 6 µL 
H2O ------ 30.55 µL 
Total volume  50µL 
The PCR was performed in a Biometra TGRADIENT PCR machine under the following 
conditions: 
Stage Cycle Temperature
 
(
o
C) Time (sec) 
1) Initial denaturation 1 94oC 300 
2) Denaturation 30 94oC 15 
   Annealing  58oC 15 
   Extension  72oC 90 
3) Final extension 1 72oC 600 
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The PCR products were subsequently digested using an AluI restriction enzyme using 
the conditions outlined in Table 2.27. The mixture was digested at 37oC for 2 hours and 
then resolved on a 3% (w/v) agarose gel. 
 
Table 2.27. Reaction mixture for restriction digestion of scFv plasmid DNA using 
AluI restriction enzyme 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.2.5 Preparation of crude bacterial lysates of anti-cTnT scFv for Biacore
TM
 4000 
analysis 
A total of 384 anti-cTnT antibodies including 192 light-chain-shuffled scFv antibodies 
and 192 heavy-chain-shuffled antibodies were randomly picked and inoculated into 100 
μL sterile SB medium containing 100 μg/mL carbenicillin and incubated overnight at 
220 rpm at 37°C. The overnight culture was subcultured into a sterile 96-deep well plate 
containing 750 µL SB with 1 x 5O5 solution and 100 µg/mL carbenicillin. The plates 
were left shaking at 220 rpm 37oC until the cell density reached an O.D. ~ 0.400 at 600 
nm. The cells were then induced with 1 mM sterile filtered IPTG solution and incubated 
overnight at 30oC. The overnight cells were pelleted by centrifuging (Eppendorf 
scFv gene           AluΙ digest 
Component Volume 
PCR product 8 µL 
10 x Buffer 4 2.4 µL 
100 x BSA 0.24 µL 
AluΙ 0.5 µL 
H2O 12.86 µL 
Total volume 24 µL 
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benchtop centrifuge 5810R, VWR, Ireland) at 5,500 g for 15 minutes and the pellets 
were then resuspended in 500 µL 1x HBS. The lysates from cells were extracted by 
placing the plates at -80oC for 10 minutes followed by thawing at 37 oC for 10 minutes. 
This step was repeated three times. The plates were centrifuged at 5,500 g for 15 
minutes to pellet the cell debris and the supernatant was transferred into fresh 96-well 
plates.  
 
2.3.2.6 Characterisation of anti-cTnT scFv clones using the Biacore
TM
 4000  
The binding ability of anti-cTnT scFv against cTnT antigen was assessed with the 
previously prepared anti-HA sensor chip (section 2.3.1.18). The assay format used for 
the analysis was previously described in section 2.3.1.19. One in three dilutions of the 
crude bacterial lysate, prepared in 1x HBS, were simultaneously passed over flow cells 
1 and 5 of the sensor chip at a flow rate of 10 µL/min for 10 minutes. The antigen, 
cTnT, at a concentration of 1 µg/mL was subsequently injected at a flow rate of 10 
µL/min for 2 minutes followed by dissociation in buffer for 10 minutes. Flow cells 2 
and 4 were used as capturing references whereas flow cell 3 was used as a blank 
reference.   
 
2.3.2.7 Analysis of the cross-reactivity of anti-cTnT scFv antibodies 
Cross-reactivity analysis was performed to assess the specific of anti-cTnT antibodies. 
It was carried out in a direct ELISA assay format using crude bacterial lysate extracted 
from 10 anti-cTnT scFv antibodies. The capacity of the anti-cTnT scFv antibodies to 
cross-react with other isoforms of troponins including skeletal troponin T (sTnT), 
cardiac troponin T (cTnI) and skeletal troponin I (sTnI) was tested. Two negative 
controls were incorporated in this assessment to eliminate false-positive responses. The 
first negative control excluded the antigen-coating step. The second negative control 
only contained 5% (w/v) Marvel blocking solution. 
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2.3.2.8 Checkboard ELISA using different cTnT coating concentrations 
Checkboard ELISA was performed to select the optimal cTnT concentrations for 
inhibition assay development. A 96 MicroWellTM solid plate was coated overnight at 
4oC with 100 L of cTnT with a series of concentration (3, 1.5, 1, 0.5, 0.25, 0.125, 0 
g/ml) and blocked with 200 L 5% (w/v) Marvel in 1 x PBS (pH 7.4) for 1 hour at 
37oC. The plate was washed once with 1 x PBST (pH 7.4) and once with 1 x PBS (pH 
7.4). A series of dilutions of crude lysate extracted from 8C2 antibody (1 in 100, 1 in 
250, 1 in 500, 1 in 1,000, 1 in 2,000, 1 in 4,000, 1 in 8,000, 1 in 16,000, 1 in 32,000, 1 
in 64,000, 1 in 128,000) were prepared in 1 x PBS (pH 7.4) and 100 L of each was 
added into wells. The plate was incubated at 37oC for 1 hour. The plate was washed 
twice with 1 x PBST (pH 7.4) and twice with 1 x PBS (pH 7.4). HRP-labelled mouse 
anti-HA monoclonal antibody was diluted 1 in 2,000 in 1 x PBS (pH 7.4) and 100 L of 
the dilution was added into the plate for 1hour at 37oC. HRP TMB substrate (100 L) 
was added to each well and the plate was incubated for 10 minutes at 37oC. The 
absorbance reading was determined at 450 nm using a Safire2TM microplate reader. 
 
2.3.2.9 Optimisation of the 8C2 scFv antibody dilution for ELISA inhibition assay 
To ensure the best performance of the inhibition assay, the concentration of 8C2 used 
for antigen detection was optimised. An immuno 96 MicroWellTM solid plate plate was 
coated overnight at 4oC with 100 L of 1 g/mL cTnT and blocked with 200 L 5% 
(w/v) Marvel in PBS (pH 7.4) for 1 hour at 37oC.  A number of concentrations of cTnT 
(1 g/mL, 500 ng/mL, 250 ng/mL, 125 ng/mL, 62.5 ng/mL, 31.25 ng/mL, 15.63 ng/mL 
and 7.81 ng/mL) were prepared in 1 x PBS (pH 7.4) and incubated with four different 
dilutions of the scFv 8C2 clone (1 in 1,000, 1 in 2,000, 1 in 3,000 and 1 in 4,000) for 1 
hour at 37oC. HRP-labelled mouse anti-HA monoclonal antibody was diluted 1 in 2,000 
in 1 x PBS (pH 7.4) and 100 L of the dilution was added to the plate for 1 hour at 
37oC. HRP TMB substrate (100 L) was added to each well and the plate was incubated 
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for 30 minutes at 37oC. The absorbance reading was determined at 450 nm using a 
Safire2TM microplate reader. 
 
2.3.3 Generation of avian anti-cTnT Fab antibody fragments  
2.3.3.1 Amplification of variable domains for the generation of avian anti-cTnT 
Fab antibodies 
The primer sequences listed below were used to generate a chimeric chicken/human Fab 
library (Table 2.28). The primers were compatible with the pComb3XSS vector. All 
primers were purchased from Eurofins MWG Operon (London, UK) and were 
immediately aliquoted into sterile tubes and stored at -20oC after arrival. 
Table 2.28. Primer sequences for the amplification of avian Fab gene fragments 
Variable heavy chain (VH) primers 
ChybVH (sense) 5′ GCT GCC CAA CCA GCC ATG GCC GCC GTG ACG TTG 
GAC GAG TCC 3′ 
ChybIg-B (Reverse) 
  
5′ CGA TGG GCC CTT GGT GGA GGC GGA GGA GAC GAT 
GAC TTC GGT CCC 3′   
Variable light chain (VL) primers 
CSCVK (sense) 
 
5′ GTG GCC CAG GCG GCC CTG ACT CAG CCG TCC TCG 
GTG TC 3′ 
CHybL-B (Reverse) 
  
5′ AGA TGG TGC AGC CAC AGT TCG TAG GAC GGT CAG 
GGT TGT CCC GGC 3′ 
Primers for amplification of the Human CHI chain from a cloned Human Fab 
HKC-F (sense) 5′ CGA ACT GTG GCT GCA CCA TCT GTC 3′ 
dpseq (reverse) 5′ AGA AGC GTA GTC CGG AAC GTC 3′ 
Primers for amplification of the Human CК
 
chain from a cloned Human Fab 
HKC-F (sense) 5′ CGA ACT GTG GCT GCA CCA TCT GTC 3′ 
Lead-B (reverse) 5′ GGC CAT GGC TGG TTG GGC AGC 3′ 
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The chicken variable domains (VH and Vλ) were amplified using previously produced 
chicken cDNA as template. The sense primer CHybVH and reverse primer CHyblg-B 
were used to amplify the VH domain. The amplification of the VH was optimised by 
using three MgCl2 concentrations (2 mM, 3 mM, 4 mM). The annealing temperature 
was 56oC. However, there was no significant product yield under these PCR conditions. 
Further optimisation was performed using an increased annealing temperature (58oC). 
The optimised PCR components for VH amplification are listed in Table 2.29. The sense 
primer, CSCVK, and reverse primer were used to amplify the Vλ domain. The PCR 
components are listed in Table 2.30. 
 
 
 
 
 
 
Primers for PCR assembly of chicken VH sequences with the Human CHI PCR product 
LeadVH (sense) 5′ GCT GCC CAA CCA GCC ATG GCC 3′ 
dpseq (reverse) 5′ AGA AGC GTA GTC CGG AAC GTC 3′ 
Primers for PCR assembly of chicken V L sequences with the Human CК PCR product 
CSC-F (sense) 
 
5′ GAG GAG GAG GAG GAG GAG GTG GCC CAG GCG GCC 
CTG ACT CAG 3′ 
Lead-B (reverse) 5′ GGC CAT GGC TGG TTG GGC AGC 3′ 
Primers for PCR assembly of chimeric light-chain sequence with chimeric heavy-chain 
sequence 
CSC-F (sense) 5′ GAG GTG GCC CAG GCG GCC CTG ACT CAG 3′ 
dep-EX (reverse) 5′ GAG AGA AGC GTA GTC CGG AAC GTC 3′ 
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Table 2.29. Composition of PCR reaction mixture used for the amplification of the 
VH domain 
PCR component Concentration in  
50 µL reaction 
Volume of  
each component 
cDNA template 50 ng 1 µL 
5 x Go Taq
®
 buffer 1x 5 µL 
CHybVH  60 pM 0.6 µL 
CHyblg-B 60 pM 0.6 µL 
dNTP (10 mM) 0.2 mM 1 µL 
Go Taq
®
 Polymerase 5 U/µL 0.25 µL 
MgCl2 (25 mM) 2 mM 4 µL 
H2O ------ 37.55 µL 
Total volume  50 µL 
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Table 2.30. Composition of PCR reaction mixture used for the amplification of the 
Vλ domain 
 
Both VH and Vλ amplifications were performed with the same PCR profile as below: 
Stage Cycle Temperature
 
(
o
C) Time (sec) 
1) Initial denaturation 1 94oC 300 
2) Denaturation 30 94oC 15 
   Annealing  58oC 15 
   Extension  72oC 90 
3) Final extension 1 72oC 600 
 
The amplification of the human constant domains (CHI and Cκ ) was performed using 
the pComb3XTT vector as template. The sense primer HIgGCH1-F and reverse primer 
dpseq were used for the PCR scale-up of the CHI fragment. Table 2.31 shows the 
components of the PCR mix for the amplification of the CHI fragment. 
PCR component Concentration in  
50 µL reaction 
Volume of  
each component 
cDNA template 50 ng 1 µL 
5 x Go Taq
®
 buffer 1 x 5 µL 
CSCVK 60 pM 0.6 µL 
CHybl-B 60 pM 0.6 µL 
dNTP (10 mM) 0.2 mM 1 µL 
Go Taq
®
 Polymerase 5 U/µL 0.25 µL 
MgCl2 (25 mM) 1 mM 2 µL 
H2O ------ 39.55 µL 
Total volume  50 µL 
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Table 2.31. Composition of PCR reaction mixture used for the amplification of the 
CHI domain 
PCR component Concentration in  
50 µL reaction 
Volume of  
each component 
pComb3XTT 20 ng 0.2 µL 
5 x Go Taq
®
 buffer 1 x 5 µL 
HIgGCH1-F 60 pM 0.6 µL 
dpseq 60 pM 0.6 µL 
dNTP (10mM) 0.2 mM 1 µL 
Go Taq
®
 Polymerase 5 U/µL 0.25 µL 
MgCl2 (25mM) 2 mM 4 µL 
H2O ------ 38.35 µL 
Total volume  50 µL 
 
The amplification of the CHI domain was performed in a Biometra TGRADIENT PCR 
machine under the following conditions: 
Stage Cycle Temperature
 
(
o
C) Time (sec) 
1) Initial denaturation 1 94oC 300 
2) Denaturation 30 94oC 15 
Annealing  58oC 15 
Extension  72oC 90 
3) Final extension 1 72oC 600 
 
The human Cκ domain amplification was performed with the sense primer, HKC-F, and 
the reverse primer, Lead-B, using the pComb3XTT as template. The amplification of 
the Cκ domain was performed using the following PCR mixture composition (Table 
2.32). 
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Table 2.32. Composition of PCR reacture mixture used for the amplification of the 
Cκ domain 
PCR component Concentration in  
50 µL reaction 
Volume of each component  
pComb3XTT 20 ng 0.2 µL 
5 x Go Taq
®
 buffer 1 x 5 µL 
HKC-F 60 pM 0.6 µL 
Lead-B 60 pM 0.6 µL 
dNTP (10 mM) 0.2 mM 1 µL 
Go Taq
®
 Polymerase 5 U/µL 0.25 µL 
MgCl2 (25 mM) 2 mM 4 µL 
H2O ------ 38.35 µL 
Total volume  50 µL 
 
The amplification of the Cκ domain was performed in a Biometra TGRADIENT PCR 
machine under the following conditions: 
Stage Cycle Temperature
 
(
o
C) Time (sec) 
1) Initial denaturation 1 94oC 300 
2) Denaturation 30 94oC 15 
   Annealing  56oC 15 
   Extension  72oC 90 
3) Final extension 1 72oC 600 
 
The PCR product was pooled and concentrated by ethanol precipitation. The 
precipitated PCR products were evaluated on a 1% (w/v) agarose gel and the 
correct-sized bands (VH / Cκ ~ 400bp) (Vλ / CHI ~ 350 bp) were carefully cut out and the 
DNA was purified, as described in 2.3.1.8. 
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2.3.3.2 Amplification of the chimeric heavy and light chains using overlap 
extension PCR 
The construction of the chicken chimeric heavy chain (Fd) fragment was achieved by 
joining the purified VH and the CHI fragments generated from the previous PCR 
amplification. The amplification was performed using the sense primer LeadVH and the 
reverse primer, dpseq. The amplification of the PCR components was optimised using 
both MgCl2 concentration gradients (1 mM, 2 mM, 3 mM, 4 mM) and temperature 
gradients (56oC, 58oC, 60oC, 62oC). The optimised PCR components are shown in 
Table 2.33.  
 
Table 2.33. Composition of PCR reaction mixture used for the amplification of the 
chimeric heavy chain 
PCR component Concentration in  
50 µL reaction 
Volume of  
each component 
VH 50 ng 1 µL 
CH 50 ng 1 µL 
LeadVH 60 pM 0.6 µL 
dpseq 60 pM 0.6 µL 
5 x Go Taq
®
 buffer 1 x 5 µL 
dNTP( 10 mM) 0.2 mM 1 µL 
Go Taq
®
 Polymerase 5 U/µL 0.25 µL 
MgCl2 (25 mM) 4 mM 8 µL 
H2O ------ 32.55 µL 
Total volume  50 µL 
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The amplification of the chimeric heavy chain was performed in a Biometra TGRADIENT 
PCR machine under the following conditions: 
Stage Cycle Temperature
 
(
o
C) Time (sec) 
1) Initial denaturation 1 94oC 300 
2) Denaturation 15 94oC 15 
   Annealing  60oC 15 
   Extension  72oC 120 
3) Final extension 1 72oC 600 
 
For the generation of the chicken chimeric light chain, the purified chicken VL and 
human Cκ fragments were amplified using the sense primer, CSC-F, and the reverse 
primer, Lead-B. The PCR components are shown in Table 2.34. 
Table 2.34. Composition of PCR reaction mixture used for the amplification of the 
chimeric light chain 
PCR component Concentration in  
50 µL reaction 
Volume of  
each component 
VL 50 ng 1 µL 
Cκ 50 ng 1 µL 
CSC-F 60 pM 0.6 µL 
Lead-B 60 pM 0.6 µL 
5 x Go Taq
®
 buffer 1x 5 µL 
dNTP( 10 mM) 0.2 mM 1 µL 
Go Taq
®
 Polymerase 5 U/µL 0.25 µL 
MgCl2 (25 mM) 2 mM 4 µL 
H2O ------ 36.55 µL 
Total volume  50 µL 
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The amplification of the chimeric light chain was performed in a Biometra TGRADIENT 
PCR machine under the following conditions: 
Stage Cycle Temperature
 
(
o
C) Time (sec) 
1) Initial denaturation 1 94oC 300 
2) Denaturation 30 94oC 15 
   Annealing  56oC 15 
   Extension  72oC 90 
3) Final extension 1 72oC 600 
 
The PCR products from the amplification of the chimeric Fd and light chain fragments 
were subject to ethanol precipitation and analysed on a 1% (w/v) agarose gel. Both 
chains were then extracted from the gel (section 2.3.1.8). 
 
2.3.3.3 Splice by Overlap Extension (SOE) PCR for the construction of Fab gene 
fragments 
The final splice overlap extension (SOE) PCR combined the purified chicken/human 
chimeric Fd fragment and the light chain fragment. The fragments were mixed equally 
in the overlap PCR reaction and amplified with the sense extension primer, CSC-F, and 
the reverse extension primer, dp-EX. The amplification was optimsed using three PCR 
polymerases (Go Taq®, Fusion Taq® and Platinum HIFI™ Taq polymerases), two types 
of magnesium compound (MgCl2, MgSO4) and a number of Mg
2+ concentrations (0 
mM, 1mM, 0.5 mM, 1 mM, 2 mM, 2.5 mM). The optimised PCR components are listed 
in Table 2.35. 
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Table 2.35. Composition of SOE-PCR reaction mixture used for the amplification 
of the Fab gene fragments 
 
The SOE-PCR was performed in a Biometra TGRADIENT PCR machine under the 
following conditions: 
Stage Cycle Temperature
 
(
o
C) Time (sec) 
1) Initial denaturation 1 94oC 120 
2) Denaturation 15 94oC 15 
   Annealing  56oC 30 
   Extension  72oC 120 
3) Final extension 1 72oC 300 
 
 
 
PCR component Concentration in  
50 µL reaction 
Volume of  
each component 
Chimeric heavy chain 60 ng 1 µL 
Chimeric light chain 60 ng 1 µL 
HIFI buffer (10 x) 1x 5 µL 
CSC-F 60 pM 0.6 µL 
dep-EX 60 pM 0.6 µL 
dNTP( 10mM) 0.2 mM 1 µL 
Platinum HIFI ™ Taq 5 U/µL 0.2 µL 
MgSO4 (50 mM) 2.5 mM 2.5 µL 
H2O ------ 38.1 µL 
Total volume  50 µL 
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2.3.3.4 SOE-PCR restriction digestion and ligation into pComb3XSS vector  
The purified SOE-PCR product and pComb 3XSS vector were digested using SfiI 
restriction enzyme (section 2.3.1.10). The digestion conditions are shown in Table 2.36. 
 
Table 2.36. Reaction mixture for restriction digestion of pComb3XSS vector and 
the SOE-PCR product 
 
 
 
 
 
 
 
 
 
 
 
 
 
The digestion mixtures were incubated for 5 hours at 50°C and ethanol-precipitated 
followed by gel purification, as described in section 2.3.1.8. The purified Fab fragment 
(~ 1500 bp) was then ligated into the pComb3XSS vector (~ 3400 bp) using the 
conditions given in Table 2.37. 
 
 
 
 
SOE  fragment          SfiI digest 
Component Volume 
SOE product 53 µL 
10 x Buffer 2 20 µL 
10 x BSA 20 µL 
SifI 5.5 µL 
H2O 101.5 µL 
Total volume 200 µL 
pComb3XSS  vector   SfiI digest 
Component Volume 
pComb3XSS 
plasmid 
95 µL 
10 x Buffer 2 20 µL 
10 x BSA 20 µL 
SifI 10 µL 
H2O 55 µL 
Total volume 200 µL 
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Table 2.37. Reaction mixture for the ligation of pComb3XSS vector and the Fab 
fragments 
 
 
 
  
  
 
 
 
 
The ligation mixture was incubated overnight at room temperature and then subjected to 
ethanol precipitation.  
 
2.3.3.5 Rescue of anti-cTnT Fab-displaying phage 
For the construction of anti-cTnT Fab libraries, the Fab-containing pComb3XSS 
plasmid was electro-transformed into commercial E. coli XL1-blue cells using the 
method described in section 2.3.1.11. The ‘overnight-grown’ transformants (200 µL) 
were scraped from 2xTY agar plates and propagated in 200 mL sterile SB medium 
contain 100 µg/mL carbenicillin and 10 µg/mL tetracycline. The culture was incubated 
at 220 rpm at 37°C until the cells reached exponential growth phase (O.D. ~ 0.4). The 
Fab library was rescued by adding 1ml of commercial M13KO7 helper phage and then 
incubated at 37°C for 30 minutes, to allow phage infection of cells. The culture was 
then left at 37oC for 2 hours, while shaking at 220 rpm, before the addition of 50 µg/mL 
kanamycin. The rescued library was incubated overnight at 37°C at 220 rpm. The 
method for selection of specific anti-cTnT Fab clones was described in section 2.3.1.13.  
 
 
Component Volume 
10 x T4 Ligase buffer 20 µL 
pComb3XSS vector (1.4 µg) 26 µL 
Fab insert 28 µL 
T4 DNA ligase 10 µL 
H2O 116 µL 
Total Volume 200 µL 
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2.3.3.6 Optimisation of Fab antibody expression conditions 
Fab expression conditions were optimised in order to improve antibody expression 
levels. Each of the overnight culture of four Fab clones (A1, C5, C7 and D3) was 
inoculated into 500 mL TB media containing 1 x 5O5 solution with 100 µg/mL 
carbenicillin and 10 µg/mL tetracycline. The culture was incubated at 37°C, while 
shaking at 220 rpm, until the cells reached exponential growth (O.D. ~ 0.4). IPTG 
concentration gradients and time-course optimisition were performed. Each of the Fab 
cultures were divided into four sterile flaskes. Four different IPTG concentrations (0.05 
mM, 0.1 mM, 0.25 mM and 0.5 mM) were added into each of the four flasks and then 
incubated at 30oC at 220 rpm. Samples were collected from each flask after 2, 4 and 6 
hours and overnight induction. Antibody-containing cell lysates from each culture was 
extracted by repeated freeze-thaw cycles at -80oC/37oC. The antibody expression levels 
were assessed by analysing the lysate using an direct ELISA format. The absorbance 
values indicated the expression levels of each of the samples. 
 
2.3.4 Studies on lactate dehydrogenase levels in normal and mastitic milk 
2.3.4.1 Description of LDH fluorescence assay  
The detection of LDH activity was based on two reactions (Huston et al., 1972). The 
primary reaction was the conversion of L-lactate into pyruvate by oxidation. In this 
reaction L-lactate was oxidised by LDH, using nicotinamide adenine dinucleotide 
(NAD+), as a co-substrate, thus producing pyruvate and NADH + H+. In the secondary 
reaction, NADH + H+ produced from primary reaction quantitatively reduced the 
non-fluorescent resazurin to the highly fluorescent substance resorufin. Diaphorase was 
the enzyme necessary to catalyse the secondary reaction (Joyce et al., 1992).  
LDH
L-Lactate + NAD+ Pyruvate + NADH + H+ Primary reaction
Diaphorase
NADH + H+ + Resazurin Resorufin + NAD+ Secondary reaction
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2.3.4.2 Determination of the optimal assay conditions for LDH measurement in 
milk 
The aim of this section was to determine the optimal reaction time for LDH detection in 
milk samples. This assay reaction was based on the two oxidation/reduction reactions 
described in section 2.3.4.1. The time used for a known amount of commercial LDH 
(0.248 mg/mL) to convert a known amount of lactate (350 mM) to pyruvate was 
measured as described below: 
 
Reaction set-up 
1. The reagent mixture was prepared as shown in Table 2.38. 
Table 2.38. Reagent mixture for LDH assay 
Component Stock concentration Volume 
added (µL) 
Final concentration 
Tris HCl, pH 8.9  750 mM 20 75 mM 
β-NAD 10 mM 20 1 mM 
Resazurin 480 µM 20 48 µM 
KCl 1 M 20 100 mM 
Triton X-100 40 ppm 20 4 ppm 
Diaphorase 10 U/mL 20 1 U/mL 
H2O ------- 53.4 ------- 
L-lactate 350 mM 20 35 mM 
Total volume  193.4  
 
2. The reagent mixture (193.4 µL) was added into each well of a 96 MicrowellTM 
polystyrene black plate containing 6.6 µL of LDH (0.248 mg/mL). Assays were 
performed in triplicate. 200 µL of 5 mM resorufin was added into one well in the plate 
as a background control in the fluorescence assay. 
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3. The production of resorufin was determined by fluorometry. Fluorescence was 
measured with excitation at 544 nm and emission at 590 nm. The Safire2TM microplate 
reader was set under the following conditions:  
- 37oC  
- Fluorescence detection 
- Excitation at 544 nm, emission at 590 nm, and a bandwidth of 20 nm 
- The gain at 44 and the Z position at 11200, (Z position has no units) 
- The bandwidth value, gain value and Z position value were automatically set by 
the plate reader                            
The fluorescent readings were recorded every 30 seconds for a time period of 330 
seconds. The fluorescent readings were plotted against time for determination of the 
optimal reaction time. 
 
2.3.4.3 Determination of LDH levels in milk  
The aim of this section was to determine LDH activity in untreated milk samples. Since 
the optimal reaction time was determined from the curve (Fig. 6.1) to be 180 seconds 
this time period was used throughout as the standard time for the detection of LDH. 
 
Reaction set-up 
The reagent mixture (193.4 µL) (section 2.3.4.2) was added into each well of a 96 
MicrowellTM polystyrene black plate containing 6.6 µL of milk. 
 
Safire2TM microplate reader set-up 
The Safire2TM microplate reader was set up to read the plate, with the parameters 
described in section 2.3.4.2. Fluorescence values were recorded at time 0 seconds. 
Samples were incubated at 37oC for 180 seconds, and fluorescence values were 
recorded again. Experiments were carried out in triplicate.  
Controls 
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The master mix (193.4 µL) and 6.6 µL 1 x PBS (pH 7.4) was used as the negative 
control in this fluorescence assay. 
Commercial LDH solution (6.6 µL) with a known concentration was added to 193.4 µL 
of the master mix as a positive control for the fluorescence assay. 
Resorufin (200 µL) was added to the plate as a background control for the fluorescence 
assay. 
 
Calculation 
1) Mean values of the fluorescence readings were calculated for all the milk samples 
and the LDH controls. 
2) Net values of the milk samples and the LDH controls were obtained by taking 0 
minute mean values away from 3 minutes mean values. Table 2.39 below shows the 
calculation of net fluorescent value. 
 
Table 2.39. Fluorescence produced in milk samples and LDH control solutions 
 Fluorescent reading 
Mean: 0 minute 
Fluorescent reading 
Mean: 3 minutes 
Net 
 
Milk sample A B E = B-A 
LDH solution C D F = D-C 
      
A and B represented the mean fluorescent values of the milk samples at 0 and 3 
minutes, respectively. C and D represented the mean fluorescent values of the LDH 
solution at 0 and 3 minutes, respectively. E and F represented the net values for milk 
sample and LDH solution, respectively.    
 
3) The enzymatic activity of the LDH solution, according to the manufacturer, was 
659 enzyme units per mg. Therefore, the enzymatic activity of the LDH solution can be 
determined by multiplying the LDH concentration (mg/mL) by the enzymatic activity 
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value (659 units/mg) to get enzyme units per mL, then multiply by 1000 to give enzyme 
units per L * ( represented by Y) 
 
For example: 0.1 mg/mL LDH solution x 659 units per mg = 65.9 units per mL                                                                               
= 65,900 units per L (U/L)* 
*in previous publications, LDH activity was presented in units per L (Larsen, 2005; Hiss et al., 2007) 
 
The LDH fluorescence unit (F) was correlated with LDH enzymatic activity (Y) by 
dividing F by Y. This correlation value represented by Z equals LDH activity (U/L) per 
fluorescence unit.  
Z = Y (U/L) / F 
For example: F= 1000 fluorescence unit, Y=65900 U/L 
Z = 65900/1000 = 65.9 
 
4) The net fluorescence value (E) of the milk samples were converted into LDH 
activity U/L (X) by multiplying Z by E.                                                                          
LDH activity in milk X (U/L) = Z x E 
For example: E = 20 fluorescence unit, Z= 65.9 
X = 65.9 x 20 = 1318 U/L 
 
Statistical analysis was performed on all milk samples using PASW statistics 18 
(formerly SPSS Statistics) for Windows. Pearson’s Product Moment Correlation 
Analysis was used to compare the mean levels of LDH, NAGase and SCC. The 
correlation value (r) can fall between 0 (no correlation) and 1.00 (perfect correlation). 
PASW statistics 18 software sets r values greater than 0.80 as a good correlation. 
One-way ANOVA was used to determine significance. Data was considered statistically 
significant at p value < 0.05. 
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Chapter 3 
Generation of avian  
 anti-troponin T antibody scFv 
fragments  
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3.1 Introduction 
This chapter outlines the production and characterisation of recombinant avian 
anti-cTnT scFv antibody fragments. It contains an in-depth description of the 
construction of an avian antibody phage library; the screening and selection of 
antigen-specific antibodies; the analysis of antibodies using the SPR technique and the 
inhibition assay development of the selected antibody. The main focus of this chapter is 
the use of phage display for antibody production and selection. 
 
Recombinant antibody fragments have become essential tools in several fields, 
including biomedical research, disease diagnostics and therapeutics (Smith et al., 2004). 
More than 30% of all biological proteins used in clinical trials for both diagnosis and 
therapeutics are recombinant antibody fragments (Hudson, 1998). The Fv fragment is 
the smallest functional antibody fragment and is comprised of single VL and VH 
domains that maintain the monovalent binding affinity of the parent antibody. In 
solution, the association of individual VL and VH domains of the Fv fragment is weak. 
The two variable domains can dissociate into its individual domains due to the low 
affinity interaction between them (Glockshuber et al., 1990; Hudson, 1998., Bronzino., 
2000). In contrast, in a recombinant format, the VL and VH domains are often tethered to 
each other using a flexible polypeptide linker to form a stable scFv antibody fragment, 
thus allowing for the co-secretion of both variable domains in the periplasm of bacteria 
cells (Freund et al., 1993). A 15 amino acid residue (Gly4Ser)3 linker is a common 
choice, in which glycine and serine provide flexibility and solubility to the antibody 
fragments (Hudson and Winter, 1991). The 15 amino acid residue length also provides 
each of the variable domains with enough freedom of movement and space to bind the 
antigen, thus ensuring there is no steric interference between each section of the scFv 
(Shan et al., 2011).  
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The production of recombinant antibody and antibody fragments involve systems such 
as mammalian cell culture, microbial cell culture (i.e. bacteria, yeast and fungi) and 
plant cells (Table 3.1). Mammalian cell systems are particularly useful in antibody 
production for therapeutic purposes. However, the process is time consuming and 
expensive. In this study, the simple and cost-effective bacterial cell systems are the 
choice for recombinant antibody production. 
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Table 3.1. Recombinant antibodies production systems 
 Advantages Disadvantages 
 
 
Mammalian system 
 
 Extensively used for full length IgG production 
 Glycosylation pattern is similar to in vivo glycoprotein 
 Particular useful for therapeutic protein production 
 
 
 Low production due to low cell growth rate 
 Production costly 
 High risk of contamination 
 
 
 
 
Microbial system –  
bacteria 
 
 High transformation efficiency   
 Rapid production due to high growth rate 
 Simple production due to simple compositions of media 
and easy cultivation  
 Robustness and scalability of fermentation process  
 Cost effective  
 
 
 Limited range of therapeutic products as protein 
glycosylation does not normally occur in bacterial hosts  
 Risk of contamination by endotoxins 
 
 
 
Yeast 
 
 
 Organisms are typically free of pyrogens and infectious 
viruses 
 These hosts can produce glycosylated protein as well as full 
length IgG and antibody fragments 
 Antibody domains fold and associate properly 
 
 
 
 Long fermentation time  
 Modest yield of antibodies 
 Lack full mammalian glycan pattern  
 High levels of proteolysis caused by host proteases  
 
 
 
      Fungi 
 
 Efficient production and secretion capacity 
 Higher growth rates than plant and mammalian cells 
 Proteins are glycosylated 
 
 High risk of antibody proteolysis 
 High culture viscosity 
 No reports of therapeutic protein production 
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Plant 
 
 Low risk of viral contamination 
 Moderate cost and time-scale of production 
 ‘Human-like’ glycosylation in transgenic plant cells 
 
 Plant harvest, handling and storage are not convenient 
 
 
 
 
(Based on references: Pluckthun, 1991; Nyyssönen et al., 1993; Keranen and Penttila, 1995; Shusta et al., 1998; Freyre et al., 2000; 
Peeters et al., 2001; Ma et al., 2003; Wiebe, 2003; Rahbarizadeh et al., 2006; Liddell, 2009). 
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The generation of recombinant antibody libraries using the avian system as the animal 
host offers a number of distinct advantages. Chickens are phylogenetically more 
distance from humans than other commonly used laboratory animal species, such as 
mice and rats. Importantly, the generation of antibodies from the avian immune system 
can achieve better immune responses to conserved mammalian proteins (Narat, 2003; 
Zhang, 2003). This may offer significant benefit for the development of diagnostic 
assays for human diseases.  
 
Interestingly, the avian immune system contains two sets of germ line genes named V 
(variable) and J (joining), which form the heavy and light chains of the antibody. The 
re-arrangement of the V and J segments in the avian systems leads to the generation of a 
large repertoire of different antibodies (Cohn and Moldave, 1993). In contrast, in 
mammalian species, such as rabbit and mouse, an extra D (diversity) segments is 
involved in repertoire production. Although the extra segment may generate greater 
repertoire diversity than in the avian species, the antibody library construction requires 
more procedures than in the avian systems, such as the need for extra sets of primers 
and PCR amplifications. Recombinant avian antibody generation is, therefore, easier 
and simpler, owing to the need of only two sets of primers and two amplification 
processes. 
  
Despite limited gene rearrangements, the avian immune system possesses a unique 
Bursa B cell development process. During this process, gene conversion leads to 
sequence change in CDRs which result in a high level of antibody diversity. It was 
suggested that this mechanism has the potential to develop more diverse antibodies than 
those found in either humans or rodents (Thompson, 1992). In addition, the avian host 
offers other benefits for antibody generation. These include low animal-housing and 
feeding costs, a rapid and sustained antibody response, and the capability of 
simultaneously responding to up to seven distinct immunogens (Hof et al., 2008). 
 
Using the phage display technique, recombinant antibodies can be produced from the 
avian system and subsequently characterised using Surface Plasmon Resonance (SPR). 
SPR is a non-invasive optical phenomenon that monitors molecular interactions 
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between ligands in ‘real-time’. SPR detects the change of refractive index of a thin 
metal film caused by the binding of mobile molecules to immobilised molecules on the 
metal film (Drescher et al., 2009). The molecular interactions lead to a change in the 
angle of reflected light, which is generated when the polarised light is impinging on the 
metal film (Rich and Myszka, 2000; Gopinath, 2010). The SPR response is dependent 
on the mass of biomolecules bound on the film surface, and is independent of the nature 
of that biomolecule. Therefore, both the quantity of ligands immobilised on the 
sensorchip surface and the quantity of molecules bound to the ligands can be 
determined with the same mass-dependent principle (Myszka, 2004). Moreover, the 
mass-dependent detection does not require protein-labeling, and this eliminates any 
possible changes that may occur to the properties of the protein during the process of 
labelling.  
 
The BiacoreTM 3000 instrument is an SPR-based biosensor system which uses chips in 
analysis. The CM5 sensor chip has a thin layer of gold to which is attached to a 
carboxy-methylated dextran polymer. Biomolecules can be linked to the dextran layer 
with a variety of established chemical methods. The amount of bound analytes can be 
detected down to picogram levels per square millimeter on the gold surface. The major 
applications performed on this system include: biosample concentration measurements; 
binding analysis between biomolecular partners; multiple binding pattern analysis; 
enzymatic process monitoring; antibody-antigen epitope mapping and kinetic analysis. 
The principle of SPR is given in Figure 3.1. 
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A. 
 
B. 
 
Figure 3.1. The principle of SPR detection. (A) A CM5 sensor chip is made up of a 
glass support coated with a thin gold film to which a covalently bound carboxy-methyl 
dextran matrix is attached. When a light source (polarised light) passes through a prism 
and strikes the gold film, the light is totally reflected (reflected light). The θr value 
represents the angle change of reflected light. (B) Correlations between the change of 
refractive index and SPR response. The SPR response represented by the response unit 
(RU) is a direct measurement of the angle of minimum reflected intensity. A change in 
the angle of reflected light of approximate 10-4 degrees correlates to a change of 
refractive index of 10-6 and this is also equivalent to one RU.  
(Based on references: BIAtechnology handbook, 1998; Gomes and Audreu, 2002). 
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Although the principle of concentration measurements using SPR-based assays is 
similar to conventional ELISA, the SPR technique has a number of distinct advantages. 
For example, SPR continuously monitors the interaction at each time-point in each step; 
in contrast, ELISA only measures the end-point level of the final interactant. Moreover, 
SPR-based assays do not require washing steps, multiple secondary reagents or 
protein-labeling. The elimination of these steps and reagents means that SPR-based 
assays are simplified. In addition, they often display increased assay sensitivity. 
      
A key application of SPR is kinetic and affinity studies on analyte-ligand interactions. 
Kinetic analysis is time-dependent and is used to describe how fast an interaction occurs, 
whereas affinity measurements describe the strength of complex formation (Fig. 3.2). 
Major parameters involved in kinetic studies are the association rate constant (ka) and 
the dissociation rate constant (kd). Affinity levels are represented by the equilibrium 
association constant (KA) and the equilibrium disassociation constant (KD). KA is the 
ratio between ka and kd whereas KD is the inverse of KA (Crescenzo et al., 2008).   
 
     
A + B AB
k a
dk
 
Figure 3.2. Formation of protein-protein complex in a 1:1 interaction. A represents 
the analyte to be measured which is free in a solution. B represents the ligand which is 
immobilised on a chip surface. AB in the complex formed by the interation between the 
analyte and ligand. Complex formation is a reversible process, and the terms ka and kd  
describe the association rate constant and dissociation rate constant, respectively. So the 
equilibrium association constant (KA) and the equilibrium disassociation constant (KD), 
descrbing the affiniteis of the complex, can be calculated using ka and kd values.   
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3.1.1 Work summary for the generation of avian anti-cTnT scFv antibodies 
This chapter describes the use of phage display to produce recombinant anti-cTnT scFv 
antibody fragments. Before the immunisation procedure, the amino acid sequence of 
human cardiac troponin T (cTnT) was compared to its skeletal counterpart (sTnT). In 
addition, the sequence of human cTnT was also aligned with cTnT from other animal 
species including rabbit, mouse and chicken. It was found that cTnT from chicken was 
evolutionarily more distant to human than other species. Therefore, chicken was an 
optimal system for anti-cTnT antibody production. Commercial cTnT protein was 
analysed using SDS-PAGE to determine its purity and was subsequently used to inject a 
chicken host. For antibody production, the antibody RNA was isolated from chicken 
spleen and bone marrow when a sufficient immune response was obtained. 
 
The scFv antibody genes were amplified from cDNA and then ligated into phagemid 
pComb3XSS vectors. The antibody phage library was subsequently constructed by 
transforming the antibody gene-containing plasmids into E.coli XL-blue cells. The 
selection of specific antibodies was achieved by performing five biopanning cycles. 
Antibodies with high cTnT binding levels were detected using a simple ELISA-based 
‘on-plate’ screening method (Appendix I) and eleven antibodies were selected. 
Inhibition ELISA analysis was then performed using the crude bacterial lysates 
extracted from the eleven clones and clone F1 showed the highest antigen-detecting 
sensitivity. The F1 clone was then isolated and characterised using SPR-based kinetic 
studies. Finally, an inhibition assay was developed based on a purified F1 antibody. The 
precision of the inhibition assay was also investigated.  
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3.2 Results 
3.2.1 Sequence alignment of cardiac troponin T with skeletal troponin T  
As previously described in section 1.2.1, most classical cardiac markers are low in 
cardiac tissue specificity as they also exist in skeletal tissues. Therefore, skeletal tissue 
damage can also cause the elevation of their levels. In contrast, cardiac TnT is highly 
specific to cardiac tissue due to its distinct structural difference from its skeletal isoform 
(sTnT). In this section, the sequence of cardiac form of TnT (cTnT) was aligned with 
the sTnT to compare their structures. The aligment of the amino acid squence of both 
forms is shown in Figure 3.3.   
 
The functional N-terminal region of the cTnT protein is the first 91 amino acids of the 
sequence (Sumandea et al., 2009). The amino acid alignment showed a shorter 
N-terminal region for human sTnT compared to cTnT. Within the first 91 amino acid 
residues of the cTnT sequence, only 57 amino acids of sTnT were aligned. ClustalW 
version 2 software also determined that the similarity score between cTnT and sTnT 
was 59%. This indicated that both isoforms were significantly different.    
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cTnT     MSDIEEVVEEYEEEEQEEAAVEEEEDWREDEDEQEEAAEEDAEAEAETEETRAEEDEEEE 60 
sTnT     MSD--------EEVEQVEEQYEEEE---EAQEEAAEVHEEVHEPEEVQEDT-AEEDAEEE 48 
         ***        ** ** *   ****   * ::*  *. **  *.*   *:* **** *** 
 
cTnT     EAKEAEDGPMEESKPKPRSFMPNLVPPKIPDGERVDFDDIHRKRMEKDLNELQALIEAHF 120 
sTnT     ---------------KPR---PKLTAPKIPEGEKVDFDDIQKKRQNKDLMELQALIDSHF 90 
                        ***   *:*..****:**:******::** :*** ******::** 
 
cTnT     ENRKKEEEELVSLKDRIERRRAERAEQQRIRNEREKERQNRLAEERARREEEENRRKAED 180 
sTnT     EARKKEEEELVALKERIEKRRAERAEQQRIRAEKERERQNRLAEEKARREEEDAKRRAED 150 
         * *********:**:***:************ *:*:*********:******: :*:*** 
 
cTnT     EARKKKALSNMMHFGGYIQKQAQTERKSGKRQTEREKKKKILAERRKVLAIDHLNEDQLR 240 
sTnT     DLKKKKALSSMG--ANYSSYLAKADQKRGKKQTAREMKKKILAERRKPLNIDHLGEDKLR 208 
         : :******.*   ..* .  *::::* **:** ** ********** * ****.**:** 
 
cTnT     EKAKELWQSIYNLEAEKFDLQEKFKQQKYEINVLRNRINDNQKVSKTRG---KAKVTGRW 297 
sTnT     DKAKELWETLHQLEIDKFEFGEKLKRQKYDITTLRSRIDQAQKHSKKAGTPAKGKVGGRW 268 
         :******:::::** :**:: **:*:***:*..**.**:: ** **. *   *.** *** 
 
cTnT     K 298 
sTnT     K 269 
         * 
 
 
Figure 3.3. Protein sequence alignment between human cardiac TnT and skeletal 
TnT. 
 
The amino acid sequences were aligned using ClustalW version 2 software. The 
variations in amino acids between the two sequences are highlighted in green. The dash 
line (‘-‘) indicates no amino acid at that position.  
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3.2.2 Sequence alignment of cTnT from human and other species  
In order to examine if chicken would be a more suitable host than other animal species, 
the protein sequence of human cTnT was aligned with cTnT from rabbit, mouse and 
chicken (Fig. 3.4). The sequences similarity score between cTnT from human and other 
cTnTs were also determined by ClustalW version 2 software (Table 3.2). 
 
It is shown in Table 3.2 that human and rabbit cTnT had 91% homology, and the 
similarity score between human and mouse was 87%, whereas human and chicken only 
had 78% homology. Therefore, cTnT from chicken is evolutionarily more distant from 
human than from other species. 
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Human   cTnT   MSDIEEVVEEYEEEEQEEAAVEEEEDWREDEDEQEEAAEEDA----EAEAETEETRAEED 56 
Rabbit  cTnT   MSDLEEVVEEYEEEQEAEEAAAEEEDWREDEDEQEAGEEEEAGGGREAEAETEETQAEED 60 
Mouse   cTnT   MSDAEEVVEEYEEEQEEQEEAVEEE--------EAGGAEPEP----EGEAETEEANVEEV 48 
Chicken cTnT   ------------------------------------------------------------ 
                                                                             
 
Human   cTnT   EEEEEAKEAEDGPMEESKPKP-RSFMPNLVPPKIPDGERVDFDDIHRKRMEKDLNELQAL 115 
Rabbit  cTnT   GQEEEDKEDEDGPVEESKPKP-RPFMPNLVPPKIPDGERVDFDDIHRKRMEKDLNELQTL 119 
Mouse   cTnT   GPDEEAKDAEEGPVEDTKPKPSRLFMPNLVPPKIPDGERVDFDDIHRKRVEKDLNELQTL 108 
Chicken cTnT   -REQEPGEGE------SKPKP-KPFMPNLVPPKIPDGERLDFDDIHRKRMEKDLNELQAL 52 
                 ::*  : *      :**** : ***************:*********:********:* 
 
Human   cTnT   IEAHFENRKKEEEELVSLKDRIERRRAERAEQQRIRNEREKERQNRLAEERARREEEENR 175 
Rabbit  cTnT   IEAHFENRKKEEEELVSLKDRIEKRRAD-AEQLRIRAEREKERQNRLAEERARREEEESR 178 
Mouse   cTnT   IEAHFENRKKEEEELISLKDRIEKRRAERAEQQRIRNEREKERQNRLAEERARREEEENR 168 
Chicken cTnT   IEAHFESRKKEEEELISLKDRIEQRRAERAEQQRIRSEREKERQARMAEERARKEEEEAR 112 
               ******.********:*******:***: *** *** ******* *:******:**** * 
 
Human   cTnT   RKAEDEARKKKALSNMMHFGGYIQKQAQTERKSGKRQTEREKKKKILAERRKVLAIDHLN 235 
Rabbit  cTnT   RKAEDEARKKKALSNMMHFGGYIQKQAQTERKSGKRQTEREKKKKILAERRKVLAIDHLN 238 
Mouse   cTnT   RKAEDEARKKKALSNMMHFGGYIQKQAQTERKSGKRQTEREKKKKILAERRKALAIDHLN 228 
Chicken cTnT   KKAEKEARKKKAFSNMLHFGGYMQK---SEKKGGKKQTEREKKKKILSERRKPLNIDHLS 169 
               :***.*******:***:*****:**   :*:*.**:***********:**** * ****. 
 
Human   cTnT   EDQLREKAKELWQSIYNLEAEKFDLQEKFKQQKYEINVLRNRINDNQKVS---KTRGKAK 292 
Rabbit  cTnT   EDQLREKAKELWQSIYNLEAEKFDLQEKFKQQKYEINVLRNRINDNQKVS---KTRGKAK 295 
Mouse   cTnT   EDQLREKAKELWQSIHNLEAEKFDLQEKFKQQKYEINVLRNRINDNQKVS---KTRGKAK 285 
chicken cTnT   EDKLRDKAKELWQTIRDLEAEKFDLQEKFKRQKYEINVLRNRVSDHQKVKGSKAARGKTM 229 
               **:**:*******:* :*************:***********:.*:***.    :***:  
 
Human   cTnT   VTGRWK 298 
Rabbit  cTnT   VTGRWK 301 
Mouse   cTnT   VTGRWK 291 
Chicken cTnT   VGGRWK 235 
               * **** 
Figure 3.4. Protein sequence alignment of cTnT between human and other species. 
The variations of amino acids between human cTnT and other species are highlighted in 
green. The number at the end of each row represents the length of the sequence. The 
dash line (‘-‘) indicates no amino acid at that position.  
 
Table 3.2. Similarity score between cTnT from human and other species 
 Human vs Rabbit Human vs Mouse Human vs Chicken 
Similarity score   91% 87% 78% 
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3.2.3 Verification of immunogen purity by SDS-PAGE  
The purity of an immunogen is vitally important for producing an antibody with high 
antigenic specificity. The commercial human cTnT protein was analysed using 
SDS-PAGE to determine its purity. Human cTnT protein (~ 35 kD) with a concentration 
of 1.92 mg/mL was purchased from Life diagnostics, Inc. (USA). The cTnT protein was 
diluted in 1 x PBS buffer and analysed for purity on SDS-PAGE (Fig. 3.5).    
 
 
 
Figure 3.5. SDS-PAGE analysis of commercial cTnT protein.  
Lanes 1 and 7 contained a Sigma-wide protein marker. Lanes 2 and 6 contained a 
Page-ruler prestain protein marker. Lanes 3, 4, 5 show a 1 in 10, a 1 in 20 and a 1 in 40 
cTnT protein dilution in 1 x PBS buffer, respectively. Each of the lanes 3, 4 and 5 
contained a single protein band at a size of approximately 35 kD, which indicated the 
presence of cTnT. No non-specific bands were observed in any of the three lanes. This 
suggested that the cTnT protein had high purity. The commercial cTnT protein was 
subsequently used as antigen for animal immunisation.  
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3.2.4 Determination of the antibody titre against cTnT in avian sera 
Human cTnT was injected into a chicken host and four immunisations were performed. 
A bleed was taken seven days after the final immunisation. The serum anti-cTnT titre 
was performed using a direct ELISA format to detect the antibody response. A series of 
dilutions ranging from neat to 1 in 128,000 of the chicken serum diluted in 1 x PBST 
were tested. An antibody titre between 1/10,000 and 1/100,000 of antigen was observed 
from the ELISA, which indicated a sufficient immune response for cTnT.  
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Figure 3.6. Determination of avian serum titre against cTnT. An ELISA plate was 
coated with 1µg/mL of the cTnT and blocked with 5% (w/v) Marvel in PBS. A 1 in 
2,000 dilution of HRP-conjugated rabbit anti-chicken antibody was used as the 
secondary antibody to detect any positively binding antibodies to cTnT. A series of 
dilutions of the chicken pre-immunisation serum in 5% (w/v) Marvel in PBS, were used 
as negative controls. The serum titre was greater than 1/10,000 but less than 1/100,000. 
No antibody response was seen in the pre-immunised chicken serum. 
 
 
 
 
127 
 
3.2.5 PCR amplification of chicken variable heavy and light chain genes  
The spleen and bone marrow were harvested from the chicken and total RNA was 
extracted. The concentration of total RNA extracted from the chicken spleen was 139.5 
µg as determined by the NanadropTM ND-1000. In contrast, only 11.7µg of total RNA 
was extracted from the bone marrow. Due to the low quantity of bone marrow RNA, 
only RNA from chicken spleen was used as template for the cDNA synthesis.  
 
The first round PCR involved the amplification of VH and VL (Fig. 3.7). Agarose gel 
analysis showed that neither the VH or VL was amplified at a low MgCl2 concentration, 
i.e. 0 mM, 0.5 mM and 1 mM. The VL amplification was optimised using a 
concentration of 2 mM MgCl2. At this concentration, the PCR reaction produced a 
strong band of ~ 350 bp. At the same MgCl2 concentration, a clear strong band at ~ 350 
bp with a small number of non-specific amplifications (greater than 350 bp) was also 
observed for the VH chain. Large-scale amplifications were performed with 2 mM 
MgCl2 for both variable genes. The PCR products were extracted, as detailed in section 
2.3.1.8. 
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Figure 3.7. Optimisation of the amplification of the VH and VL genes using 
different magnesium concentrations.  
Lanes 1 and 16 represent a 1 kb plus DNA molecular weight ladder (Invitrogen, USA). 
Lanes 2 to 8 represent amplifications of VH with a series of MgCl2 concentrations (0 
mM, 0.5 mM, 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, respectively). Similarly, lanes 9 to 15 
represent amplifications of VL with various MgCl2 concentrations (0 mM, 0.5 mM, 1 
mM, 2 mM, 3 mM, 4 mM, 5 mM, respectively). Lane 9 was intentionally left blank.  
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3.2.6 Anti-cTnT scFv-Splice by Overlap Extension (SOE) PCR 
The SOE primers, CSC-F and CSCB (section 2.3.1.9), were used to link the purified VH 
and VL fragments with a glycine-serine linker (Gly4Ser)3.. The SOE-PCR was optimised 
using different Mg2+ concentrations. In addition, the pComb3XSS vector was digested 
using a SfiI restriction enzyme (see section 2.3.1.10). The digested pComb3XSS vector 
(~ 3400 bp) and stuffer fragments (~ 1400 bp), as well as the SOE-PCR product, were 
resolved on a 1% (w/v) agarose gel (Fig. 3.8). 
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Figure 3.8. Optimised SOE-PCR and the digestion of the pComb3XSS vector. 
Lanes 1 and 4 contained a 1 kb plus DNA molecular weight ladder. Lane 2 contained 
the SfiI digested pComb3XSS vector and stuffer fragment. Lane 3 contained the 
gel-purified SOE-PCR product. The PCR optimisation was performed by using a series 
of Mg2+ concentrations (0 mM, 0.5 mM, 1 mM, 2 mM, 3 mM, 4 mM). The optimal 
condition was selected as 3 mM MgCl2. A large-scale SOE-PCR was performed and the 
PCR product was extracted, as described in section 2.3.1.8. A clear band (~ 750 bp) in 
lane 3 indicated the success of the SOE-PCR. In addition, the upper band between 3,000 
bp and 4,000 bp shows the fully digested pComb3XSS, whereas, the lower band, near 
the 1,650 bp marker, is the vector’s stuffer fragment.  
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3.2.7 Avian anti-cTnT scFv library construction and enrichment via biopanning 
The gel-purified SOE-PCR product was extracted from a 1% (w/v) agarose gel and 
concentrated by ethanol precipitation. The PCR product and pComb3XSS vector were 
digested with the SfiΙ restriction enzyme followed by overnight ligation with T4 DNA 
ligase. The ligated product was ethanol-precipitated and transformed into 
electrocompetent E. coli XL1-Blue cells by electroporation, as described in section 
2.3.1.11. The transformed avian anti-cTnT scFv library had a size of 2.6 x 108 cfu/mL. 
Recombinant anti-cTnT scFv clones were selected from this library by performing five 
rounds of phage display biopanning against immobilised cTnT antigen, as described in 
section 2.3.1.12. The number of phage (phage titre) before and after each round of 
biopanning is shown in Table 3.3.  
 
Table 3.3. Phage input and output titres over the 5 rounds of biopanning of the 
avian anti-cTnT scFv library 
 
 
 
                                                                                                               
 
 
 
 
 
 
 
 
 
 
 
Biopanning round Input (cfu/mL) Output (cfu/mL) 
1 1.3 x 1012 1.0 x 105 
2 1.7 x 1012 9.0 x 104 
3 1.5 x 1012 5.2 x 105 
4 1.0 x 1011 5.0 x 104 
5 1.6 x 1011 1.3 x 104 
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3.2.8 Soluble expression of avian anti-cTnT scFv antibodies 
A total of 96 anti-cTnT scFv antibodies were selected from biopanning round 5 output 
plates. These clones were subsequently analysed using a simple ‘on-plate’ monoclonal 
ELISA screening method (section 2.3.1.14). Positive clones were selected based on 
their absorbance. Generally, the threshold is set at three times the background signal 
(Updegraff and Anderson, 1991). In this study, the ELISA threshold was set at three 
times the absorbance of the blank sample.  
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Figure 3.9. Screening of anti-cTnT scFv phage clones from round five of 
biopanning. Each of the blue bars represents the absorbance reading of each scFv 
antibody. A blank reference was also included in the analysis, which is represented by 
the black bar (96). To identify the positive antigen-binding clones, a red horizontal line 
which indicates the ELISA threshold was drawn at the absorbance level (~ 1.1). The 
threshold is three times of the absorbance value of the blank reference. 
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3.2.9 Titration ELISA analysis of anti-cTnT scFv antibodies 
A total of eleven scFv clones that had significant binding reactivity against cTnT, as 
determined from monoclonal ELISA analysis, were grown up and expressed overnight. 
Crude bacterial lysates were prepared and subjected to a titration ELISA. Analysis 
revealed that individual anti-cTnT scFv clones had large differences in antibody 
expression. The midpoint of the linear range of the antibody titre was selected as the 
dilution value for a subsequent inhibition ELISA (Fig. 3.10).   
 
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
1 10 100 1,000 10,000 100,000
A
b
so
rb
a
n
ce
 @
 4
5
0
 n
m
Lysate dilution
scFv F10
scFv A6
scFv G9
scFv G4
scFv G2
scFV C2
scFv F1
scFv B8
scFv C8
scFv C4
scFv A10
 
 
Figure 3.10. Antibody titre determination of anti-cTnT scFv antibodies. An ELISA 
plate was coated with 100 µL of 1 µg/mL cTnT and blocked with 200 µL 5% (w/v) milk 
Marvel in PBS. A series of dilutions of crude antibody lysates (1 in 5, 1 in 10, 1 in 20, 1 
in 40, 1 in 80, 1 in 160, 1 in 320, 1 in 640, 1 in 1280 and 1 in 2,650) were prepared and 
100 µL of each dilution was added into separate wells. The scFv antibodies were 
detected using HRP-labeled mouse anti-HA monoclonal antibody. The ELISA was 
developed with TMB substrate and the absorbance was read at 450 nm. 
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3.2.10 Inhibition ELISA analysis of anti-cTnT scFv antibodies 
Inhibition ELISAs were performed with the same set of clones previously described in 
section 3.2.9. The dilution factors of the crude lysates of each clone were based on the 
midpoint value obtained from the titration ELISA (Fig 3.10). An A0 standard, which is 
the absorbance of antibody lysate dilution without any inhibition of free antigen, was 
also included in the analysis. The degree of inhibition was calculated by dividing the 
absorbance value at each cTnT concentration (A) with the A0 absorbance value. The 
data were fitted into a four parameter equation using SigmaPlot version 11.0 software. 
Out of the eleven clones tested, clone F1 had the lowest IC50 value of 214 ng/mL (Fig. 
3.10). 
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Figure 3.11. Inhibition ELISA analysis of anti-cTnT scFv antibodies.  
An ELISA plate was coated with 1 µg/mL cTnT and blocked with 200 µL of 5% (w/v) 
Marvel in PBS. Various concentrations of cTnT (1,000, 500, 250, 125, 62.5, 31.25 and 
15.63 ng/mL) were incubated with a 1 in 40 dilution of the scFv clone F1, for 1 h at 
37oC. ScFv binding was detected using HRP-labeled mouse anti-HA monoclonal 
antibody. The ELISA was developed with TMB substrate and the absorbance was read 
at 450 nm.  
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3.2.11 Purification of Anti-cTnT F1 scFv antibody using immobilised metal affinity 
chromatography (IMAC) 
The F1 antibody demonstrated the lowest the IC50 value, as determined through the 
antibody selection process, and it was subsequently purified using the IMAC protocol, 
as described in section 2.3.1.16. The fractions from the different purification stages 
were analysed by SDS-PAGE and Western blotting (Fig. 3.12).  
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Figure 3.12. SDS-PAGE and Western blotting analysis of the F1 scFv.  
Lanes 1, 6, 7 and 12 contained a set of page-ruler prestain protein markers. Lanes 2 and 
8 contained crude lysates, extracted by sonication. Lanes 3 and 9 contained ‘flow- 
through’ that was obtained after passing the E. coli cell lysate through a Ni-NTA 
agarose resin. Lanes 4 and 10 contained the washed fractions. Lanes 5 and 11 contained 
the eluted fractions.  
 
Lanes 2 and 3 contained a large number of contaminant proteins of various sizes. No 
significant protein banding differences were observed between the crude lysates in lane 
2 and the ‘flow-through’ solution in lane 3. In contrast, lanes 4 and 10, which contained 
wash fractions collected after passing washing buffer through the column, had little or 
no protein bands. This indicated the removal of non-specific proteins from the column 
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resin. A clear strong band just below 27 kDa was observed in lane 5 (marked by a red 
circle) and this indicated the successful purification of the F1 scFv antibody (25 kD). In 
addition, a small number of non-specific bands were also observed in the eluted sample. 
The SDS-PAGE analysis was performed in duplicate. A second gel was used for 
Western blotting verification, and a single band just below 27 kDa was observed in each 
of the lanes 8 and 9, thus indicating the presence of specific anti-cTnT scFv antibodies. 
No protein bands were observed in lane 10 thus indicating that non-specific proteins 
were removed. Lane 11 contained the elution fragment. The major band (marked by a 
red circle) was present just below the 27 kDa marker, thus verifying the identity of the 
F1 scFv. However, a number of non-specific bands (smeary bands) close to the major 
band were also present in lane 11. These may be due to the concentration of the 
secondary antibodies being too high, or the incubation with the secondary antibodies 
being too long. The protein concentration of the highly purified F1 scFv was 0.74 
mg/mL (a total of approximately 0.37 mg antibody) as determined by the NanodropTM 
ND-1000. An ELISA was subsequently performed to determine the titre of the purified 
F1 scFv (Fig. 3.13).  
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Figure 3.13. Antibody titre determination of purified anti-cTnT scFv F1 antibody. 
An ELISA plate was coated with 100 µL of 1 µg/mL cTnT and blocked with 200 µL 
5% (w/v) Marvel in PBS. A series of dilutions of purified F1 antibody (1 in 100 to 1 in 
102,400) was prepared and 100 µL of each was added into the wells. The scFv 
antibodies were detected using HRP-labeled mouse anti-HA monoclonal antibody. The 
ELISA was developed with TMB substrate and the absorbance was read at 450 nm. 
 
The midpoint of the linear range (1 in 6,400) of the titration ELISA was selected as the 
optimal dilution for an inhibition ELISA. Kinetic studies and inhibition studies were 
then performed using the purified F1 scFv. 
 
3.2.12 Preconcentration analysis of rabbit anti-HA polyclonal antibody for 
immobilisation on a dextran chip surface 
A CM5 dextran chip surface was prepared for kinetic studies of the F1 scFv using the 
BiacoreTM 3000. The preparation process involved a preconcentration study and ligand 
immobilisation (section 3.2.13). This section describes the preconcentration on a CM5 
dextran chip surface.  
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Preconcentration allows the identification of the optimal conditions for ligand 
immobilisation on the chip surface. A suitable pH value is selected from this step and 
this maximises the amount of ligand that is covalently linked to the dextran surface. 
Sodium acetate buffer solution has a low ionic capacity and its use favours the 
electrostatic attraction between the negatively charged dextran matrix and the positively 
charged ligand, which is dissolved in the sodium acetate solution. A preconcentration 
study was performed using a rabbit anti-HA epitope tag polyclonal antibody as a 
capture ligand mixed with sodium acetate buffer solutions at six different pH values 
(Fig. 3.14). Initially, a desorb procedure was performed on the BiacoreTM instrument to 
clean the microfluidic tubes, chamber, and injection port. A CM5 dextran was then 
docked and primed five times with 1 x HBS buffer prior to the preconcentration run.      
 
Figure 3.14 shows increased RU with decreased pH values. The lowest RU level was 
obtained at pH 5.0 whereas the highest RU level was observed at pH 4.0. In general, the 
optimal pH value is the one which can generate the maximum surface binding response. 
This value should also be lower than the isoelectric point (pI) of the immobilised ligand. 
Due to the negatively charged chip surface, the lower pH can maintain the positive 
charge of the ligand solution thus keeping the electrostatic attraction pattern between the 
ligand and the chip surface. pH 4.0 was selected as optimal for the immobilisation of 
anti-HA antibodies. 
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Figure 3.14. Preconcentration profile of an anti-HA polyclonal antibody for 
immobilisation on a CM5 chip. Six different sodium acetate buffer (10 mM) solutions 
(at pHs of 5.0, 4.8, 4.6, 4.4, 4.2 and 4.0) were mixed with anti-HA polyclonal antibody 
to give a final antibody concentration of 12.5 µg/mL. The experiment was set-up using 
the BiacoreTM 3000 surface preparation wizard. The levels of ligand binding were 
indicated by response units. The highest level of binding occurred at pH 4. 
  
3.2.13 Immobilisation of rabbit anti-HA polyclonal antibody on a dextran chip 
surface 
Many different chemistries for surface coupling of protein to a metal surface have been 
developed (Karlsson and Larsson, 2004; Rich and Myszka, 2005). Amino coupling is a 
common approach for attaching the ligand covalently to the dextran matrix (Rich and 
Myszka, 2005). Using a mixture of equal volumes of EDC (0.4 M) and NHS (0.1 M), 
the carboxymethylated dextran matrix can be activated resulting in the formation of 
functional succinimide ester groups. Primary amine groups on a ligand can be 
covalently linked with succinimide ester groups thus enabling the immobilisation of the 
ligand on the chip surface. The unbound functional groups on the chip surface are 
inactivated with ethanolamine-HCl (1M). Subsequent regeneration steps remove non 
covalently linked substances from the coupling process. The RU difference between the 
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end of regeneration step and the beginning of activation step indicates the level of 
immobilisation obtained (Fig. 3.15). The final RU is correlated with the amount of 
antibodies immobilised, which was approximately 7,120 RU.     
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Figure 3.15. Immobilisation of anti-HA antibodies on a BiacoreTM CM5 chip 
surface. Anti-HA antibody was diluted in 10 mM sodium acetate buffer (pH 4.0) to a 
final concentration of 25 ng/mL. Four main steps, indicated by letters A to D in Figure 
3.15, show the sequential steps involved in the immobilisation process. Step A: surface 
activation occured when a mixture of EDC and NHS was passed over the dextran 
surface. Step B: antigen was covalently bound to the activated dextran via the amine 
groups. In step C, ethanolamine-HCl was used to block unreacted groups on the surface. 
Finally, in step D, the chip surface was regenerated using five injections of 20 mM 
NaOH, which was found to be the optimal procedure for surface regeneration.  
 
3.2.14 Kinetic studies of anti-cTnT scFv F1 antibody 
‘Real-time’ monitoring of protein-protein interactions on BiacoreTM 3000 can be 
applied to antibody kinetic studies. The data collected over a specified time are used for 
the determination of both the association rate constant (ka) and the disassociation rate 
constant (kd). The equilibrium association rate constant (KA) and the equilibrium 
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dissociation rate constant (KD) can be calculated subsequently. Kinetic studies on F1 
antibody were performed using a capture assay format (see section 2.3 .1.19). A range 
of cTnT antigen concentrations were selected for binding studies and the experimental 
binding curves were fitted to the theoretical curves (binding model). A number of 
factors were involved for choosing a suitable model for the anti-cTnT scFv studies. For 
example, for efficient estimation of the binding constant, the binding model is required 
to be as simple as possible. In this study, the interaction between cTnT antigen and 
anti-cTnT scFv was a homogeneous 1:1 interaction, therefore, complicated 
heterogenous binding models did not suit. In addition, the model selected should allow 
analysis of a wide range of ligands and analyte concentrations. The 1:1 Langmuir 
binding model is a simple classical model which can be used for the majority of 
protein-protein interaction studies. It assumes that both the analyte and ligand are 
homogeneous. It also assumes that the analyte is monovalent, which is particularly 
useful for antigen-specific antibody studies. Moreover, a range of analyte concentration 
can be used for this model. Therefore, the F1 kinetic curves were fitted to a 1:1 
Langmuir binding model. Association and disassociation information was recorded 
throughout the process (Fig. 3.16). 
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Figure 3.16. Kinetic characterisation of anti-cTnT F1 scFv antibody on BiacoreTM 
3000. The F1 scFv antibodies were passed over the anti-HA antibody surface. Then 
cTnT, at concentrations of 50, 25, 12.5, 6.25, 3.125 and 1.625 nM, were passed over the 
chip surface. The analysis of cTnT binding at a concentration of 12.5 nM was carried 
out in duplicate. The curves (in color) represent the six different cTnT concentrations 
and were fitted to a 1:1 Langmuir binding model (black dotted line). Kinetic parameters 
were evaluated using the Biaevaluation 4.1 software. Poor fitting of the experimental 
curves with the binding model was observed.  
 
Table 3.4 lists the kinetics constants obtained from the evaluation. The affinity of F1 
was determined as 2.4 nM. However, this data was not reliable due to poor curve fitting.  
 
Table 3.4. Parameters determined from scFv F1 kinetic analysis 
 
 
 
 
ka (M-1s-1) kd (s-1) KA(M-1) KD (M) 
2.7 x 105 6.5 x 10-4 4.2 x 108 2.4 x 10-9 
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3.2.15 Inhibition assay analysis of anti-cTnT scFv F1 antibody 
In order to obtain accurate data to determine the antigen detection capacity of F1 
antibody, an inhibition assay was performed. An inhibition assay is based on the 
capacity of analyte binding to free molecules in solution, resulting in an inhibition 
binding of the analyte to the ligand which is linked on a surface. It is an effective 
method for measuring the concentration of free molecules in solution. Assay 
performance generally can be validated by its precision, specificity and accuracy. 
Precision of an assay refers to the agreement between data collected from replicate 
measurements on the same sample, which can be represented by the standard deviation 
(SD) and coefficient of variation (CV). Assay specificity refers to the capacity of the 
assay to measure the analyte without the interference from other substances present in 
the sample. Assay accuracy describes the agreement of measured concentrations with 
accepted reference value. Data collected from a standard reference assay are required 
for assay accuracy validation. Terms such as limit of detection (LOD), limit of 
quantification (LOQ) and IC50 often used to describe the performance of an assay.  
 
3.5. Description of parameters in an inhibition assay 
(Based on references: Armbruster et al., 1994; Armbruster and Pry, 2008)  
 
The inhibition assay of F1 was performed using an ELISA format. The purified F1 
antibody was diluted 1 in 6,400 in PBS (see section 3.2.11) and then incubated with 
different concentrations of free cTnT antigen. The mixture was added into a cTnT- 
coated ELISA plate thus allowing competitive binding of F1 antibody with free cTnT 
and cTnT bound on ELISA plate. Intra-day assays (three assays on the same day) were 
also performed to assess the assay performance. The collected data were fitted in a 
four-parameter calibration curve using SigmaPlot version 11.0 software (Fig. 3.17). 
Parameters Description 
LOD Lowest analyte concentration in a sample that can be detected            
LOQ 
Valid range of analyte concentrations (from lowest to highest)  within which the 
assay performance is acceptable 
IC50 The concentration of analyte which gives 50% of the maximum response 
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Figure 3.17 shows all the five data points are in the linear range of the inhibition assay, 
thus, the precision of the assay was determined using the data of the five points. 
 
The precision (repeatability) of the F1 inhibition assay was assessed using the 
coefficient of variation in percentage (% CV) values. Percentage for CV was 
determined from the ratio between the Standard deviation (SD) and mean then 
multiplying by one hundred. Table 3.6 shows the mean of A/A0 values, SD and % CV 
for the intra-day assays. The % CV values showed a precision ranging from 1.9% to 
11.6%.  
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Figure 3.17. Inhibition ELISA analysis of purified anti-cTnT scFv F1 antibody. An 
ELISA plate was coated with 1 µg/mL cTnT and blocked with 200 µL of 3% (w/v) 
BSA in PBS. Various concentrations of cTnT (500, 250, 125, 62.5, 31.25, 15.63 ng/mL) 
were incubated with the F1 scFv antibodies for 1 hour at 37oC. The scFv antibodies 
were detected using HRP-labeled mouse anti-HA monoclonal antibody. The ELISA was 
developed with TMB substrate and the absorbance was read at 450 nm. A 
four-parameter fitted curve was plotted using SigmaPlot version 11.0 software. The IC50 
value of purified F1 antibody was determined as 85 ng/mL. The error bars represent the 
mean values +/- the standard deviation.  
 
 
Table 3.6. Parameters determined for the evaluation of inhibition assay precision 
[cTnT] ng/mL Mean SD %CV 
500 
250 
125 
62.50 
31.25 
15.63 
0.25 
0.33 
0.44 
0.73 
0.84 
0.93 
0.01 
0.04 
0.01 
0.02 
0.05 
0.03 
3.1 
11.6 
1.9 
3.7 
6.1 
3.6 
145 
 
3.3 Discussion 
This chapter described the generation of recombinant antibody fragments against cTnT, 
a ‘gold standard’ for CVD diagnosis. It was focused on the construction of an avian 
immune antibody library using a chicken host and the selection of a cTnT-specific scFv 
using the phage display technique. Antibody purification, characterisation and assay 
development were also described.  
 
Cardiac TnT is unique to cardiac muscle due to the fact that it possess unique epitopes 
not found in the skeletal isoform (sTnT) (Mair et al., 1992). In order to obtain an 
in-depth understanding of their structural differences, the amino acid sequence between 
cTnT and sTnT was aligned and compared. It was found that sequence homology was 
59% (Fig. 3.3). The dissimilarity value is higher than described by Mair. He reported 
that cardiac troponin T was 10% to 30% structurally different from its skeletal form 
(Mair, 1997). In addition, Perry also reported the structural differences between cTnT 
and sTnT, where cTnT always contains more amino acid residues than sTnT (Perry, 
1998). Furthermore, a longer N-terminal portion of cTnT than present in sTnT was also 
observed from sequence alignment. Only 57 amino acid residues of sTnT were aligned 
with the first 91 amino acid residues of the cTnT sequence (Fig. 3.4). This observation 
concurs with Perry’s study, which reported the N-terminal of TnT from rabbit cardiac 
muscle was approximately 50 Å longer than its skeletal isoform (Perry, 1998). 
Similarly, Gusev also indicated that TnT isoforms synthesized from skeletal and cardiac 
muscles vary in length and amino acid composition of the N-terminal 40-60 member 
peptides (Gusev et al., 1983). Therefore, the high levels of structural difference enabled 
the production of specific antibodies binding solely to cTnT.  
 
In order to ensure that a chicken was a suitable host for antibody generation, its cTnT 
sequence was aligned with cTnT from other animal species. The similarity score 
revealed that human and chicken only had 78% homology. This score was lower than 
that found in human and rabbit (91%) and between human and mouse (87%). The low 
similarity confirmed that cTnT from chicken species was in evolutionary terms, more 
distant from human and therefore, the production of antibody in chickens should 
achieve a better immune response than in rabbits and mice.  
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For antibody production, both a suitable animal host and a antigen of good quality are 
important. An immunogen of low purity (containing contaminating proteins) can lead to 
the animal host responding to non-related proteins thus producing antibodies with low 
antigenic specificity. Human cTnT was used as an immunogen in this study and was 
purchased from Life Diagnostics Inc. (USA). The purity of immunogen was verified by 
SDS-PAGE analysis. As shown in Figure 3.5, a single clean protein band indicated that 
the cTnT immunogen had a high level of purity (Fig. 3.5). This commercial cTnT 
protein was subsequently used to immunise a chicken. After the 4th immunisation, the 
chicken serum had a titre in excess of 1 in 10,000 against the cTnT antigen, which 
indicated the chicken host had generated a sufficient polyclonal response. A preliminary 
inhibition ELISA showed that the crude bacterial lysates from the F1 scFv antibody had 
an IC50 value of 214 ng/mL (Fig 3.11). Crude lysate solutions are routinely extracted 
from cells by destroying the cell membrane, using freeze-thaw cycles or sonication. 
During cell lysis, the desired proteins and a large quantity of non-specific substances are 
released. Due to the simplicity of the technique, crude lysates are widely used in 
immunoassay development. For example, Yin and colleagues successfully developed an 
assay for the quantification ‘collagen-like’ polymer based on crude cell lysates (Yin et 
al., 2002). An ELISA assay was also reported for the detection of a blood coagulation 
factor XIII subunit A using crude cell lysates (Katona et al., 2001). However, 
non-specific substances can interfere the performance of the assay. For instance, the 
target recombinant protein fragment can be easily degraded by proteolytic enzymes in 
the cell lysates. Therefore, purified antibody is still the choice for protein 
characterisation studies and assay development. In this study, the F1 scFv antibody was 
purified prior to kinetic analysis and assay development. 
 
The BiacoreTM 3000 biosensor system used the ‘real-time’ and ‘label-free’ approach for 
SPR-based protein-protein interaction studies. Pre-concentration pH analysis revealed 
that sodium acetate buffer, pH 4.0, was optimal for immobilisation of rabbit anti-HA 
polyclonal antibody onto a CM5 sensorchip surface (Fig. 3.14). In contrast, Leonard 
and co-workers reported that a sodium acetate buffer with a pH 4.5 was optimal for 
anti-HA antibody immobilisation (Leonard et al., 2011). The difference in pH may be 
due to the variation between chip surfaces or the sources of anti-HA antibodies used. An 
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RU level of 7,120 was obtained after the immobilisation of anti-HA antibodies onto the 
CM5 sensor chip. This amount was considered sufficient for subsequent SPR studies.  
 
Kinetics analysis was performed on the purified F1 scFv antibody using the previously 
prepared anti-HA sensor chip. A 1:1 Langmuir binding model was chosen for curve 
fitting (section 3.2.14). The kinetic study showed the anti-cTnT F1 antibody had an 
affinity (KD) of 2.4 nM (Table 3.4). However, figure 3.16 displayed that all six of the 
experimental curves poorly overlaid the binding model curves. Significant deviations 
were observed in both the association phase and the disassociation phase (Fig. 4.11). A 
number of factors may have affected the accuracy of this kinetic study and thus 
impacted on the curve fitting. One key factor was the amount of ligand (F1 antibodies) 
captured on the sensorchip surface. Generally, a low ligand capture level can prevent 
the rebinding of the analyte during the disassociation process (Karlsson and Larsson, 
2004). In this study, the amount of F1 antibodies captured on the sensorchip surface 
generated a low cTnT binding level (52 RU), hence indicating a relative low ligand 
capture level.  
 
It is possible that mass transport may have negatively impacted the kinetic study. Mass 
transport describes the movement of antibody molecules from the buffer solution to the 
sensorchip surface. Mass transfer can be influenced by the flowrate of buffer solution 
hence affecting ligand-analyte binding (Goldstein et al., 1999). It is possible that the 
kinetic experiment was mass transport limited, either due to the excess levels of 
immobilised anti-HA or captured scFv antibodies. It is also possible that the scFv 
solution was heterogeneous and consisted of monomers, dimers and other multimers, 
therefore, avidity effects on the sensorchip surface prevented the accurate determination 
of the kinetic rate constants.   
 
In order to obtain more reliable data to interpret the antigen binding capacity of the F1 
antibody, an inhibition assay was developed (Fig. 3.17). It was shown that the F1 had an 
IC50 of 85 ng/mL and this value was lower than that observed from the crude lysate 
analysis (214 ng/mL). Elimination of interferences from non-specific protein in crude 
lysate may have improved the antigen detection levels of the F1 scFv. Analysis of the 
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linear range of the F1 antibody intra-day assays, showed that the assay precision (1.9% 
to 11.6%) was within an acceptable range (< 20%), as reported by Reed and co-workers. 
They demonstrated that CV levels in an immunoassay that exceed 20% are expected to 
cause a loss of precision. Such large variations in CV are often seen when quantifying 
samples at the extreme ends of an assay’s range (Reed et al., 2002). In contrast, Makin 
demonstrated that the acceptable assay precision of an immunoassay was less that 10% 
(Makin, 2010). Using highly purified F1 antibodies may improve the cTnT ELISA 
inhibition assay.      
 
In conclusion, recombinant anti-cTnT scFv fragments were successfully produced and 
SPR-based kinetic analysis indicated that this recombinant antibody fragment had 
nanomolar cTnT binding affinity. However, this data was not reliable as the theoretical 
and experimental SPR sensorgrams differ significantly from each other. A successfully 
developed ELISA-based inhibition assay revealed that the purified F1 scFv had an IC50 
value of 85 ng/ml for the cTnT antigen. In addition, the assay precision was within an 
acceptable range. Further improvements are required for the anti-cTnT scFv antibodies 
in order to meet the recommended criteria for CVD diagnosis. Protein engineering 
strategies such as random or site-direct mutagenesis can increase the affinities of 
antibody. Such an approach is described in the next chapter, where a shuffling method 
was applied to the construction of heavy and light chain-shuffled libraries for the 
selection of anti-cTnT antibodies with enhanced affinities. 
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4.1 Introduction 
This chapter outlines the application of mutagenesis for the generation of improved 
avian anti-cTnT scFv antibodies. It contains an in-depth description of the mutagenesis 
used for the production of new chain-shuffled scFv antibodies. In addition, the isolation, 
SPR-based characterisation and the development of an inhibition assay for new mutant 
anti-cTnT scFv antibodies are also described.        
 
Although recombinant antibody technology is useful for the generation and isolation of 
many different proteins, it is still has a number of limitations. For instance, many 
enzymes produced by recombinant technology have limited utilities due to their 
degradation when exposed to unsuitable reaction conditions, such as high temperature, 
high pH and chemical solvents (Shaw, 1987). Furthermore, some recombinant 
antibodies may have limited use in diagnostic assays due to poor specificity and low 
antigen affinity (Gronwall and Stahl, 2009).  
 
Protein engineering allows the researcher to alter the properties of a recombinant protein 
in order to meet the required criteria. In protein engineering, genetic manipulations are 
used to modify the coding sequence of a gene, and this can lead to an improvement in 
the required traits of the protein encoded by that gene. Examples include improving 
protein thermal tolerance, enhancing enzymatic activities, increasing protease resistance, 
strengthening reactivity in organic solvents, increasing pH stabilities, eliminating 
cofactor requirements or altering the binding specificity of antibodies. These 
improvements can be achieved using a number of approaches, such as adding disulfide 
bonds, replacing labile amino acids or altering the CDRs of antibodies (Chen et al., 
1991; Wilson and Agard, 1991; Zoller, 1991,1992; Markert et al., 2001; Eijsink et al., 
2004 and Mathieu et al., 2010).  
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So far, the properties of a number of industrial enzymes have been successfully 
modified by protein engineering (Goodenough, 1995; Rubingh, 1997). The thermal 
stability of Xylanase, an enzyme used for paper bleaching, was improved two fold after 
incorporation of a disulfide bond into the enzyme (Wakarchuk et al., 1994; Gruber et 
al., 1998). A second example includes subtilisins which are essential agents in 
detergents as they can degrade proteins by hydrolysis. In natural extracellular 
environments, subtilisins are stabilized by binding with calcium. However, in an 
industrial environment, there are a large number of metal-chelating agents that can bind 
to calcium ions (Strausberg et al., 1995). To overcome this problem, 
calcium-independent subtitisins were generated by protein engineering. This was 
achieved by deleting the amino acids which were responsible for calcium binding 
(Kumar and Takagi, 1999; Bryan, 2000).    
 
In general, protein engineering is performed by indirectly modifying the encoded gene 
rather than direct modification of the protein. The modification of the gene allows 
continuous production of the modified product by the host organism. However, if the 
mutation is performed directly on the protein, every single batch of protein has to be 
modified, which can be time-consuming and expensive. Mutagenesis can be divided 
into two major categories: random mutagenesis and site-directed mutagenesis. Random 
mutagenesis refers to mutations that can occur at any site within the DNA, whereas, 
site-directed mutagenesis targets mutations to particular sites (Carter, 1986; Cadwell 
and Joyce, 1994). Generally, a large number of variants are produced from random 
mutagenesis and this eliminates the need to know the detailed gene information of the 
protein. In contrast, site-directed mutagenesis requires specific knowledge of the gene 
sequence which encodes the target protein. This method generates mutant proteins with 
fewer amounts of variants, thus saving time on analysis. A wide range of mutagenesis 
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strategies have been developed and several strategies may be used for either 
site-directed mutagenesis or random mutagenesis (Fig. 4.1). 
 
Figure 4.1. Strategies for random mutagenesis and site-directed mutagenesis. Both 
random mutagenesis and site-directed mutagenesis are often used in protein 
engineering. (Based on references: Carter, 1986; Wilson and Keefe, 2001; 
Chusacultanachai and Yuthavong, 2004; Antikainen and Martin, 2005)  
 
DNA shuffling, invented by Stemmer in 1994, can be used in both random and 
site-directed protein mutagenesis (Joern, 2003). This method can be used to recombine 
pools of homologous genes by random fragmentation and PCR reassembly (Stemmer, 
1994a). Typically, three-experimental steps are used. In the first step, the gene 
fragments are digested into small DNA fragments. Next, these fragments are randomly 
ligated together to form recombinant gene fragments and finally, the new fragments are 
amplified using PCR (Stemmer, 1994a). This technique has been applied to the 
improvement of activity of TEM-1 β-lactamase toward cefotaxime. Stemmer reported 
that the mutant TEM-1β-lactamase had a 32,000 fold increase in activity over the 
original enzyme (Stemmer, 1994b).  
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An alternative approach is ‘chain shuffling’ which is often used to improve the affinities 
of recombinant antibodies (Bacher et al., 2002; Finlay et al., 2006). Chain-shuffling is a 
method for in vitro recombination of pools of antibody chain genes by random 
fragmentation and PCR reassembly (Fig.4.2). Generally, a mutant antibody library can 
be generated by assembly of antibody chain genes from an original library (library prior 
to biopanning), with antibody genes from an antigen-specific library (library post 
biopanning). Subsequently, the new mutant antibody library can undergo biopanning 
and screening procedures for the selection of antibodies with higher antigen-binding 
capacities.  
Antibody library with a large number   
variants prior to biopanning 
Antigen-specific library with fewer  
variants post biopanning
New chain-shuffled library with a 
large number of specific variants 
Linking of the light and heavy 
chains from each library 
 
Figure 4.2. Antibody chain shuffling strategy. Antibody chain genes were amplified 
from the original antibody library (library prior to biopanning) and antigen-specific 
library (library post biopanning). The amplicons from the two libraries are assembled by 
PCR thus generating a new chain-shuffled library.  
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A number of studies have shown that the affinity of antibodies can be improved using 
the chain shuffling approach. For example, Fitzgerald and colleagues showed that the 
halofuginone detection level of an anti-halofuginone scFv antibody was increased 185 
fold using the light-chain shuffling approach (Fitzgerald et al., 2011). Similarly, 
Tachibana and co-workers used chain shuffling to improve the affinity of a lectin Fab 
fragment, CP33. The affinity of the Fab fragment was increased either 4.8 or 1.7 fold 
with single amino acid modifications to the light chain (Tachibana et al., 2004). 
Moreover, Yoshinaga and co-workers also improved the affinity of anti-human MCP-1 
antibody by 15 fold (Yoshinaga et al., 2008). In this work, both light chain and heavy 
chain shuffling were performed in order to achieve a greater number of variants for 
biopanning of the anti-cTnT scFv library. 
 
4.1.1. Work summary for the generation of chain-shuffled avian anti-cTnT scFv 
antibodies 
In this chapter, mutant avian antibody libraries (light chain-shuffled and heavy chain 
shuffled) were constructed. Variable antibody chain genes were amplified from the 
original avian anti-cTnT scFv antibody library (section 3.2.7). In addition, variable 
antibody chain genes were also amplified from the fifth round of the biopanning of the 
anti-cTnT scFv library. The amplified variable chain genes were assembled by 
SOE-PCR and ligated into a phagemid pComb3XSS vector. The mutant antibody phage 
libraries were subsequently constructed by transforming the antibody gene-containing 
plasmids into E.coli XL-Blue cells. The enhancement of specificity of anti-cTnT scFv 
antibodies was achieved by performing five separate rounds of biopanning and positive 
scFv clones were selected using a simple ELISA-based ‘on-plate’ screening method.  
 
DNA fingerprinting was used to assess the variety of anti-cTnT scFv antibodies 
generated in the libraries. In addition, 384 anti-cTnT scFv clones were analysed using a 
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SPR-based ranking method. From the ranking results, ten antibodies were selected and 
subjected to kinetic studies. Four clones, showing high affinity levels, were assessed for 
cross reactivity and temperature stability. From the kinetic analysis, the experimental 
curves of clone 8C2 had closer fitting with the theoretical binding curves and hence it 
was selected for further study. This 8C2 clone was subsequently purified and 
incorporated into an inhibition assay. Following chain shuffling, the 8C2 clone showed 
improved antigen-binding capacity compared to the wild-type F1 clone. 
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4.2 Results 
4.2.1. PCR amplification of the avian cTnT variable heavy and light chain genes 
Two types of mutant antibody libraries were produced; a light chain-shuffled library 
and a heavy chain-shuffled library. For the construction of the light chain-shuffled 
antibody library, the variable light (VL) chain genes were amplified from the original 
unpanned cTnT library. In addition, the variable heavy (VH) chain genes were amplified 
using the DNA plasmids extracted from the fifth round of biopanning of the cTnT 
library. In contrast, for heavy chain shuffling, the VH genes were amplified from the 
original unpanned cTnT library. In addition, the VL genes were amplified from the fifth 
round of biopanning of the cTnT library (section 2.3.2.1). After PCR optimisation, 
amplicons were analysed on a 1% (w/v) agarose gel (Fig. 4.3) and, as shown in the gel 
image below, the variable genes were successfully amplified.  
400bp
300bp
400bp
300bp
1          2            3                                4         5        6
 
Figure 4.3. PCR amplification of the avian cTnT variable heavy and light chain 
genes. Lanes 1 and 4 contained 1kb plus DNA molecular weight ladders (Invitrogen, 
USA). Lane 2 contained VL (~ 350 bp) genes from the original unpanned library. Lane 3 
contained VL (~ 350 bp) genes from the fifth round biopanned library. Lane 4 and 5 
contained VH (~ 400 bp) genes from the original unpanned library and the fifth round 
biopanned library, respectively. 
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4.2.2. Anti-cTnT chain-shuffled scFv-Splice by Overlap Extension (SOE) PCR 
The cTnT light chain-shuffled SOE-PCR was generated by linking the VL amplified 
from the unpanned library with the VH fragment from the fifth round of biopanning. The 
cTnT heavy chain-shuffled SOE-PCR was generated by linking the VH amplified from 
the unpanned library, with the VL fragment from the fifth round of biopanning. The 
pComb3XSS plasmid was subsequently digested using a SfiI restriction enzyme. Both 
the vector and the stuffer was gel-purified and resolved on a 1% (w/v) agarose gel, in 
addition to the SOE-PCR products (Fig. 4.4). The gel image shows the pComb3XSS 
vector was successfully digested. Both the VL and the VH genes were also successfully 
amplified.  
1                 2                 3                 4                 5                   6  
4000 bp
3000 bp
850 bp
650 bp
2000 bp
1650 bp
 
 
Figure 4.4. SOE-PCR amplification of chain-shuffled fragments and SfiI digested 
pComb3XSS vector. Lanes 1 and 6 contained 1 kb plus DNA molecular weight 
ladders. Lanes 2 and 3 contain SfiI digested pComb3XSS vector and stuffer, 
respectively. Lanes 4 and 5 contained light chain-shuffled and heavy chain-shuffled 
SOE-PCR products, respectively.  
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4.2.3. Avian anti-cTnT chain-shuffled scFv library construction and enrichment 
via biopanning 
Large-scale amplifications for both the light chain-shuffled and heavy chain-shuffled 
SOE-PCRs were carried out and the SOE-PCR products were resolved on a 1% (w/v) 
agarose gel. After gel electrophoresis, these PCR products were extracted and 
concentrated by ethanol precipitation. The PCR products and pComb3XSS vector were 
subsequently digested with a SfiΙ restriction enzyme, and ligated overnight with T4 
DNA ligase. The ligated product was ethanol precipitated and subsequently 
electroporated into electrocompetent E. coli XL1-Blue cells, as described in section 
2.3.1.11. The sizes of the transformed avian anti-cTnT light chain-shuffled and heavy 
chain-shuffled libraries were 1.5 x 108 cfu/mL and 3.6 x 107 cfu/mL, respectively. 
Recombinant anti-cTnT scFv clones were selected from these libraries by performing 
five rounds of biopanning against immobilised cTnT antigen, as described in section 
2.3.1.12. Table 4.1 (A) and (B) show the input and output titres for each of the 5 rounds 
of biopanning of the heavy and light chain-shuffled scFv anti-cTnT libraries.  
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Table 4.1 (A). Input and output titres of light chain-shuffled anti-cTnT scFv 
library over five rounds of biopanning 
 
Biopanning round Input (cfu/mL) Output (cfu/mL) 
1 9.0 x 1011 1.1 x 106 
2 5.0 x 1011 7.5 x 105 
3 1.6 x 1011 1.3 x 105 
4 1.7 x 1012 5.0 x 105 
5 4.8 x 1011 2.9 x 105 
 
 
Table 4.1 (B). Input and output titres of the heavy chain-shuffled anti-cTnT scFv 
library over five rounds of biopanning 
 Biopanning round Input (cfu/mL) Output (cfu/mL) 
1 6.0 x 1011 4.7 x 106 
2 2.4 x 1011 5.6 x 106 
3 5.4 x 1011 1.2 x 105 
4 1.4 x 1012 1.5 x 105 
5 1.6 x 1012 8.0 x 104 
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4.2.4. Soluble expression of avian anti-cTnT chain-shuffled scFv antibodies  
To identify clones with high cTnT binding levels from the biopanned libraries, thirty 
two clones from the chain shuffled-library were picked from biopanning rounds three, 
four and five and analysed using the ‘on-plate’ ELISA screening method, described in 
section 2.3.1.14. The ELISA threshold was set as three times of the absorbance value of 
the blank sample, as described in section 3.2.8. Figures 4.5 (A) and (B) revealed a 
number of light and heavy chain-shuffled scFv clones that appeared to bind strongly to 
the cTnT antigen. 
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Figure 4.5 (A). Screening of the light chain-shuffled anti-cTnT scFv clones from 
rounds three, four and five of biopanning. Each blue bar represents the absorbance 
reading of a scFv antibody. A blank reference was also included in the analysis, which 
is represented by the black bar (96). To identify positive antigen-binding clones, a red 
horizontal line, which indicates the ELISA threshold, was drawn at the absorbance level 
of ~ 0.2. The threshold value is three times the blank reference absorbance.  
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Figure 4.5 (B). Screening of heavy chain-shuffled anti-cTnT scFv phage clones 
from rounds three, four and five of biopanning. Each blue bar represents the 
absorbance reading of an individual scFv antibody. A blank reference was also included 
in the analysis, which is represented by the black bar (96). A red horizontal line drawn 
at background absorbance level of ~ 0.3 marks the ELISA threshold. It is three times the 
blank reference absorbance. 
 
4.2.5. Comparison of the number of positive parental and chain-shuffled anti-cTnT 
scFv fragments 
The binding reactivity of clones to cTnT from both the heavy and light chain shuffled 
libraries were recorded and the percentages of positive clones were calculated. These 
data were then compared with the data obtained from the parental anti-cTnT library 
(Table 4.2). It was shown that the overall percentage of positive clones isolated from the 
parental scFv cTnT library was 56.3%. In contrast, an overall higher level of positive 
clones was isolated from both the heavy chain-shuffled (66.7%) and light chain-shuffled 
(75%) scFv cTnT libraries. Interestingly, the light-chain-shuffled library had the highest 
number of positive clones. The increase in the number of cTnT-binding clones indicates 
162 
 
that the chain-shuffling approach can generate a superior library by the elimination of 
non-specific clones. 
 
Table 4.2. Parental and chain-shuffled anti-cTnT scFv clones isolated from 
biopanning rounds 3, 4 and 5  
 
4.2.6. DNA fingerprinting analysis of anti-cTnT scFv clones 
In comparison to DNA sequencing, DNA fingerprinting is a relatively inexpensive and 
effective technique for the identification of gene diversity. In this technique, restriction 
enzymes are used to digest the antibody gene fragments which are then resolved on an 
agarose gel. Based on the gene fragments pattern presented on the agarose gel, different 
clones can be identified. This approach is extremely useful when dealing with a large 
number of clones. AluI and BstNI are commonly used restriction enzymes (Cai and 
Garen, 1997; Stahl et al., 2010; Chang et al., 2011). In general, genes with different 
restriction mapping patterns represent different clones.   
 
Biopanning 
Round 
Parental scFv cTnT 
library 
VH shuffled scFv cTnT 
library 
VL shuffled scFv cTnT 
library 
No. of 
positive 
clones  
Percentage of 
positive 
clones 
No. of 
positive 
clones 
Percentage of 
positive 
clones 
No. of 
positive 
clones  
Percentage of 
positive 
clones  
Round 3 9/32 28.1 % 20/32 62.5 % 22/32 68.8% 
Round 4 14/32 43.8% 22/32 68.8% 22/32 68.8% 
 Round 5 67/96 69.8% 22/32 68.8% 28/32 87.5% 
Overall 90/160 56.3% 64/96 66.7% 72/96 75% 
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Plasmids of eighteen scFv antibodies which showed positive binding against cTnT from 
monoclonal ELISA analysis were PCR-amplified. The genes were digested using the 
restriction enzyme, AluI. The digested products were analysed on a 3% (w/v) agarose 
gel (Fig. 4.6). The analysis of the eighteen scFv antibodies exhibited six different 
restriction map patterns, which indicated a moderate diversity level of scFv. However, 
two clones (in lanes 14 and 16) had no clear restriction digest profile, perhaps due to the 
poor quality of isolated plasmid DNA which was not amplified by PCR.  
 
1000 bp
500 bp
100 bp
1   2   3    4   5   6    7   8    9   10 11 12  13  14  15  16  17 18  19  20
A   A A A   A A   A   
B  B B   B   D   C   
E  
F    F
Figure 4.6. Restriction digestion profile of anti-cTnT scFv clones. Lanes 1 and 20 
contained a 100 bp DNA molecular weight ladder. Lanes 2 to 19 contained 18 
anti-cTnT scFv clones which were digested by the restriction enzyme, AluI. Six 
different DNA patterns, indicated by the letters A to F, were observed. Seven scFv 
antibodies, located in lane 1, 2, 3, 7, 8, 10 and 13 showed the same restriction profile 
(A). Four scFv antibodies, located in lane 5, 6, 9 and 12 showed the same restriction 
profile (B). Lanes 11, 15 and 17 had the restriction profiles C, D and F, respectively. 
Lanes 18 and 19 showed the same restriction profile (F). Lanes 14 and 16 did not show 
any clear restriction profiles. 
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4.2.7. Characterisation of avian anti-cTnT chain-shuffled scFv clones using the 
Biacore™ 4000 system.  
The SRP-based BiacoreTM 4000 system (GE healthcare, Sweden) was used to rank the 
cTnT-binding capacities of scFv clones. The BiacoreTM 4000 system has four 
independent flow cells with five detection spots on each flow cell. Up to 16 ligands can 
be immobilised on the chip surface, therefore, this system can analysis 16 analytes in 
one single run (Safsten et al., 2006). A total of 384 anti-cTnT chain–shuffled scFv 
clones which included 192 light chain-shuffled and 192 heavy chain-shuffled clones 
were analysed on the BiacoreTM 4000 system using the format depicted by Figure 2.1. 
 
In SPR analysis, a number of parameters can be used to characterise the clones, such as 
antibody capture levels; antigen binding early level; antigen binding late level; 
antibody-antigen complex stability early level; antibody-antigen complex stability late 
level and complex percentage left level. Antibody capture levels indicate the amount of 
scFv antibodies captured on the anti-HA surface. The antigen binding early value 
describes the amount of cTnT antigen bound to scFv antibodies just after the start of the 
cTnT injection. In contrast, the binding late value represents the amount of cTnT 
antigen bound to scFv antibodies just before the end of cTnT injection. ScFvs that have 
high binding late values indicate good antigen association. The stability early represents 
the amount of antigen binding just after the end of the sample (cTnT) injections. In 
contrast, the stability late represents the amount of antigen binding after a fixed period 
of dissociation. In addition, the binding stability can be represented by percentage left 
value (left %), which is the ratio of stability late and stability early. The sensorgram 
curves from the mutant scFv analysis are shown in Figure 4.7. A representative number 
of the sensorgram curves from the light and heavy chain-shuffled scFv analysis are 
shown in Figure 4.7. Three different stages (A, B and C) were observed through the 
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scFv-cTnT interaction process. Figure 4.7 reveals the anti-cTnT scFv clones had 
different surface capture and antigen binding levels.  
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Figure 4.7. Sensorgram profiles of anti-cTnT scFv antibodies using the BiacoreTM 
4000 system. The X axis represents time in seconds, and the injection of the cTnT 
antigen occurred at time 0 seconds. Each line represents the capture and binding profile 
of different anti-cTnT scFv antibodies. Stage A shows the level of scFv captured. Stage 
B showed the association between cTnT antigen and the captured scFv antibodies. Stage 
C represents the disassociation between the cTnT antigen and the scFv antibodies.  
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4.2.8. Ranking of avian anti-cTnT chain-shuffled scFv clones by antibody captured 
on the CM5 sensorchip surface  
Based on the values obtained from the binding analysis, the 384 clones were ranked by 
plotting the capture levels versus the binding late levels (Fig. 4.8). In Figure 4.8, clones 
were classified into three groups. Data points within or close to region A indicated low 
capture levels and low binding levels, which can be regarded as representing negative 
clones. Clones within or close to region B were captured onto the chip surface but had 
very low binding levels to the cTnT antigen. These clones can be used as negative 
antigen-binding controls. Clones within or close to region C show both high capture 
levels and high antigen-binding levels.  
 
Figure 4.8. Anti-cTnT light and heavy chain-shuffled scFv antibodies ranked by 
capture level. Each individual blue point represents a scFv antibody. The X-axis 
represents the response units of antibody captured on the anti-HA immobilized chip 
surface. The Y-Axis represents the response unit at the stage just before the end of 
sample (cTnT) injection (i.e. the binding late levels). Three regions (A, B, C) marked 
with black circles represented clones with different capture and binding capacities.  
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 4.2.9. Ranking of the anti-cTnT chain-shuffled scFv clones by percentage left 
Capture level-based ranking only indicates the amount of antigen which binds to the 
captured antibodies. However, it does not show how strong or stable the 
antibody-antigen interaction is. Whereas, percentage left indicates the stability of the 
antigen-antibody interaction. This percentage left value was calculated by dividing the 
stability late level by the stability early level. The anti-cTnT scFv clones were hence 
ranked by the percentage left (% left) (Fig. 4.9 (A) and (B)). A wide range of % left 
levels (from 7.2 to 76%) was observed.  
 
 
Figure 4.9 (A). Ranking of anti-cTnT light chain-shuffled scFv clone by % left.  
The X axis shows the anti-cTnT scFv clone number. Y axis represents the % left level 
of each clone. A wide range of % left values was observed, varying from 7.2 to 75.71%.  
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Figure 4.9 (B). Ranking of anti-cTnT heavy chain-shuffled scFv clone by % left. 
The X axis shows the anti-cTnT scFv clone number. The Y axis represents the % left 
level of each clone. A moderate range of % left values was observed, varying from 
39.92 to 76%.  
 
As the % left values for the clones with high stabilities were very similar i.e. between 
70% to 76%, it was possible that these clones were genetically identical. Therefore, to 
avoid choosing the same clones, ten antibodies with various antigen-binding stabilities 
(from 33.75 to 76%) (Fig. 4.9 (A) and (B)) were selected for further precision kinetic 
studies (Table 4.3). 
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Table 4.3. Antigen binding stability levels of ten avian anti-cTnT scFv antibodies 
Clone name Stability early (RU) Stability late (RU) % left 
7D8 182.1 138.4 76.00 
8C2 162.8 120.7 74.14 
8C10 145.6 106.3 73.01 
7D6 148.9 108.6 72.93 
8A6 131.8 94.9 72.00 
8D2 145.3 103.4 71.16 
8F5 135.8 74.2 63.07 
7H8 179.4 107.4 59.86 
8H6 206.5 80.2 39.93 
7G2 63.7 21.5 33.75 
 
4.2.10 Kinetic studies of ten anti-cTnT chain-shuffled scFv antibodies 
For kinetic analysis, a total of six different cTnT antigens concentrations were tested 
(section 2.3.1.19). The kinetic curves were fitted in a 1:1 Langmuir binding model and 
kinetic parameters were generated using Biaevaluation 4.1 software. The kinetic curves 
of four clones which revealed higher affinities levels were shown in Figure 4.10. The 
experimental curves of a heavy chain-shuffled clone, 8C2, had a better overlay with the 
1:1 Langmuir binding model than other three clones (7D8, 8C10 and 7H8).   
 
In addition, the kinetic constants for each of the four clones were calculated by 
Biaevaluation 4.1 software (Table 4.4). Interestingly, all four antibodies had 
subnanomolar affinities. However, 8C2 displayed the lowest Chi2 value. The Chi2 value 
indicates the goodness of the curve fit, thus describing the accuracy of kinetic 
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parameters generated. A low Chi2 value generally indicates that the kinetic analysis is 
more reliable. 
8C2 8C10
7D8 7H8
 
Figure 4.10. Kinetic characterisation of anti-cTnT scFv antibodies. The blue curves 
represented the experimental curves of the four anti-cTnT scFv antibodies (8C2, 8C10, 
7D8, and 7H8) with six cTnT concentrations (50 nM, 25 nM, 12.5 nM, 6.25 nM, 3.12 
nM and 1.56 nM). They were fitted using a 1:1 Langmuir binding model (in black). In 
addition, the analysis of cTnT with 12.5 nM concentration was carried out in duplicate.  
 
Table 4.4. Parameters determined from scFv kinetic studies 
*8C2 has the best kinetic curve fit 
Clone  ka (1/Ms) kd (1/s) KA(1/M) KD (M) Chi2(RU2) 
*8C2 6.90 x 106 2.73 x 10-4  2.53 x 1010 3.95 x 10-10 0.29 
8C10 2.17 x 106 7.11 x 10-4  3.05 x 109 3.28 x 10-10 0.85 
7D8 1.76 x 106 5.37 x 10-4  3.27 x 109 3.05 x 10-10 0.70 
7H8 1.28 x 106 6.17 x 10-4  2.07 x 109 4.82 x 10-10 0.79 
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4.2.11 Cross reactivity analysis of anti-cTnT chain-shuffled scFv antibodies 
Cross reactivity studies are used for the determination the capacity of an antibody 
binding site to cross react with non-target proteins. Often cross reactivity occurs when a 
protein shares a common epitope with the target antigen, or it has an epitope which is 
structurally similar to the desired antigen (Porrozzi et al., 2004). 
 
To assess the cross reactivity of anti-cTnT scFv antibodies, all four clones were 
analysed with other troponin isoforms: Skeletal troponin T (sTnT), Cardiac troponin I 
(cTnI) and skeletal troponin I (sTnI). The sTnT protein is a major type TnT isoform that 
exists in skeletal muscle tissue. In addition, cTnI and sTnI are also very common 
troponin isoforms. The cross reactivity study of the anti-cTnT scFv antibodies were 
performed using the troponin isoforms (sTnT, cTnI and sTnI) in a direct ELISA format 
(section 2.3.1.15). Figure 4.11 revealed all four clones displayed high specificity for 
cTnT with no significant cross reactivity to any of the sTnT, cTnI or sTnI isoforms. 
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Figure 4.11. Cross reactivity studies of anti-cTnT scFv antibodies. The yellow bar 
represents the absorbance from the binding analysis between scFvs with cTnT protein. 
The light blue, black and red bars represent the absorbance from the binding analysis 
between scFvs with sTnT, cTnI and sTnI, respectively. The dark blue bar represents 
control 1 with no antigens coated in the plate wells. The dark red bar represents control 
2 which contained only blocking solutions Marvel (5% (w/v)). The analysis was 
performed in triplicate. The error bars represent the standard deviation. 
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4.2.12 Temperature stability studies of anti-cTnT chain-shuffled scFv antibodies 
The four scFv antibodies (8C2, 7D6, 7D8 and 7H8) were further assessed for their 
temperature stability. An antibody that exhibits high stability levels over a range of 
temperature has added value as a diagnostic reagent. The anti-cTnT scFv antibodies 
were analysed using the BiacoreTM 4000 at three different temperatures (30oC, 25oC, 
20oC). The same assay format used for the analysis was illustrated by Figure 2.1. Figure 
4.12 shows the affinities levels of each scFv antibodies at three temperatures. This data 
was generated by plotting the association rate constant (ka) against dissociation rate 
constant (kd).  
 
Over three different temperatures, the four clones displayed a very narrow range of 
cTnT affinity (0.427 nM to 2.74 nM). In addition, clone 7H8 and 7D8 had 
subnanomolar affinities at all three temperatures (less than 1 nM). In contrast, clone 
8C2 and 7D6 only revealed subnanomolar affinities at 30oC or 25oC. At 20oC, their 
affinity levels were greater than 1 nM. Although clones 8C2 and 7D6 showed greater 
variations in affinity levels than 7H8 or 7D8, the variations were not significant due to 
the narrow affinity range. All four clones remained stable over the three temperatures. 
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Figure 4.12. Temperature stability studies of anti-cTnT scFv antibodies. The X-axis 
represents the dissociation constant Kd (1/s). The Y-Axis represents the association 
constant Ka (1/Ms). The blue, green and red points represent three different assay 
temperatures (30oC, 25oC, 20oC), and each point was labeled with the clone name (8C2, 
7H8, 7D6 and 7H8). The black straight line which crosses the plot indicates an affinity 
level of 1 nM. Data points above the straight line have an affinity less than 1 nM, 
whereas, the data points below have an affinity greater than 1 nM.  
 
4.2.13 Purification of anti-cTnT 8C2 scFv antibody using immobilised metal 
affinity chromatography (IMAC) 
As the 8C2 scFv displayed high cTnT affinity, the best kinetic curve fit and the 
antigen-binding was stable over a range of temperatures, the 8C2 scFv was chosen for 
further analysis. The 8C2 was firstly purified using the IMAC protocol as previously 
described in section 2.3.1.16. Subsequently, an inhibition ELISA was performed using 
the IMAC-purified antibodies. The fractions from the different purification stages were 
analysed by SDS-PAGE and Western blotting (Fig. 4.13 (A) and (B)). The protein 
concentration of the purified scFv was 0.5 mg/mL as determined using the Nanodrop™ 
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ND-1000. A total of 0.3 mg of 8C2 antibody was purified. The purified antibody was 
then used for inhibition assay development. 
 
 
 
Figure 4.13 (A). SDS-PAGE analysis of the IMAC-purified 8C2 scFv antibody. 
Lanes 1 and 6 contained a page-ruler prestain protein marker. Lane 2 contained crude 
lysates extracted by sonication. Lane 3 contained ‘flow-through’ that was obtained after 
passing the E. coli cell lysates through a Ni-NTA agarose resin. Lane 4 contained a 
wash fraction, and lane 5 contained the elution fraction. Both lanes 2 and 3 contained a 
large number of irrelevant proteins with various sizes. In contrast, lane 4, which 
contained the column wash eluent, had no protein bands. This indicated the removal of 
non-specific proteins from the column resin. A clear strong band just below 27 kDa 
marker was observed in lane 5 (marked by a red circle), and this indicated the successful 
purification of the 8C2 scFv antibody. In addition, a minor number of non-specific 
bands were also observed in the eluted sample. The SDS-PAGE analysis was performed 
in duplicate and a second gel was used for Western blotting (Fig. 4.13 (B)). 
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Figure 4.13 (B). Western blotting analysis of the IMAC-purified 8C2 scFv 
antibody. Lanes 1 and 6 contained a page-ruler prestain protein marker. Lane 2 
contained crude lysates extracted by sonication. Lane 3 contained ‘flow-through’ that 
was obtained after passing the E. coli cell lysates through a Ni-NTA agarose resin. Lane 
4 contained a wash fraction, and lane 5 contained the eluted antibody fraction. A strong 
band just below 27 kDa was observed in lane 1, thus indicating the presence of specific 
anti-cTnT scFv antibodies. However, a second non-specific band was also observed just 
above 15 kDa, which could have occurred due to the degradation of the 8C2 antibody in 
unstable lysates. In contrast, the ‘flow-through’ fraction (lane 4) had no protein bands 
and thus indicates that non-specific proteins were removed during this step. Lane 5 
contained the eluted fragment; a clear strong band (marked by a red circle) at 
approximately 25 kDa was observed.  
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4.2.14 Checkerboard ELISA analysis of the 8C2 scFv antibody  
A checkerboard ELISA analysis was performed to indentify an optimal cTnT coating 
concentration for the inhibition assay. Seven different concentrations of the cTnT 
antigen were coated on an immuno 96 MicroWellTM solid plate and detected by the 
addition of a series of 8C2 antibody dilutions. The ELISA profiles were shown in 
Figure 4.14.  It was shown that cTnT concentrations 1, 1.5 and 3 µg/mL generated 
higher detection signals than other concentrations. The IC50 values at these three 
concentrations were very close. However, in order to minimize the consumption of 
cTnT protein (due to its cost), a concentration of 1,000 ng/mL was selected as the 
optimal coating concentration for the inhibition assay. 
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Figure 4.14. Checkerboard ELISA using different cTnT coating concentrations. A 
range of cTnT concentrations (0, 125, 250, 500, 1,000, 1,500 and 3,000 ng/mL) were 
coated on an immuno 96 MicroWellTM solid plate. A series of dilutions of the 8C2 scFv 
antibodies (1 in 100, 1 in 250, 1 in 500, 1 in 1,000, 1 in 2,000, 1 in 4,000, 1 in 8,000, 1 
in 1,6000, 1 in 32,000, 1 in 64,000 and 1 in 128,000) were added to the plate. Binding 
of the scFv antibodies was detected using HRP-labeled mouse anti-HA monoclonal 
antibody. The ELISA was developed with TMB substrate and the absorbance read at 
450 nm. 
 
4.2.15 ELISA optimisation of the 8C2 scFv antibody  
A second optimisation procedure was performed to detect the optimal concentration of 
the 8C2 scFv to be used in the assay. This was achieved by using different 8C2 antibody 
dilutions in an inhibition ELISA. The 8C2, which had an original concentration of 0.5 
mg/mL, was diluted 1 in 1,000 (500 ng/mL), 1 in 2,000 (250 ng/mL), 1 in 3,000 (166.77 
ng/mL) and 1 in 4000 (125 ng/mL) in PBS (pH 7.4). The ELISA profiles are shown in 
Figure 4.15. It was observed that antibody at a 1 in 1,000 dilution showed a 
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significantly higher IC50 value than at any of the other three concentrations. In contrast, 
no significant variations of the IC50 values were observed for the 1 in 2,000, 1 in 3,000 
and 1 in 4,000 dilutions. To minimise the antibody consumption, a 1 in 4000 dilution, 
equivalent to 125 ng/mL 8C2 antibody, was chosen as the optimal concentration.   
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Figure 4.15. Optimisation of 8C2 scFv concentrations for use in an inhibition 
ELISA assay. The immuno 96 MicroWellTM solid plate was coated with a previously 
determined optimal cTnT concentration of 1,000 ng/mL. The blue, red, green and purple 
lines represent four antibody dilutions: 1 in 1,000, 1 in 2,000, 1 in 3,000 and 1 in 4,000, 
respectively. The scFv antibodies were detected using HRP-labeled mouse anti-HA 
monoclonal antibody. The ELISA was developed with TMB substrate and the 
absorbance was read at 450 nm. 
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4.2.16 ELISA inhibition assay of the 8C2 scFv antibody  
An inhibition cTnT assay was developed with the purified 8C2 scFv in order to 
determine its cTnT antigen detection capacity. The assay used an optimal cTnT coating 
concentration 1,000 ng/mL and the optimal 8C2 concentration of 125 ng/mL. Intra-day 
assays (three assays on the same day) were performed to validate the cTnT inhibition 
assay. The collected data were fitted in a four-parameter calibration curve using the 
SigmaPlot version 11.0 software (Fig. 4.16). The IC50 value of purified 8C2 scFv was 
determined as 38 ng/mL. 
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Figure 4.16. Inhibition assay of purified anti-cTnT 8C2 scFv antibody. An ELISA 
plate was coated with 1 µg/mL cTnT and then blocked with 200 µl of 5% (w/v) Marvel 
in PBS (pH 7.4). Different concentrations of cTnT (250, 125, 62.5, 31.25, 15.63 and 
7.81 ng/mL) were incubated with the 8C2 scFv (at a final concentration 125 ng/mL) for 
1 hour at 37oC. The scFv antibodies were detected using HRP-labeled mouse anti-HA 
monoclonal antibody. The ELISA was developed with TMB substrate and the 
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absorbance was read at 450 nm. The assay was performed in triplicate. The error bars 
represent the mean values +/- the standard deviation.  
 
In an inhibition assay, an A0 standard indicates the absorbance of antibody lysate 
dilution without any inhibition of free antigen. The A/A0 value indicates the degree of 
inhibition which is calculated by dividing the absorbance value at each cTnT 
concentration (A) with the A0 absorbance value. The precision of the assay can be 
evaluated using the coefficient of variation in percentage (% CV) values. Table 4.5 
shows the mean of A/A0 values, SD and % CV of the intra-day analysis. The assay 
precision had a range from 0.8% to 20.4%.  
 
Table 4.5. Parameters used to determine the precision of the cTnT inhibition assay  
[cTnT] ng/mL Mean SD %CV 
250 
125 
62.50 
31.25 
15.63 
7.81 
0.23 
0.23 
0.43 
0.69 
0.96 
1.01 
0.01 
0.05 
0.04 
0.01 
0.09 
0.02 
3.3 
20.4 
10.0 
0.8 
9.0 
2.0 
4.2.17 Comparison of antigen-binding capacities of chain-shuffled 8C2 and 
wild-type anti-cTnT F scFv antibodies   
The heavy chain-shuffled 8C2 scFv was compared to the wild-type scFv F1. The IC50 
values obtained from inhibition assays and affinity levels obtained from kinetics studies 
were compared (Fig. 4.17). The 8C2 had an improved IC50 value of 38 ng/mL, in 
contrast, the wild-type scFv F1 had an IC50 value of 85 ng/mL. The heavy chain 
shuffled 8C2 showed an improvement of approximately 2.2 fold compared to the 
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wild-type F1. In addition, kinetic analysis showed that 8C2 had an affinity level of 0.39 
nM, whereas, F1 had an affinity level of 2.40 nM. The 8C2 showed an improvement of 
approximately 6 fold in comparison to F1.  
 
Figure 4.17. Comparison of cTnT-binding capacities between wild-type scFv F1 
and chain-shuffled scFv 8C2. The blue bars represent the IC50 value (85 ng/mL) and 
affinity level (2.4 nM) of scFv F1; the red bars represent the IC50 value (38 ng/mL) and 
affinity level (0.39 nM) of scFv 8C2. 
 
4.3 Discussion 
This chapter describes the use of the chain shuffling approach for the generation of an 
affinity-enhanced avian anti-cTnT scFv antibody. In addition, the construction of new 
chain-shuffled antibody libraries and the selection of an antigen-specific antibody using 
the phage display technique is also described. DNA fingerprinting, antibody cross 
reactivity studies, SPR-based kinetic analysis and inhibition assay development are also 
discussed.  
 
Using the previously constructed wild-type anti-cTnT scFv library, new heavy and light 
chain-shuffled libraries were generated. After five rounds of biopanning, it was shown 
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that both the heavy and light chain-biased scFvs have an increase in the number of 
positive cTnT-binding clones. A total of 66.7% of the heavy chain-shuffled clones and 
75% of the light chain-shuffled clones demonstrated positive binding to the cTnT 
antigen. In comparison, only 56.3% of the wild-type clones were cTnT binders. This 
may indicate that a chain-shuffling approach can generate a larger number of positively 
binding clones. Therefore, the chain shuffling approach would enhance the production 
of antibodies especially when the parental library has a very low number of positive 
antigen-binding clones. This observation is in agreement with the work of Yuan and 
co-workers who reported that gene recombination from library pools enable a 
substantial increase in the number of positive mutants that had phenotypic 
improvement. (Yuan et al., 2005). 
 
DNA fingerprinting was used to assess the diversity of the scFv antibodies. Analysis of 
eighteen antibodies revealed six different restriction mapping profiles, which indicated a 
moderate level of clonal diversity (Fig. 4.6). Although two clones did not show any 
restriction profiles this may have been due to the poor quality of DNA plasmids. 
Overall, however, this method still gave a good indication of the diversity of the scFv 
antibodies generated.  
 
In order to identify scFv antibodies that had high cTnT binding stability, a total of 384 
heavy and light chain-shuffled antibodies were assessed using SPR. The BiacoreTM 
4000 system facilitated the rapid analysis of the clones (less than 10 hours), which 
saved valuable experimental time and costs. Furthermore, lower volumes of reagents 
were required by the BiacoreTM 4000 than conventional ELISA. In addition, the 
experimental conditions were consistent for each clone, as the analysis was completed 
in one single run; therefore, the data obtained were more reliable and accurate. The % 
left value-based ranking revealed that the scFv antibodies had a broad stability range 
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(7.2% to 76%). Although the highest value, 76%, for an anti-cTnT antibody was less 
than what was reported by Leonard and co-workers for an anti-CRP scFv antibody 
(92%). However, this value is still considered to be a relatively good stability level as is 
discussed previously by Leonard and co-workers (Leonard et al., 2007). Leonard and 
co-workers used 75% as a ‘cut-off’ value for the ranking of anti-CRP antibodies; 
therefore, the anti-cTnT scFvs in this study displayed good stability levels.  
 
It is crucial that the selected antibodies are highly specific for cTnT. Therefore, 
cross-reactivity studies were performed against different troponin isoforms present in 
the troponin complex (sTnT, cTnI and sTnI). Four scFv antibodies showed high 
specificity towards cTnT with no significant cross reactivity to the other troponin 
isoforms. These scFv antibodies can be the potential candidates for CVD diagnosis.  
 
Antibodies with high levels of temperature stability are often preferred in clinical 
diagnostics and therapeutics. The affinity levels of four anti-cTnT scFv antibodies were 
determined at 20, 25 and 30oC to investigate its variation with temperature. Two scFvs 
had affinity levels less than 1 nM over the three temperatures (Fig. 4.12). Overall, 
clones showed a very narrow range of affinity level (0.427 to 2.74 nM). Therefore, 
temperature changes did not appear to affect the antigen-binding capacities of these 
anti-cTnT scFv antibodies to any significant extent. 
 
Another important feature of an antibody is its affinity level, which indicates association 
and disassociation of the antibody-antigen complex. Ten scFv antibodies with various 
% left values were subjected to kinetic studies. The curves were fitted to the 1:1 
Langmuir binding model. Kinetic analysis showed that four clones had subnanomolar 
affinity levels (Table 4.4). Since all four clones had very close subnanomolar affinities, 
the curve fits were examined in order to select a clone for further analysis. Visual 
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inspection of the experimental curve (blue curves) of 8C2 clone showed closer fitting 
with the theoretical binding curves (black curves) than for the other three clones. There 
were no significant deviations in both the association phase and disassociation phase. 
Moreover, the quality of curve fitting was also assessed and is represented by the Chi2 
value. Generally, smaller Chi2 values indicate better data fitting to the chosen binding 
model (Poduslo et al., 2010). In Table 4.4, 8C2 had the lowest Chi2 (0.29) compared to 
the other three clones (0.70, 0.79 and 0.85) and it was, therefore, chosen for further 
studies. 
 
The purified 8C2 antibody was subsequently incorporated in an inhibition 
immunoassay. A checkerboard ELISA was performed to identify both the optimal cTnT 
coating concentration and the optimal 8C2 antibody concentration. The ultimate goal 
was to use the least amount of reagents while maintaining the highest assay sensitivity. 
Similar IC50 values were observed for the cTnT concentrations of 1, 1.5 and 3 µg/mL 
(Fig. 4.14). For least antigen consumption, the lowest concentration (1 µg/mL) was 
selected. The optimal 8C2 antibody concentration (125 ng/mL) was also determined for 
inhibition assay development (Fig. 4.15).  
 
An inhibition assay was successfully developed using the previously selected optimal 
conditions. 8C2 was determined to have a cTnT IC50 value of 38 ng/mL (Fig. 4.16). The 
assay precision analysis showed the CV% had a range of 0.8% to 20.4%. In this range, 
six data points had the CV% less than 10%, showed that the assay precision was in an 
acceptable range (< 20%) (Reed et al., 2002). Although large variations in CV are often 
seen when quantifying samples at the extreme ends of an assay’s range (Reed et al., 
2002). At the extreme ends of an assay curve, sample concentrations are relative high or 
low, thus, a minor variation in these concentrations can cause large variations in the 
precision analysis. However, an unexpected CV% value of 20.41 (at 125 ng/mL cTnT 
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concentration) was observed in this study. It exceeded the acceptable range (< 20%). 
The high CV% value may be due to uneven sample mixing, it also may due to sample 
was not homogeneous which might contain higher order of antibody structures (dimers, 
trimers or multimers).  
 
To assess the efficiency of chain-shuffling for the enhancement of antibody affinity, the 
antigen detection capacity of mutant 8C2 and wild-type F1 antibody were compared 
(Fig. 4.17). The 8C2 had an IC50 value of 38 ng/mL, which showed an improvement of 
approximately 2.2 fold compared to the wild-type F1 (85 ng/mL). In addition, the 
mutant scFv, 8C2 had a KD value of 0.39 nM, which indicated an improvement of 
approximately 6 fold compared to the wild-type F1 (2.40 nM). These results indicated 
that chain shuffling can be successfully applied to produce affinity enhanced anti-cTnT 
scFv. Using a light chain shuffling approach, the detection level for halofuginone of an 
anti-halofuginone scFv antibody was improved by 185 fold (Fitzgerald et al., 2011). 
Similarly, Park and co-workers showed an increase in affinity of two natural antibodies 
(1C2 and 1E4), against preS1 of hepatitis B virus (HBV), by factors of 2.8 and 6.5 
compared to the parental clones (Park et al., 2000), whereas, Lou and colleagues 
improved affinities of botulinumb neurotoxin scFv antibodies from 9 to more than 77 
fold using the chain-shuffling approach (Lou et al., 2010). Thus, chain shuffling is an 
effective approach for enhancing antibody- antigen binding capacity. 
 
In conclusion, using the chain shuffling approach, the antigen binding capacity of the 
anti-cTnT antibody was successfully enhanced. A 2.2 fold improvement in affinity and 
a 6 fold improvement in the IC50 were shown by the mutant 8C2 scFv compared to the 
wild type F1. In the next chapter, the production of a second avian anti-cTnT fragment, 
the Fab fragment, will be described.    
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Chapter 5 
Generation of avian  
anti-troponin T Fab antibody 
fragments 
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5.1 Introduction 
This chapter describes the production and expression of avian anti-cTnT Fab 
recombinant antibodies. It contains an in-depth description of the properties of Fab 
fragments. The focus of this chapter is the generation the Fab antibodies using phage 
display. In addition, the optimisation studies for the improvement of Fab antibody 
expression levels are also described.   
 
Both scFv and Fab are commonly used recombinant antibody fragments. They share a 
number of similar features. For examples, both of them have the same antigen-binding 
sites as their parental antibodies.In addition, the small molecular size of both scFv (~25 
kD) and Fab (~50 kD) can facilitate tissue penetrability. 
  
In comparison to the scFv, the Fab antibody antibody fragment has a number of distinct 
advantages (Table 5.1). Lee and co-workers reported that the intra-molecular disulfide 
bonds in Fab fragments lead to higher stability than the corresponding scFv fragments 
(Lee et al., 1998). The additional domains within the Fab structure contribute to the 
interaction between the light and heavy chains, hence leading to increased structural 
stability. Rothlisberger and co-workers compared the neutralisation capacity of Fab and 
scFv fragments against Centruroides noxius. They found that the Fab antibody 
fragments had greater neutralisation capacity for Centruroides noxius (Rothlisberger et 
al., 2005). Similarly, Quintero-Hernandez and co-workers showed that a mouse Fab 
antibody (BCF2), to a scorpion toxin (Cn2), had improved neutralisation capacity and 
stability compared to equivalent scFv formats (Quintero-Hernandez et al., 2007).  
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Table 5.1 Comparison of Fab and scFv antibody fragments  
(Based on references: Bird and Walker, 1991; Marks et al., 1991; Kramer et al., 2002; 
Hust and Dubel, 2004; Daniela et al., 2005 and Jordan et al., 2007) 
 
Enzymatic digestion and recombinant techniques are being routinely used for the 
generation of Fab antibody fragments. In the late 1950s, Porter digested IgG into three 
fragments using papain. The Fab fragments were then purified using ion exchange 
chromatography (Porter, 1958). Papain is an enzyme extracted from papaya. It is 
routinely used for proteolysis of IgG antibodies, thus producing Fab fragments. Fab' and 
F(ab')2 are derivative forms of Fab fragments, that are widely used for research and 
clinical purposes. The production of Fab' involves use of an aspartic acid protease, 
pepsin, which cleaves the hinge region of the IgG molecule and forms an F(ab')2 with a 
molecule weight of 100 kD. The F(ab')2 can be subsequently reduced, using reducing 
reagents such as dithiothreitol. This process yields two Fab' fragments with free cysteine 
residues near the C-terminus (Fig. 5.1). Although enzymatic digestion is often used as a 
routine method for Fab generation, the generation of antibody fragments by 
 Advantages Limitations 
Fab  Small size (~50 kD) facilitates high 
mobility and tissue penetration  
 Can be simply generated using the 
papain and pepsin proteases 
 Exist as monomers and tend not to  
aggregate 
 Stable over long-term storage 
 Can be humanised for therapeutic 
purposes 
 Crystallisation process is easier than IgG 
 Short half-life in blood circulation  
 Lower expression levels in E. coli 
cells compared to scFv 
 
scFv  Small size (~25 kD) facilitates high 
mobility and tissue penetration  
 High expression levels in E. coli cells  
 Crystallisation process is easier than IgG 
 Cannot be generated using 
proteolysis    
 Unstable over long-term storage  
 Aggregates can form higher order 
structures (dimmers and trimers) 
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recombinant technology has a number of distinct advantages. For example, recombinant 
technology allows the production of antibodies in E. coli cells, which can generate high 
yields at a reduced cost, provided the conditions are optimized. Moreover, mutagenesis 
can be used to improve the affinity and the expression levels of Fab fragments. 
Furthermore, small peptide affinity tags, such as His, can be incorporated to the 
C-terminus of the heavy chain or the light chain thus facilitating purification. The 
production of recombinant Fab antibodies can be achieved using an immune antibody 
library and the phage display approach (Fig. 5.2). 
 
Papain
Pepsin Reduction
 
Figure 5.1. Generation of Fab and its derivative fragments using enzymatic 
proteolysis. Papain cleaves the IgG molecule to form Fab molecules. Pepsin cleaves the 
IgG molecule to form a F(ab')2 fragment, which can then reduced to a Fab' fragment 
using reducing reagents.  
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Phagemid vector
SOE-PCR amplification of Fab genes
Ligation of  Fab gene into phagemid vector 
Transformation of  the 
Plasmid vector into E. coli cells 
Fab antibodies are displayed 
on phage particles
VH VL
cDNA isolated from 
immunised animal
Plasmids DNA containing 
cloned Human Fab fragment
Amplification of 
variable chains
Amplification of 
constant chains
VHVL
Amplification of 
chimeric light chains
Amplification of 
chimeric heavy chains
VHVL
 
Figure 5.2. Generation of recombinant Fab antibody using phage display. The 
production of Fab antibody involves initial immunisation of an animal host with the 
antigen of interest. Total RNA is extracted from the animal spleen and bone marrow, 
once a sufficient antibody response is obtained. cDNA is subsequently generated by 
reverse transcription of mRNA. In the first round of PCR, variable and constant chains 
(VH, VL, Cκ and CH1) are amplified. In the second round of PCR chimeric heavy and 
light chains are assembled, and the Fab genes are finally amplified using Splice by 
Overlap Extension (SOE) PCR. The Fab genes are subsequently ligated into phagemid 
vectors. The ligation product is transformed into E. coli cells and the cells are then 
infected by phage particles. Fab fragments are expressed in E. coli and subsequently 
displayed on the surface of the phage particles (Lee et al., 1998). 
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The expression of Fab antibodies in E. coli cells involves the production of VH, VL, Cκ 
and CH1 regions as well as an inter-chain disulfide bond. The disulfide bond is required 
for the connection of the variable and constant regions. In E. coli cells, the reducing 
environment in the cytoplasm prevents the formation of the disulfide bond. Therefore, 
Fab expression takes place in the periplasm where the four heavy and light chains are 
secreted independently. The disulfide bond is subsequently formed and associated with 
the CH1 and Cκ chains to form the Fab fragments. The periplasm provides an oxidising 
environment and it also contains thiol-disulfide oxidoreductases, which catalyse the 
formation of the disulfide bond. Fab fragments are most often purified from the 
periplasm of E. coli rather than the cytoplasm, due to the lower protein concentration 
and smaller number of proteins found in periplasm (Rader 2009). 
 
Protein expression in E coli systems is a complex process and a number of factors can 
affect the levels of expression, for example, the types of media used for E. coli 
cultivation, the induction concentrations of IPTG, the period of incubation the  
incubation temperature and culture agitation conditions.   
 
5.1.1 Work summary for the generation of avian anti-cTnT Fab antibody 
fragments 
Phage display was used to produce recombinant avian anti-cTnT Fab fragments. The 
avian cDNA which was used to generate the scFv antibodies, was also used for Fab 
production. The amplification of Fab genes involved optimisation steps such as the use 
of a range of magnesium concentrations, different annealing temperatures and different 
types of DNA polymerases. For antibody phage library construction, the Fab genes 
were ligated into the pComb3XSS vector and transformed into E. coli XL1 blue cells. 
The library was subjected to five rounds of biopanning against the cTnT antigen, and 
phage particles were infected into E. coli Top10 F' cells for soluble expression. Positive 
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Fab clones were selected using an ELISA-based ‘on-plate’ screening method. ELISA 
analysis revealed the positive cTnT-binding Fab clones had low expression levels. 
Therefore, in order to improve the expression levels, optimisation was performed using 
different types of media for cell cultivation, different IPTG concentrations and different 
periods of incubation. It was demonstrated that the expression levels of three Fab 
antibodies (A1, C5 and D3) were successfully optimised.  
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5.2 Results 
5.2.1. PCR amplification of avian variable domains and human constant domains  
In comparison to scFv library generation, more PCR amplification steps are required for 
the construction of a Fab library. Four gene fragments were amplified in the first round 
of PCR, including the chicken variable chains (VH, Vλ) and human constant chain (CHI, 
Cκ). In the second round of PCR, chicken/human chimaeric heavy chain and light chains 
were amplified. In the final SOE-PCR, one PCR amplification step was used to 
assemble the Fab fragment. This section describes the first round of PCR 
amplifications. 
 
In the chapter 3 and 4, the generation of avian anti-cTnT scFv antibodies was outlined. 
Chicken cDNA, harvested from the immunised chicken, was used for the amplification 
of Fab genes. PCR optimisation of VH, Vλ, CHI and Cκ was performed using different 
concentrations of MgCl2 (Fig. 5.3 (A)). The gel image shows that the Cκ chains were 
successfully amplified at three MgCl2 concentrations (2, 3 and 4 mM). Although some 
non-specific bands were observed for the Vλ amplifications, these were far distant from 
the amplified Vλ genes (~ 350 bp). Therefore, the Vλ genes could be extracted by 
carefully cutting out the large-scale product bands. A concentration of 2 mM MgCl2 
was chosen for the PCR amplification of Vλ and Cκ genes, since high magnesium 
concentrations may increase the error rate of Taq DNA polymerase (Eckert and Kunkel, 
1990). Neither the VH or CHI genes were amplified under the three different MgCl2 
concentrations (2, 3 and 4 mM). Further optimisation was performed using different 
annealing temperature as well as different MgCl2 concentrations. 
 
For further PCR optimisation of VH and CHI gene amplifications, the annealing 
temperature was increased from 56oC to 58oC, and a series of MgCl2 concentrations (1, 
2, 3 and 4 mM) were also tested. Figure 5.3 (B) shows that the optimal MgCl2 
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concentration for the VH amplification was 2 mM. In addition, the CHI gene was 
successfully amplified at all MgCl2 concentrations tested. The amplification of VH/CHI 
(2 mM IPTG at 58oC) and Vλ/Cκ (2 mM IPTG at 56
oC) were performed on a 
large-scale,. The PCR products were resolved on a 1% (w/v) agarose gel and the PCR 
products were extracted. The purified PCR products are shown in Figure 5.3 (C).  
 
400 bp
300 bp
400 bp
300 bp
400 bp
300 bp
1    2    3    4     5      6     7     8     9    10   11 12   13   14   15   16   17
 
Figure 5.3 (A). Optimisation of the amplification of avian variable chain (VH ,Vλ) 
and human constant chain (CHI, Cκ) using different Mg
2+ 
concentrations. Lanes 1, 
9 and 17 contained 1kb plus DNA molecular weight markers. Lanes 2, 3 and 4 
contained the VH gene amplified with 2, 3 and 4 mM MgCl2, respectively. Similarly, 
lanes 6, 7 and 8 contained the Vλ gene amplified with 2, 3 and 4 mM MgCl2, 
respectively. In addition, Lanes 10, 11, 12 contained the CHI genes amplified with 2, 3 
and 4 mM MgCl2, respectively, whereas, lanes 14 to 16 contained the Cκ genes 
amplified with 2, 3 and 4 mM MgCl2, respectively. Lanes 5 and 13 were left blank.  
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400 bp
300 bp
1          2            3         4           5             6            7            8            9      
Figure 5.3 (B). Optimisation of the amplification the chicken variable heavy chain 
(VH) and human constant heavy chain (CHI). Lane 1 represents a 1kb plus DNA 
molecular weight ladder. Lanes 2 to 5 represent the amplification of VH with a series of 
MgCl2 concentrations (1, 2, 3, and 4 mM) using 58
oC as the annealing temperature. 
Similarly, Lane 6 to 9 represent the amplification of CHI with a series of MgCl2 
concentrations (1, 2, 3 and 4 mM) using 58oC as the annealing temperature.  
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1           2             3             4              5              6
400 bp
300 bp
 
Figure 5.3 (C). Agarose gel analysis of purified PCR product of chicken variable 
chain (VH, Vλ) and human constant chain (CHI, Cκ). Lanes 1 and 6 contained a 1kb 
plus DNA molecular weight ladder. Lanes 1 to 4 contained the purified PCR product of 
the Vλ (~ 350bp), VH (~ 400bp), CHI (~ 400bp) and Cκ (~ 350bp), respectively.  
 
5.2.2. PCR amplification of chicken/human chimeric heavy and light chain genes 
The generation of the chicken/human chimeric heavy chain (Fd) fragment, was achieved 
by assembling the avian VH and human CH1 fragments. In addition, the chicken/human 
chimeric light chain region was assembled using the avian VL fragment and human Cκ 
fragments. The chimeric heavy and light chain PCRs were optimised using different 
MgCl2 concentrations (1, 2, 3 and 4 mM) and different temperatures (56, 58, 60 and 
62oC). The optimal conditions for the amplification of the chimeric heavy chain were 4 
mM MgCl2 with an annealing temperature of 60
oC. Similarly, the optimal PCR 
conditions for the amplification of chimeric light chains were 2 mM MgCl2 with an 
annealing temperature of 57oC. Both the chimeric light chain (~ 750 bp) and heavy 
chain (~ 800 bp) were successfully amplified and the PCR products were resolved on a 
1% (w/v) agarose gel (Fig. 5.4).  
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800 bp
650 bp
1         2             3
 
Figure 5.4. Amplification of the chicken/human chimeric heavy chain and light 
chains. Lane 1 contained a 1kb plus DNA molecular weight ladder. Lanes 2 and 3 
contained the amplified chicken/human chimaeric light (~ 750 bp) and heavy chains (~ 
800 bp), respectively.  
 
5.2.3 Anti-cTnT Fab-Splice by Overlap Extension (SOE) PCR  
The final splice by overlap extension (SOE) PCR involved assembling the 
chicken/human chimaeric heavy chain fragment with the light chain fragment. A 
number of optimisation steps were performed. These included testing different PCR 
polymerases (Go-Taq® polymerase, Fusion Taq® and Platinum HIFI™ Taq polymerase) 
and optimisation of magnesium chloride (0, 0.5, 1, 2 and 2.5 mM) and magnesium 
sulfate (0, 0.5, 1, 2 and 2.5 mM) concentrations. The PCR was optimised using 
platinum HIFI™ Taq polymerase and a concentration of 2.5 mM magnesium sulfate 
(Fig 5.5). 
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1650 bp
1000 bp
1              2
 
Figure 5.5. SOE-PCR amplification of Fab fragment using optimised PCR 
conditions. Lane 1 represents a 1kb plus DNA molecular weight ladder. Lane 2 
represents SOE-PCR fragment (~ 1500 bp).  
 
5.2.4. Avian anti-cTnT Fab library construction and enrichment via biopanning 
A large-scale amplification of the SOE-PCR was subsequently performed. The PCR 
product was extracted from a 1% (w/v) agarose gel and concentrated by ethanol 
precipitation. The PCR product and pComb3XSS vector were digested using a SfiΙ 
restriction enzyme followed by overnight ligation at room temperature with T4 ligase. 
The ligated product was ethanol-precipitated and transformed into electrocompetent E. 
coli XL1-Blue cells by electroporation, as described in section 2.3.1.10. The 
transformed avian anti-cTnT scFv library had a size of 1.2 x 107 cfu/mL. Recombinant 
anti-cTnT Fab clones were selected from this library by performing five rounds of 
phage display biopanning against immobilised cTnT antigen, as described in section 
2.2.1.12. Table 5.2 shows the input and output titres for each of the 5 rounds of 
biopanning of the avian Fab anti-cTnT libraries.  
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Table 5.2. Input and output titres of anti-cTnT Fab clones over five rounds of 
biopanning. 
 
 
 
 
 
 
 
 
 
 
5.2.5. Expression of soluble chicken anti-cTnT Fab antibodies 
A total of 96 anti-cTnT Fab antibodies were picked from biopanning round 5 output 
plates. These clones were subsequently analysed using a simple ‘on-plate’ monoclonal 
ELISA screening method (section 2.3.1.14). Figure 5.6 shows a small number of soluble 
Fab antibodies (13 out of 96) that were specific to the cTnT antigen. 
Biopanning round Input (cfu/mL) Output (cfu/mL) 
1 1.7 x 1012 4 x 106 
2 1.2 x 1012 3 x 106 
3 1.5 x 1012 5 x 105 
4 9.5 x 1011 1.2 x 105 
5 3.2 x 1011 3.9 x 104 
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Figure 5.6. Screening of anti-cTnT Fab phage clones from round five of 
biopanning. Each of the blue bars represents the absorbance readings from each Fab 
clone. A black bar (Number 96) represents the absorbance reading of a blank reference. 
A red horizontal line drawn at background absorbance level (~ 0.18) marks the ELISA 
threshold. The threshold value was set at three times the absorbance value of the blank 
reference.  
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5.2.6. Titre determination of anti-cTnT Fab antibodies by ELISA 
A total of eight Fab clones that had previously displayed high cTnT-binding levels from 
monoclonal ELISA analysis were selected for further studies. These clones were grown 
in a 5 mL SB media and expressed overnight at 30oC, and induced with 1 mM IPTG. 
Crude bacterial lysates were prepared and subsequently analysed by ELISA (Fig. 5.7). 
All eight clones had very low levels of antibody expression. The clone D3 had a 
maximum absorbance of only approximately 0.3. 
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Figure 5.7. Antibody titre determination of anti-cTnT Fab antibodies. An ELISA 
plate was coated with 100 μL of 1 μg/mL cTnT and blocked with 200 μL 5% (w/v) 
Marvel in PBS. A series of dilutions of the crude antibody lysates (1 in 2, 1 in 4, 1 in 8, 
1 in 16, 1 in 32, 1 in 64, 1 in 128, 1 in 256, 1 in 512 and 1 in 1,024 dilutions) were 
prepared and 100 μL of each dilution was added into the wells. The Fab antibodies were 
detected using HRP-labeled mouse anti-HA monoclonal antibody. The ELISA was 
developed with TMB substrate and the absorbance was read at 450 nm. 
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5.2.7. Optimisation of Fab antibody expression conditions 
In orde to improve the expression levels of the Fab clones in the E.coli system, a 
number of optimsation steps were performed. Protein expression in E.coli is a complex 
process and depends on a wide number of parameters such as the type of growth media 
used, IPTG concentration used induction, expression temperature, culture shaking speed 
and the period of incubation. In this study, the optimistaion process involved the 
substitution of SB media for TB media; optimisation of the IPTG induction 
concentration and selection of the optimal period for incubation. The expression levels 
of four Fab clones (A1, C5, C7 and D3) were optimised (Fig. 5.7). The Fab cultures 
were induced with four different IPTG concentrations (0.05, 0.1, 0.25 and 0.5 mM), and 
subsequently incubated at 30oC. After IPTG induction, samples from each culture were 
collected after 2 hours, 4 hours, 6 hours and overnight (~ 16 hours) incubation. The 
ELISA absorbance values, which indicated the expression levels of each of the samples, 
are shown in Figure 5.8.  
 
Figure 5.8 reveals that the expression levels of clone A1, C5 and D3 were successfully 
optimised. Clone A1 had a maximum Fab expression level after 2 hours induction using 
a IPTG concentration of 0.05 mM. Similarly, both the clones C5 and D3 had a 
maximum Fab expression level after 6 hours induction using a IPTG concentration of 
0.5 mM. Interestingly, the expression levels of clones A1, C5 and D3 were significantly 
decreased after overnight incubation (~ 16 hours). Furthermore, the expression levels of 
clone C7 were low across all the conditions tested and, therefore, this clone was 
excluded from further studies.  
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Figure 5.8. Optimisation of Fab antibody expression levels. Each bar chart represents 
the expression levels of different Fab antibody (A1, C5, C7 and D3). Cultures were 
incubated at 30oC and induced with 0.05, 0.1, 0.25 and 0.5 mM IPTG. Samples were 
collected over a period of 2, 4, 6 hours and overnight (~ 16 hours). Fab antibody 
expression levels were determined using a direct ELISA.  
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5.3 Discussion 
This chapter describes the generation of avian anti-cTnT Fab antibodies using phage 
display. In addition, selection of cTnT-specific Fab antibodies and optimisation of their 
expression levels is also described. 
 
In comparison to scFv antibodies, Fab antibodies have a number of distinct advantages, 
as described in section 5.1. Fab format was, therefore, also chosen for the generation of 
anti-cTnT antibodies. Using the previously isolated avian cDNA, an anti-cTnT Fab 
library was generated. After five rounds of biopanning, only 25% (13 out of 96) bound 
specifically to cTnT. This figure is significantly less than that found from the selection 
of the scFv antibodies (section 4.2.5, Table 4.3). Table 4.3 shows up to 56.3% of the 
wild-type clones, 66.7% of heavy chain-shuffled clones and 75% of light chain-shuffled 
clones were selected as positive cTnT-binding clones. The smaller number of positive 
Fab clones may indicate that the Fab antibodies had lower displaying efficiency in 
comparison to the scFv antibodies. It is possible that the more complex E. coli 
expression process negatively impacted on the levels of Fab antibodies. For scFv 
antibodies, E. coli expression only involves two variable chains (VH, VL), whereas, the 
expression of Fab requires the production of four chains (VH, VL, CL and CH1) and a 
disulphide bond for the connection of the two Fab chimeric regions. Thus, the folding 
and assembly of Fab fragments in the periplasm of E. coli is more complex than for 
scFv antibodies. This observation is consistent with the work of Skerra and co-workers. 
They found that the display of Fab on the phage particles due to its large molecule size 
(50 kD) (Skerra et al., 1993). Moreover, Pluckthun also reported Fab antibodies had a 
slower folding rate than scFvs in E. coli cells (Pluckthun, 1990; Pluckthun, 1991).  
 
E. coli systems have been utilised for the production of recombinant proteins for more 
than two decades (Hudson et al., 1988; Skerra and Pluckthun, 1988; Bird et al., 1998; 
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Graumann and Premstaller, 2006). A total of eight Fab clones having positive binding 
for cTnT were analysed by a titration ELISA. However, all eight antibodies had low 
expression levels (Fig. 5.7). In order to improve the Fab expression level, the type of 
growth media, the IPTG induction concentration and the period of inculation were 
optimised. It was shown that three Fab clones (A1, C5 and D3) were successfully 
expressed (Fig. 5.8). Using the TB media, clone A1 showed a maximum expression 
level when using 0.05 mM IPTG and incubating for a period of 2 hours. Clones C5 and 
D3 required 0.5mM IPTG and incubation for 6 hours for optimal expression. Although 
both SB and TB are highly enriched media often used in the cultivation of E. coli, TB 
contains glycerol which provides an extra carbohydrate source for E. coli growth. In 
addition, the potassium phosphates in TB may enhance protein expression. For example, 
Manderson and co-workers compared SB and TB as growth media for the production of 
recombinant hydatid vaccine (Eg95). They reported a higher biomass of the Eg95 
vaccine was produced using TB media (Manderson et al., 2006).  
 
In conjunction with media type, IPTG concentration was also optimised. IPTG triggers 
the lac operon required for the metabolism of lactose in E.coli. As an expensive reagent, 
the minimum concentration of IPTG which can fully induce the lac promoter is the 
optimal condition. In addition, excessive IPTG concentrations may reduce cell viability 
and diminish Fab expression. Generally, the concentration of IPTG required to fully 
induce the lac promoter can vary widely depending on the clone. Figure 5.8 shows A1 
and C7 had the highest Fab expression levels with 0.05 mM ITPG induction, whereas, 
C5 and D3 showed the highest expression levels at 0.5 mM IPTG. These IPTG 
concentrations are less than those reported by Mohkam and co-workers. They found the 
maximal expression level of recombinant Fab against human leptin receptor was 
achieved with a 1 mM IPTG concentration (Mohkam et al., 2011). In addition, Robbens 
and co-workers used 2 mM IPTG to achieve high levels of recombinant murine 
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interleukin-2 protein (Robbens et al., 1995). In contrast, a four-fold lower IPTG 
concentration (0.05 mM) was used by Donovan and co-workers to increase the yield of 
a monoclonal antibody Fab fragment (Donovan et al., 2000). Furthermore, IPTG 
concentrations of between 0.1 mM and 2 mM have also been used to induce the lac 
promoter for recombinant proteins (Yee and Blanch 1993; Bhattacharya and Dubey 
1997; Li et al. 1999; Madurawe et al. 2000). Therefore, the optimal IPTG concentration 
for maximum expression is strongly dependent on the individual clone.  
 
Period of induction is another parameter affecting antibody expression. The expression 
levels of anti-cTnT Fab antibodies were analysed after 2, 4, 6 hours and overnight (~ 16 
hours) incubation. Interestingly, clone A1 had a maximum expression level after a short 
period of incubation (2 hours) incubation with a low IPTG (0.05 mM) induction, 
whereas, clones C5 and D3 requried a longer period for induction (6 hours) with a 
higher IPTG (0.5 mM) induction. This observation is contrary to that found by Azaman 
and co-workers. They showed for the production of interferon-α2b in E. coli, high yield 
occurred when using longer induction time and lower IPTG concentrations or shorter 
induction time and higher IPTG concentrations (Azaman et al., 2010). This may be due 
to using different E. coli strains for protein expression, using different types of growth 
media or incubation temperatures. However, the different inherent protein structure 
between Fabs and interferon-α2b may well be the major factor. 
 
In conclusion, chicken anti-cTnT Fab antibodies were successfully generated. 
Expression conditions for Fab antibodies were also successfully optimised. Further 
work will involve SPR-based characterisation and affinity chromatographic purification 
of the selected anti-cTnT Fab antibodies. The ultimate goal is to develop a highly 
sensitive cTnT immunoassay that incorporates either the anti-cTnT scFv or the Fab 
antibody fragments, or both in a sandwich format. 
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Chapter 6 
Determination of LDH levels  
in milk samples  
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6.1 Introduction 
This chapter outlines an investigation of the effectiveness of LDH as a biomarker for the 
detection of sub-clinical mastitis. It contains an in-depth description of the 
standardisation and optimisation of a fluorescence-based ‘end-point’ assay and the use 
of this assay for the determination of LDH in various milk samples.  
 
Enzymatic assays for the determination of LDH activity can use either a kinetic or an 
‘end-point’ method. A kinetic method involves monitoring the change of parameters, 
such as fluorescence or absorbance, at short time intervals. The change of parameter is 
normally related to the amount of product formation and substrate consumption. An 
enzyme’s progress curve (rate curve) is a plot of absorbance or fluorescence as a 
function of time. The best fit enzyme progress curve allows estimation of the reaction 
rate therefore allowing determination of the initial concentrations of reagents 
participating in the reaction. An ‘end-point’ assay measures the change of parameters 
caused by the quantity of substrates consumed or products formed over a fixed period of 
time. During this time period, normally at the steady-state of an enzyme-based reaction, 
the rate of substrate converted and products generated are linear. This linearity allows 
quantitative analysis of the initial concentrations of substrates based on the parameter 
changes at the end of the reaction (Rose and Warms, 1987; Bravo et al., 2004).  
 
Kinetic analysis is sometimes considered as a more sensitive analytical method than 
‘end-point’ analysis. Monitoring the change of parameters in ‘real-time’ may increase 
the assay accuracy. However, it also has a number of disadvantages. The assay 
performance is a time-consuming and expensive process especially with large numbers 
of samples. Plotting of rate curves for reaction rate estimation can be problematic and 
considerable judgment is required for interpretation (Hicks et al., 1973). In comparison 
to kinetic assays, an ‘end-point’ assay can be easily developed, with monitoring of 
changes of parameters only at two time points throughout the assay. Therefore, it is a 
rapid, convenient and cost effective approach (Srisawasdi et al., 2007). These features 
are particularly useful when analysing a large number of samples, as for example, in the 
determination of LDH levels in 12 batches of milk samples used in this project. In 
addition, Srisawasdi and co-workers reported that an ‘end-point’ assay had better 
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precision for the determination of serum cholesterol than kinetic analysis (Srisawasdi et 
al., 2007). The ‘end-point’ assay was, therefore, chosen for the determination of LDH 
levels in milk samples.   
 
6.1.1 Work summary for the determination of LDH levels in milk samples 
Using a fluorescence-based ‘end-point’ assay, the LDH levels in various milk samples 
were determined. The correlation of LDH levels with other markers of mastitis (SCC 
and NAGase) in milk samples was also investigated. Moreover, the analysis of the 
effectiveness of using composite milk samples for mastitis diagnosis is examined. In 
addition, the effects of the lactation stage, storage and handling on LDH activity in milk 
samples were also investigated.  
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6.2 Results 
6.2.1 Optimal reaction conditions for LDH levels determination in milk samples 
The aim of this section is to determine an optimal ‘end-point’ reaction time where the 
reaction rate of the conversion of LDH to pyruvate can reach a maximum level. A 
known amount of LDH (0.248 mg/ml) was used to convert a known amount of lactate 
(350 mM) to pyruvate. The fluorescence was measured at 30 second intervals for 330 
seconds, as described in section 2.4.3.2. A time curve was generated by plotting 
fluorescence values against time (Fig. 6.1).    
 
Figure 6.1 shows the fluorescence values started increasing as soon as the incubation 
began. The increase of fluorescence values is due to the formation of the highly 
fluorescent substance, resorufin. The values stayed constant from approx. 250 seconds 
to 300 seconds. A sixth order polynomial rate curve was fitted to the data which had a 
R-square value of 1, thus showing a very good fit. In addition, the estimated rate from 0 
second to 300 seconds was found to be 205 FU/s from the sixth order polynomial 
equation. However, this value only indicates the reaction rate at 330 seconds; the 
optimal ‘end-point’ reaction time where the reaction rate can reach a maximum level 
was still yet to be determined.  
 
 
 
 
 
212 
 
y = -6E-11x6 + 7E-08x5 - 3E-05x4 + 0.007x3 - 1.2851x2 + 205x + 415.88
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Figure 6.1. Measurement of fluorescence values produced by a reduction reaction 
catalysed by LDH. Measurements started at time zero (0 seconds) and finished at time 
330 seconds. A rate curve was plotted with the data points to estimate the rate of the 
reaction.  
 
Generally, the rate of an enzymatic reaction reaches its maximum level at the steady-
state or exponential phase of the reaction. To determine an optimal ‘end-point’ reaction 
time where the rate has a maximum value, different orders of polynomial rate curves 
were fitted to the data at time points of 120, 150, 180, 210, 240, 270, 300 and 330 
seconds. The estimated reaction rates are listed in Table 6.1.   
 
Table 6.1 shows the overall estimated reaction rates of converting L-lactate to pyruvate 
following the formation of the final product, resorufin, are in a range from 177 to 215 
FU/s. The maximum rate 215 FU/s was found at time 180 seconds, which may suggest 
the reaction was at its exponential reaction phase. In addition, a rate curve of the 
reaction from 0 seconds to 180 seconds is shown in Figure 6.2, a fifth order polynomial 
equation show that at 180 seconds the reaction rate reached the maximum level (215 
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FU/s). Therefore, 180 seconds was selected as an optimal ‘end-point’ reaction time for 
the determination of LDH levels in the enzymatic assay for use in milk samples.   
 
Table 6.1. Estimation of reaction rate at each time point by fitting rate curves 
                                         * FU/s stands for fluorescent units per second  
y = 1E-07x5 - 7E-05x4 + 0.0139x3 - 1.7407x2 + 215.26x + 409.63
R² = 1
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Figure 6.2.  Rate curve of the reduction reaction catalysed by LDH at 180 seconds. 
A rate curve was plotted with the data points from 0 to 180 seconds, and the fifth order 
polynomial equation shows the reaction rate reached its maximum level of 215 FU/s. 
            Estimated Rate          
(FU/s)* 
Time (s) 
3rd order  
polynomial fit 
4th order  
polynomial fit 
5th  order 
polynomial fit 
120 203 204 ------ 
150 196 210 199 
180 191 202 215 
210 188 198 209 
240 185 196 203 
270 182 194 202 
300 180 191 200 
330 177 190 197 
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6.2.2 Linearity study of resorufin produced using different LDH concentrations at 
180 seconds 
A linearity study was performed to show that the formation of fluorescent product, 
resorufin, was proportionally related with LDH concentration at 180 seconds. A series 
of LDH dilutions was prepared with a range of concentrations from 0.13 to 17 µg/mL. 
The assay was performed as described in section 2.3.4.2. Fluorescence readings were 
obtained at time 0 seconds and 180 seconds. The linearity between net fluorescence 
readings and LDH concentrations is shown in Figure 6.3. 
 
It is shown that when 180 seconds was used as the ‘end-point’ for LDH activity 
determination by the fluorescence assay, the amount of resorufin formation was linearly 
proportional with LDH concentrations. The ‘end-point’ of 180 seconds was, therefore, 
suitable for the determination of LDH in milk samples. 
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Figure 6.3. Linearity of fluorescence values for the reaction catalysed by varying 
LDH concentrations. Measurements started at time 0 seconds and finished at 180 
seconds.  
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6.2.3  Determination of LDH levels in milk samples 
Milk samples produced by 80 Holstein Friesian cows over a 7 months period were 
collected. The milk samples, representing different stages of lactation, are shown in 
Table 6.2. The teat end for each quarter was cleaned with 70% (v/v) ethanol prior to 
sampling.  A total of 30 mL of each milk sample was collected in sterile tubes, after 
discarding the first 5 mL of milk taken during sampling. All samples were kept cool (at 
4oC) during transportation and were processed in the laboratory within 8 hours of 
collection. Milk was taken from each udder quarter of each individual cow. Samples 
were named according to the quarter position, i.e. front left, front right, back left, and 
back right. 
 
Table 6.2. Summary of milk samples collected from 80 Holstein Friesian cows 
Batch No. Date of sampling Total No. of milk 
samples * 
No. of cows 
sampled 
Lactation stage 
1 17/10/07 25 7 Mid-late 
2 26/10/07 25 7 Mid-late 
3 30/10/07 25 7 Mid-late 
4 09/11/07 25 7 Late 
5 27/11/07 38 10 Late 
6 06/12/07 25 7 Late 
7 15/01/08 24 6 Early 
8 11/02/08 24 6 Early 
9 13/02/08 25 7 Early 
10 14/02/08 10 3 Early 
11 03/03/08 24 6 Early 
12 17/04/08 25 7 Early 
Total  295 80  
* Milk samples were not obtained from all four quarters of the cow in some cases. 
LDH levels were determined for all milk samples as detailed in section 2.3.4.3. 
However, for samples from batch 1 the LDH activity of the positive control gave no 
results indicating that the LDH assay did not work. Analysis on samples from batch 1 
was therefore excluded from this study.  LDH levels detected from batch 2 to 12 ranged 
from a minimum 0 U/L to a maximum of over 10,000 U/L (Data not shown).   
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6.2.4 Correlation of LDH levels with Somatic Cell Count and NAGase 
concentrations 
The LDH levels of all milk samples from batch 2 to 12 were measured, as detailed in 
section 2.3.4.3. The SCC of milk samples were determined by the Portacheck® milk test, 
as described in section 1.4.4. NAGase activity was determined using a fluorometric 
assay, as reported by Schuttel (Schuttel et al., 1999). NAGase level determinations were 
only carried out on samples in batches 2-5, and batch 9. SCC levels were determined 
from batches 3-5, batch 7 and batch 9.  The aim of this work was to investigate the 
correlation between LDH and SCC and LDH and NAGase in milk samples, in order to 
analyse the value of using LDH as a mastitis marker. Statistical analysis was carried 
out, as detailed in section 2.3.4.3. PASW statistics 18 software sets correlation values 
(r) greater than 0.80 as a good correlation. One-way ANOVA was used to determine the 
significance value (p). Data was considered statistically significant when the p value is 
less than 0.05. The p values and r values for comparison of LDH versus NAGase levels 
and LDH versus SCC levels are shown in Tables 6.3 (A) and (B), respectively.  
 
The r value of batch 2 for LDH and NAGase (0.64) was lower than 0.80. However, it 
was still considered significant as the p value was 0.001 (less than 0.05). The r values of 
batch 3, 4 and 5 for LDH and NAGase were greater than 0.80 which indicated that the 
correlations between LDH and NAGase were good (Table 6.3 (A)). However, for the 
correlation between LDH and SCC levels, the r values of 3 out of the 5 batches (batch 3, 
5 and 7) were less than 0.8, which, overall, indicated a poor correlation between LDH 
and SCC.  
 
Tables 6.3 (A) and (B) show that LDH levels had a higher correlation with NAGase 
levels than SCC in milk samples. The reason could be that both LDH and NAGase are 
released from damaged cells in milk samples, while somatic cells (white blood cells) are 
produced as an inflammatory response to infection. Chagunda et al. (2006) reported a 
correlation of LDH to SCC of 0.48 and the correlation of LDH to NAGase of 0.43. 
These correlation values are much lower than the mean correlations (0.70 for LDH 
versus SCC and 0.86 for LDH versus NAGase) observed in this study. It was also 
reported that LDH showed a closer correlation to SCC than to NAGase contrary to what 
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was observed in this study (Chagunda et al., 2006). The differences in findings may be 
due to the fact that Chagunda used the Fossomatic 5000TM for SCC determination 
whereas a Portacheck® device was used for this study. The SCC detection of Fossomatic 
5000TM is based on the measurement of fluorescence levels which are produced from 
the interaction between ethidium bromide and the nuclear DNA of somatic cells. The 
Portacheck® test is based on the interaction between a dye on the test strips with 
enzymes present in the somatic cells. The difference in testing principles between the 
two devices may cause differences in correlation of results. 
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Table 6.3 (A). Correlation between LDH and NAGase 
 
Table 6.3 (B). Correlation between LDH and SCC 
 * p-value refers to significance levels. The standard level for a p value, from PASW statistics 18 
software, to be significant is 0.05. If PASW gives 0.000 in the output for a p-value, it can be reported as p 
< 0.001 
 
 
 
 
 
 
 
 
 r  (correlation) p  (significance) 
Batch 2 0.64 0.001 
Batch 3 0.89 0.000 (< 0.001) 
Batch 4 0.98 0.000 (< 0.001) 
Batch 5 0.92 0.000 (< 0.001) 
Mean 0.86 ------ 
 r  (correlation) p  (significance) 
Batch 3 0.59 0.002 
Batch 4 0.86 0.000 (< 0.001) 
Batch 5 0.42 0.008 
Batch 7 0.67 0.001 
Batch 9 0.96 0.000 (< 0.001) 
Mean 0.70 ------ 
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Figure 6.4. Scatter plot of the correction between LDH activity with NAGase 
activity and SCC. Graph A shows the correlation between NAGase and LDH activity 
in four batches of milk samples (batches 2, 3, 4, and 5), graph B shows the correlation 
between SCC and LDH activity in five batches of milk samples (batches 3, 4, 5, 7 and 
9).  The red straight lines indicate the best fitting line between two sets of data. The R2  
values indicate the correlation.  
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The scatter plots show good correlation between LDH and NAGase, LDH and SCC, 
which were 0.86 (Fig. 6.4(A)) and 0.70 (Fig. 6.4(B)). There values are corresponded to 
the values obtained by PASW statistics 18 in this study, 0.86 and 0.70 (Table 6.3).  
 
6.2.5 LDH as a marker for the identification of mastitic milk samples 
A LDH ‘cut-off’ level for mastitis in cows was reported to be 107.2 U/L (Dohoe and 
Leslie, 1991). Using batch 11 as an example, LDH levels in milk samples were 
measured and the mastitis status was identified using the ‘cut-off’ level of 107.2 U/L as 
determined by Dohoe and Leslie (1991) (Table 6.4). 
 
As shown in Table 6.4, a total of 7 samples had LDH levels greater than the ‘cut-off’ 
level and, therefore, they were classified as ‘mastitis-positive’. The remaining samples 
were below the ‘cut-off’ level and, therefore, they were classified as healthy.   
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Table 6.4. LDH levels as an indicator of mastitis  
Sample No. LDH (U/L) 
Mastitis 
status* 
254 FR 29 - 
254 FL 35 - 
254 BR 42 - 
254 BL 37 - 
260 FR 80 - 
260 FL 42 - 
260 BR 46 - 
260 BL 115 + 
319 FR 78 - 
319 FL 88 - 
319 BR 8436 + 
319 BL 242 + 
350 FR 28 - 
350 FL 33 - 
350 BR 92 - 
350 BL 63 - 
380 FR 164 + 
380 FL 182 + 
380 BR 493 + 
380 BL 1475 + 
704 FL 35 - 
704 BR 22 - 
* Mastitis status is represented by ‘- ‘or ‘+’ as mastitic-negative and positive, 
respectively. 
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6.2.6 Individual quarter vs composite milk samples for the identification of mastitis 
To assess the value of using composite milk for the identification of mastitis status, 
SCC and LDH concentrations were analysed in a total of 100 milk samples including 80 
milk samples from individual udder quarters and 20 composite milk samples. The 
variation of SCC concentrations and LDH concentrations between different quarters of 
20 cows tested were shown in Figures 6.5 (A) and (B), respectively. 
 
A variation in quarter health is observed across the animals tested (Fig. 6.5). In all 20 
cows tested, increases and decreases observed in SCC concentrations corresponded to 
increases and decreases observed in LDH concentrations. Both SCC and LDH 
concentrations were above the ‘cut-off’ point for mastitis for all four quarters in 3 cows, 
3 quarters in 1 cow, 2 quarters in 2 cows, 1 quarter in 5 cows and none of the quarters 
for 9 cows. Five cows (cow 2, 7, 14, 16, 18) in which one quarter showed SCC and 
LDH concentrations above the ‘cut-off’ point for mastitis gave a composite sample with 
levels below the ‘cut-off’ for mastitis for both LDH and SCC (Fig. 6.5). This shows that 
if milk from unhealthy quarters is diluted with milk from healthy quarters the 
identification of mastitis maybe problematic or even missed entirely. 
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A.
B. 
 
Figure 6.5. Variation of SCC concentrations and LDH concentrations between 
different quarters of 20 cows. Graph shows the SCC (A) and LDH activity (B) 
concentrations of milk samples in the four different quarters (quarter 1 (Q1) shown in 
white, Q2 shown in black and white stripes, Q3 shown in grey, Q4 shown in grey 
marble) and from a composite sample containing a mixture of all of these quarters 
(shown in black) from 20 different cows.  Values shown represent the mean value ± 
standard deviation for assays measured in triplicate.  The black line represents the ‘cut-
off’ level for SCC (200,000 cells/mL) and for LDH (107.2 U/L) for the classification of 
mastitic or non-mastitic samples. 
Cow No. 
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6.2.7 Effect of lactation stages on SCC and LDH 
The SCC and concentrations of LDH and NAGase were analysed in milk samples at 
different stages of lactation. The variation of SCC concentrations and LDH 
concentrations over lactation stages are shown in Figures 6.6 (A) and (B), respectively. 
 
The levels of indicators suggested as potential markers of mastitis were found to vary 
naturally depending on the stage of lactation (Fig. 6.6). The profiles of LDH and 
NAGase over the different lactation stages are different to that of the SCC profile.  
Samples from mid-late and late lactation stages showed a decrease in LDH and NAGase 
levels (results not shown) when compared to samples from an early stage of lactation,  
whereas samples from an early stage of lactation showed a decrease in SCC when 
compared to samples from the mid-late and late stages (Fig. 6.6 (A)). There was no 
significant difference observed in the levels of LDH between samples from the mid-late 
and the late stages of lactation (Fig. 6.6 (B)). Similarly, the SCC concentrations showed 
no significant changes in samples from the mid-late lactation stage when compared to 
samples from the late lactation stage. Lactation stage, therefore, had a significant 
influence on both SCC and LDH concentrations even in healthy cows. 
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Figure 6.6. Variation of SCC concentrations and LDH concentrations over 
lactation stages. Graphs showing SCC (A) and LDH activity (B) of milk samples from 
healthy cows (SCC < 200,000 cells mL-1) at different stages of lactation. Values 
represent mean values ± standard deviation for 76 milk samples from 19 different cows. 
All assays were performed in triplicate. 
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6.2.8 Detection of LDH levels in milk samples after storage   
The aim of this element of the research was to examine the effect of different storage 
conditions on the LDH levels in milk samples. 
 
6.2.8.1 Detection of LDH levels in milk samples stored for 56 hours at 4
o
C 
LDH activities in 24 milk samples from batch 12 were detected using the previously 
described fluorescence assay (section 2.3.4.3) before, during and after storage at 4oC for 
56 hours. The first LDH assay was performed on the milk samples 8 hours after 
sampling. LDH levels at 8 hours represent the time from sampling to arrival in the 
laboratory. Milk was stored at 4oC after sampling and transported to the laboratory 
within 8 hours. These milk samples were then stored at 4oC for an additional 24 and 48 
hours and LDH levels were measured at 8, 24, and 48 hours.  Using LDH levels at the 8 
hour time point, samples were divided into healthy and mastitic sample groups using a 
LDH ‘cut-off’ level of 107.2 U/L (Dohoe and Leslie, 1991). A total of 22 samples were 
classified as healthy and one sample was classified as mastitic. Table 6.5 (A) presents 
LDH activities in the 22 healthy samples measured at 8 hours, 32 hours (8 hours plus 24 
hours storage) and 56 hours (8 hours plus 48 hours storage) after sampling. The 
percentage differences from 8 hours to 32 hours, 8 hours to 56 hours and 32 hours to 56 
hours were calculated. Table 6.5 (B) shows LDH levels in the one mastitic sample 
available for study. 
 
Results shown in Tables 6.5 (A) and (B) indicate that LDH levels increased with 
storage. LDH levels increased 125% from 8 hours to 32 hours and a further 45% from 
32 hours to 56 hours for healthy samples (Table 6.5 (A)). The increase could be caused 
by cell lysis resulting in the release of LDH during storage. Interestingly, all samples, 
except 273BR, showed an increase in LDH levels from 8 hours to 32 hours. However, 
four samples (350FL, 350BR, 704BL and 916FR) showed a decrease in LDH levels 
from 32 hours to 56 hours. This decrease may be due to proteolytic activity in the milk 
resulting in the breakdown of LDH. 
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Table 6.5 (A). Determination of LDH activities in healthy milk samples over a 
storage period of 56 hours 
Sample 
No. 
LDH (U/L) 
8 h 
LDH (U/L) 
32h 
LDH % difference 
from 8 to 56 h 
LDH (U/L)  
56 h 
LDH % difference 
from 8 to 56 h 
LDH % difference 
from 32 to 56 h 
185 FR 20 43 115% 57 185% 33% 
185 FL 48 69 44% 98 104% 42% 
185 BR 34 92 171% 127 274% 38% 
185 BL 20 55 175% 81 305% 47% 
273 FR 18 35 94% 47 161% 34% 
273 FL 16 21 31% 41 156% 95% 
273 BR 53 50 -6% 69 30% 38% 
273 BL 18 40 122% 41 128% 3% 
350 FR 17 44 159% 57 235% 30% 
350 FL 19 56 195% 44 132% -21% 
350 BR 28 79 182% 39 39% -51% 
350 BL 28 70 150% 81 189% 16% 
426 FR 26 30 15% 55 112% 83% 
426 FL 0 55 ----- 59 ----- 7% 
426 BR 32 36 13% 82 156% 128% 
426 BL 23 45 96% 64 178% 42% 
704 FR 35 66 89% 78 123% 18% 
704 FL 22 30 36% 35 59% 17% 
704 BL 41 144 251% 96 134% -33% 
916 FR 29 87 200% 83 186% -5% 
916 FL 9 42 367% 60 567% 43% 
916 BR 31 72 132% 73 135% 1% 
Mean 25 57 125% 66 170% 28% 
STDEV 12 27 90% 23 113% 40% 
 
Table 6.5 (B). Determination of LDH activities in a mastitis milk sample over a 
storage period of 56 hours 
Sample 
No. 
LDH (U/L) 
8 h 
LDH (U/L) 
32h 
LDH % difference 
from 8  to 32 h 
LDH (U/L)   
6h 
LDH % difference 
from 8 to 56 h 
LDH % difference 
from 32 to 56 h 
704 BR 741 2257 205% 2281 208% 1% 
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6.2.8.2 Detection of LDH levels in Freeze-thawed and 4
o
C-stored milk samples 
To assess the effects of storage and handling conditions on LDH activities in milk 
samples, LDH level in 24 milk samples from batch 11 were investigated. The LDH 
assay was performed when the samples arrived in the laboratory (8 hours after 
sampling).  The samples were then aliquoted into two sets. One set was stored at 4oC, 
and a second set was stored at -20oC. LDH activities at both 4 oC and -20 oC in the two 
sets were monitored after 32 hours (8 hours and additional 24 hours storage) storage 
since sampling. Healthy samples and mastitis samples were again classified using a 
LDH ‘cut-off’ level of 107.2 U/L (Dohoe and Leslie, 1991). Tables 6.6 (A) and (B) 
show the LDH levels in healthy (16) and mastitis (7) samples, respectively, at 8 hours 
and after 32 hours storage at both 4oC and -20oC. LDH percentage differences from 8 
hours to 32 hours (stored at 4oC), and from 8 hours to 32 hours (stored at -20oC) were 
calculated.     
 
Tables 6.6 (A) and (B) show that LDH activity increased after storage at both 4oC and -
20oC for 32 hours.  The LDH activity levels of both healthy and mastitic samples after 
storage at -20oC were higher than those stored at 4oC indicating that 4oC is a better 
storage temperature for LDH in milk samples.  This may be as a result of the bursting of 
epithelial cells due to freeze-thawing. Overall, the percentage of LDH increase for 
healthy samples is lower than in mastitis-infected cows.  The high standard deviation 
values in Table 6.11 (B) indicated high variations of LDH levels in mastitic samples. 
Storage of milk sample should therefore be at 4oC rather than -20oC but ideally LDH 
activity should be measured as soon as possible after sampling with minimum storage 
time.   
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Table 6.6 (A).  LDH activities in healthy milk samples stored under different 
conditions 
Sample 
No. 
LDH(U/L) @ 
time 8 h 
LDH (U/L) @ 32 h 
(stored at 4oC) 
LDH % difference 
from 8 to 32 h  
( stored at 4oC) 
LDH (U/L) @ 32 h 
(stored at -20oC) 
LDH % difference 
from 8 to 32 h  
( stored at  -20oC) 
254 FR 29 91 214% 68 133% 
254 FL 35 71 103% 88 154% 
254 BR 42 66 56% 79 87% 
254 BL 37 64 72% 79 113% 
260 FR 80 107 34% 142 78% 
260 FL 42 70 68% 84 100% 
260 BR 46 75 63% 95 105% 
319 FR 78 116 49% 128 64% 
319 FL 88 143 62% 198 124% 
350 FR 28 65 131% 61 115% 
350 FL 33 67 106% 71 120% 
350 BR 92 139 52% 155 69% 
350 BL 63 99 56% 110 74% 
704 FR 60 88 47% 84 40% 
704 FL 35 68 95% 64 83% 
704 BR 22 64 190% 73 229% 
Mean 50 87 87% 98 105% 
STDEV 22 26 51% 38 43% 
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Table 6.6 (B). LDH activities in mastitis milk samples stored under different 
conditions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample 
No. 
LDH(U/L) @ 
time 8h 
LDH (U/L) @ 32h 
(stored at 4oC) 
LDH % difference 
from 8 h to 32 h    ( 
stored at 4oC) 
LDH (U/L) @ 32 h 
(stored at -20oC) 
LDH % difference 
from 8 h to 32 h    ( 
stored at  -20oC) 
260 BL 115 177 54% 252 119% 
319 BR 8436 7961 -6% 9557 13% 
319 BL 242 550 128% 1086 350% 
380 FR 164 242 47% 296 81% 
380 FL 182 366 101% 420 131% 
380 BR 493 1465 197% 1748 255% 
380 BL 1475 5160 250% 8828 499% 
Mean 1586 2274 110% 3169 206% 
STDEV 3057 3067 89% 4153 170% 
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6.3 Discussion 
In this chapter, the determination of LDH levels in milk samples was described. In 
particular, the investigation of the correlation of LDH with other mastitis-associated 
biomarkers and the identification of healthy and mastitic samples using a previously 
reported LDH ‘cut-off’ level was discussed. In addition, studies on the effect of using 
composite milk samples for mastitis diagnosis and the effects of storage conditions on 
LDH levels are also described.  
 
Using a reliable and reproducible fluorescence-based assay, LDH levels from a total of 
295 milks samples were calculated, as detailed in section 2.3.4.3 (Table 6.2). Changes 
in SCC, LDH and NAGase were observed at different lactation stages. A rise of 
polymorphonuclear leukocytes in normal milk has been reported in late lactation 
resulting in a SCC increase in milk samples taken at this stage (Blackburn, 1966).  An 
increase in SCC concentrations at the late lactation stage when compared to the early 
lactation stage was also observed in this study.  There are conflicting reports in relation 
to NAGase concentrations at different stages of lactation. Chagunda et al. (2006) 
reported that in healthy cows, NAGase concentrations were higher in the early lactation 
stage and the concentrations decreased at the mid-lactation stage whereas, Lehtolainen 
et al. (2003) reported that NAGase concentrations were lower in the early rather than 
later stages of lactation.  In this study milk samples in the early lactation stage showed 
higher concentrations of both LDH and NAGase activity than samples from the mid-late 
and late lactation stages (Fig. 6.6). However, the SCCs were lower at early lactation 
stage when compared to late lactation stages.  It has been suggested by Erdem et al. 
(2010) that elevated SCC at the late stage of lactation can be explained by the increase 
in injured udder cells towards the end of the lactation.   
 
Current assays for the detection of mastitis in milk usually involve the determination of 
SCC, however, NAGase is also used as an indicator for mastitis ((Malmqvist et al., 
1991; Lehtolainen et al., 1998). The correlation of LDH with SCC and NAGase would 
indicate that LDH can be used as a marker for mastitis detection.  Kitchen et al. (1980) 
and Zank and Schlatterer (1998) reported a correlation between LDH and SCC of 0.53 
and 0.57, respectively (Lehtolainen et al., 1998) (Malmqvist et al., 1991). The 
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correlation of 0.70 observed in this study is higher than in these reports.  Kitchen et al. 
(1980) and Zank and Schlatterer (1998) showed a correlation between LDH and 
NAGase of 0.76 and 0.74, respectively.  This is lower to the correlation of 0.86 (Table 
6.3) observed in this study. This result is not surprising as LDH and NAGase are 
released at the same time upon the destruction of the epithelial cells in the udder during 
mastitis infection (Dohoo and Leslie, 1991). The good correlation between LDH and 
NAGase indicates that LDH may also be a suitable marker for mastitis detection. 
 
Babaei and co-workers (2007) reported that the activities of LDH and alkaline 
phosphatase (ALP) in milk significantly increase in cases of mastitis in cows (Place and 
Power, 1984). This was also recently studied by Katsolous and co-workers (2009), who 
reported that LDH was a more reliable indicator for mastitis in sheep and goats than 
ALP and aspartate aminotransferase (Pyorala, 2003). Time-series measurements of 
LDH levels in milk were made by Friggens and co-workers (Friggens et al., 2007). 
LDH analysis was found to be able to demonstrate significant differences between 
healthy and mastitic cows. The time-series measurements of LDH levels in milk could 
also identify mastitic milk samples at early stage in the disease.  
 
A LDH ‘cut-off’ level of 197 U/L for both sheep and goats was reported by Katsoulos 
et al. (2009), however, few ‘cut-off’ levels of LDH for the determination mastitic and 
non-mastitic samples for cows are reported.  The LDH ‘cut-off’ level for mastitis of 
107.2 U/L, selected for use in this report was originally determined by Dohoe and 
Leslie (Dohoe and Leslie, 1991). This ‘cut-off’ level was similar to that of 127±29.6 
U/L reported by Babaei et al. (2007).  They also reported LDH ‘cut-off’ levels for 
different grades of subclinical mastitis milk, i.e. 222.0±34.67 U/L for grade 1, 
943.5±105.3 U/L for grade 2 and 1,098.5±107.1 U/L for grade 3. The determination of 
LDH levels has, therefore, the potential to discriminate between subclinical and clinical 
mastitis as well as different levels of sub-clinical mastitis infection.   
 
Previous studies have shown that the ability of a mastitic marker to evaluate udder 
status is diminished when composite samples are used (Bansal et al., 2005; Nielsen et 
al., 2005; Forsbäck et al., 2010). This is consistent with the observations in this study 
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where in five cases both LDH and NAGase concentrations were above the ‘cut-off’ 
point for mastitis in one quarter but the composite sample was below the ‘cut-off’ (Fig. 
6.5).  
 
The kinetic properties of LDH, like most proteins, are affected by environmental 
temperature. The environmental temperature may weaken the hydrogen bonds or 
hydrophobic bonds within the protein molecule, hence altering the protein’s structure 
and subsequently affecting the activities of the protein. It was reported by Stillman and 
Somero (2001) that LDH activities from claw muscle tissue of porcelain crabs 
decreased by 50% in 10 minutes at a temperature range of 65oC to 75oC (Stillman and 
Somero, 2001). LDH activity in human plasma is stable for four to six weeks at -90oC 
(Shain et al., 1983). Few LDH stability studies in milk are reported. However, the 
activity of LDH purified from Ralstonia eutropha was stable for 3 months when stored 
at -20oC and stable for six months when stored at 4oC in 0.2-1M potassium chloride and 
3.2 M ammonium sulfate (Steinbuechel and Schlegel, 1983). Similarly, the activity of 
LDH purified from Fundulus heteroclitus is stable at 4oC for more than 8 months when 
stored in ammonium sulfate (Stillman and Somero, 2001). These reports show that 
when purified using affinity chromatography and stored in elution buffer without 
addition of protein stabilisers, LDH activity remains stable at both 4oC and -20oC which 
is contrary to what was observed in this study. In this study, however, the LDH was not 
purified and the LDH activity was measured in a complex milk matrix, where other 
factors such as cell lysis and proteolysis could affect LDH activity. Joyce and co-
workers (1992) reported cell lysis in milk samples after freeze-thaw cycles. Cell lysis 
can release more LDH from the cells resulting in increased LDH activity (Viguier et al., 
2009). Freezing of the samples may be used as a storage method for milk but when the 
milk is thawed cell lysis can occur and, for this reason, freezing is not considered a 
good storage method. Proteolytic activity also naturally exists in raw milk which results 
in milk protein degradation and, thus, could also reduce LDH activity levels in milk. 
Larsen and co-workers (2004) showed that proteases digest protein in milk from cows 
infected with Streptococcus uberis. It was also reported by Larsen et al. (2004) that the 
level of degradation of milk proteins increased in milk with a high somatic cell count 
(Zank and Schlatterer, 1998). LDH activities in both healthy and mastitic samples were 
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significantly affected by storage at 4oC following sampling. This observation has 
indicated that the measurement of LDH levels in milk samples should be performed 
immediately after sampling to avoid cell lysis and proteolysis. 
 
The correlation between LDH and NAGase suggests LDH may be used as an indicator 
to detect bovine mastitis (Fig. 6.4). However, for efficient and effective use of LDH as a 
mastitis biomarker, LDH determinations should only be made on samples properly 
stored with due consideration given to lactation stage. Various samplings/storage 
conditions were shown to effect LDH levels and hence they must be considered when 
using LDH as an effective sub-clinical mastitis biomarker. 
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            Chapter 7  
Overall conclusions 
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7.1 Overall conclusions 
Cardiovascular diseases (CVDs) are the number one cause of death globally. The World 
Health Organization estimated approximately 23.6 million people will die from CVDs 
by 2030. The impact of the use of classic CVD biomarkers such as creatine kinase (CK) 
and lactate dehydrogenase (LDH) has been limited due to lack of tissue specificity and 
sensitivity. Troponin, due to the presence of tissue-specific isoforms in cardiac muscle, 
was recommended as a biomarker for the diagnosis of the acute myocardial infarction 
(AMI) by the European Society of Cardiology and the American College of Cardiology 
in 2000. Troponin I, T and C make up a 3-unit troponin complex located on the actin 
filaments, which control muscle contraction by regulating calcium binding. Troponin T 
has two isoforms that are specific for cardiac and skeletal muscle, respectively (O’Brien, 
2008). The cardiac isoform has a longer N-terminal and is 20% more helical than its 
skeletal isoform. Since cTnT has a distinctive structure compare to sTnT, it was selected 
as a ‘gold-standard’ biomarker for diagnosis of cardiovascular disease.  
 
Bioanalytical tools that use antibodies in various immunoassay formats have a major 
impact on disease diagnosis. The current commercially available troponin T 
immunoassay involves using Fab fragments from two monoclonal antibodies. However, 
this cTnT assay was reported to have failed to meet recommended AMI analysis 
standards. Hence, one objective of this work was to produce anti-cTnT recombinant 
antibodies fragments (scFv and Fab) for the generation of an improved cTnT 
immunoassay. 
 
The work in chapter three described the construction of avian anti-cTnT scFv antibodies. 
Using chicken as the host for immunisation can bring a number of advantages, as 
described in Chapter 3.1. One important advantage is that chickens are phylogenetically 
more distant to humans than other animal species, commonly used for immunisations. 
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Thus, the avian system can produce better immune responses to mammalian proteins. 
The chicken serum had a titre in excess of 1 in 10,000 after the 4th immunisation, which 
indicated a sufficient serum polyclonal response against cTnT.   
 
A simple ‘on-plate’ screening method was used to select cTnT-specific scFv antibodies. 
It was shown that this method could analyse the specificity of the clones in 
antigen-coated ELISA plate wells, yielding high binding signals and also saving 
valuable selection time. In addition, this method eliminated the requirement for an 
antibody extraction process (Guo et al., 2010). Further inhibition studies were 
performed using crude bacterial lysates extracted from a number of positive scFv 
clones. The F1 clone had the lowest IC50 value of 214 ng/mL. However, since 
non-specific proteins in crude bacterial lysates may interfere with performance studies, 
the F1 antibody was subsequently purified using immobilised metal affinity 
chromatography (IMAC). 
 
An SPR kinetic study was performed to monitor the ‘real-time’ interaction between F1 
antibodies and cTnT protein, thus determining its affinity for cTnT. Using an amine 
coupling approach, sufficient anti-HA antibodies (7,120 RU) was immobilised on the 
CM5 sensorchip surface. Kinetic analysis indicated that the F1 antibody had an affinity 
(KD) of 2.40 nM. However, the experimental kinetic curves from F1 poorly overlaid the 
binding model curves, thus questioning the reliability of the kinetic results. An inhibition 
assay was subsequently developed to obtain reliable data for the determination of the 
antigen binding capacity of F1 antibody. It was revealed that the IMAC-purified F1 had 
an IC50 value of 85 ng/mL. 
 
In chapter 4, the use of chain-shuffling to improve the antigen-binding capacity of 
anti-cTnT scFv antibodies was described. Both the heavy and light chain-shuffled 
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libraries were constructed and cTnT-specific clones were identified using biopanning 
and the ‘on-plate’ screening method. Interestingly, the chain-shuffled libraries had an 
increased number of positive cTnT-binding clones, being 66.7% for heavy 
chain-shuffled clones and 75% for the light chain-shuffled clones, in comparison to the 
wild-type clones (56.3%). This demonstrated that chain shuffling could enhance the 
generation of antibodies. 
 
SPR-based BiacoreTM 4000 ranking of a total of 384 heavy and light chain-shuffled 
antibodies showed the clones had a wide stability range (7.2% to 76%).  In further 
kinetic studies, four scFv antibodies (8C2, 7D6, 7D8 and 7H8) was found to have 
subnanomolar affinities. Importantly, cross reactivity studies demonstrated all four 
clones showed high specificity to cTnT with no significant cross reactivity to other 
troponin isoforms (sTnT, cTnI and sTnI). Furthermore, no significant variations were 
observed in the affinities of the four scFv clones over three different temperatures (20, 
25 and 30oC). Hence, temperature changes did not appear to affect the antigen-binding 
capacities of these anti-cTnT scFvs, indicating good stability.  
 
Although all four clones (8C2, 7D6, 7D8 and 7H8) showed subnanomolar affinities, the 
8C2 clone showed closer fitting with the theoretical binding curves (1:1 Langmuir 
binding model) than the other three clones on BiacoreTM kinetic analysis. The 8C2 clone 
was subsequently purified using immobilised metal affinity chromatography (IMAC). 
An ELISA inhibition assay demonstrated that the 8C2 scFv had an IC50 concentration of 
38 ng/mL, which showed an improvement of approximately 2.2 fold compared to the 
wild-type F1 (85 ng/mL). In addition, the mutant scFv, 8C2 had a KD value of 0.39 nM, 
which indicated an improvement of approximately 6 fold compared to the wild-type F1 
(2.40 nM). These results indicated that chain shuffling was successfully applied to 
produce an affinity enhanced anti-cTnT scFv.   
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Chapter 5 described the production of avian anti-cTnT Fab antibodies. Fab fragments 
potentially have a number of distinctive advantages over scFv antibodies. An avian 
anti-cTnT Fab library was constructed and cTnT-specific Fab clones were selected 
using both biopanning and the ‘on-plate’ screening method. The number of positive Fab 
clones (25%) was significantly lower than the number of scFvs (56.3%) generated. The 
more complex expression process for Fab antibody fragments in E.coli cells, compared 
to scFvs, may lead to a lower displaying efficiency for display. 
 
ELISA analysis of eight positive anti-cTnT Fab clones showed that the clones had low 
antibody expression levels. A number of parameters, including growth media, IPTG 
induction concentration and period of induction, were optimised in order to improve the 
expression levels. Using TB as the cell cultivation medium, Fab antibody A1 showed 
maximum expression level after 2 hours induction with 0.05 mM IPTG. Clone C5 had 
maximum expression after 6 hours induction with 0.5 mM IPTG. With clone D3, the 
highest expression occurred after a period of 6 hours induction with 0.5 mM IPTG. 
Future work on the anti-cTnT Fab antibodies involved the charactersiation of the 
successfully expressed Fab antibodies using SPR-based kinetic studies and, ELISA 
inhibition analysis. Ultimately the Fab antibodies will be paired with the scFv 8C2 
antibody for the development of a sensitive cTnT immunoassay.  
 
The work in chapter 6 involved an investigation of the use of LDH as an indicator for 
mastitis. To investigate the effectiveness of LDH as a biomarker for sub-clinical 
mastitis detection, the correlations between the concentrations of LDH, NAGase and 
SCC in milk samples were examined. The effect of lactation stage, storage conditions 
and choice of milk samples on LDH levels were also examined.   
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LDH activities were measured in 295 milk samples collected from each udder quarter of 
80 cows using a standardised fluorescence assay. Milk samples were subsequently 
indentified as either healthy or mastitic using a LDH ‘cut-off’ level of 107.2 U/L 
(Dohoe and Leslie, 1991). Studies also demonstrated that the correlation between LDH 
and NAGase levels was better (0.86) than between LDH and somatic cell count (SCC; 
0.7). 
  
Lactation stages were found to affect SCC, LDH and NAGase levels. Milk samples in 
the early lactation stage showed higher concentrations of both LDH and NAGase than 
samples from the mid-late and late lactation stages. In contrast, the SCC levels were 
lower at early lactation stages when compared to late lactation stages. Studies of 100 
milk samples from 20 cows showed that the SCC and LDH levels in a number of milk 
samples from individual udder quarters were above the ‘cut-off’ level for mastitis. 
However, their concentrations in the composite sample were below the ‘cut-off’ level. 
Therefore, the use of composite milk samples for the identification of mastitis could be 
problematic.  
 
LDH activities in both healthy and mastitic samples were significantly affected by 
different storage conditions. The LDH activity levels of both healthy and mastitic 
samples after storage at -20oC were higher than those stored at 4oC, indicating that 4oC 
is a better storage temperature for LDH in milk samples. Therefore, the lactation stage 
of cows and milk storage conditions must be considered when choosing to use LDH as a 
marker to ensure efficient diagnosis of mastitis.  
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Short Abstract:  
A new ‘on-plate’ technique for the screening of recombinant antibodies is described and a 
comparative analysis with common antibody extraction processes is made. Using this approach, 
antibody-expressing clones can be analysed rapidly in antigen-coated ELISA plate wells yielding 
high binding signals and also saving valuable selection time. 
 
Long Abstract:  
Phage display technology is routinely used for selecting antibodies to antigens of interest for 
both therapeutic and diagnostic purposes. The selection of antibodies against the desired antigen 
is achieved by iterative cycles of biopanning. The conventional ELISA-based antibody screening 
method is wildly used for the selection and ranking antigen-specific clones post biopanning. In 
addition, automated robotic systems facilitate the selection and ranking process from a large 
number of putative antigen-specific antibodies [1]. The antibody screening process involves the 
inoculation of colonies from clone output titre plates from the final rounds of biopanning process 
into microtitre plates allowing antibody expression [2]. In conventional ELISA-based antibody 
screening methods, an antibody extraction step by cell lysis is involved. Typically, repeated 
freeze-thaw cycles at -70oC/37oC [3, 4], periplasmic extraction with Tris-EDTA Sucrose buffer 
[5] or sonication [6] are utilized to extract antibody-containing cell lysate. Post extraction step, 
cell lysates are incubated in antigen-coated microtitre wells and antibody-antigen binding signals 
are measured with a labeled secondary antibody. Antibody binding data can be obtained within 
 3 
36 hours after colony inoculation. Based on the conventional ELISA screening approach, herein 
we describe a simple ‘on-plate’ screening method for antibody analysis. In comparison with 
common ELISA-based analysis, this simple ‘on-plate’ method eliminates bacterial cell removal 
step, therefore, requires less screening time. It also generates high binding signals and facilitates 
automation [7]. During the ‘on-plate’ screening process, interaction time between antibody and 
antigen is significantly increased due to the overnight growth of antibody-expressing clones on 
antigen-coated ELISA plates, allowing binding reaction reach equilibrium (Fig. 1). Low 
expression clones can also be detected due to the long interaction time. The analysis on both 
scFv and Fab antibody fragments revealed that the simple ‘on-plate’ technique produces higher 
binding signals than other screening methods that require an antibody exaction step.  
    
Protocol Text:  
1 ‘on-plate’ antibody screening process 
This experiment is designed to aid the screening of antibodies and antibody fragments after 
phage-based selection. Phage infected E. coli cells are cultured on agar plates and colonies 
harbouring antibody genes of interest selected for ‘on-plate’ ELISA analysis [8]. 
 
1.1) Rescue output phage from selected rounds of biopanning and infect the phage into E. coli 
cells by mixing phage particles with exponentially growing E. coli cells. Dilute the infected 
culture in sterile media and spread on Luria broth agar plates (10 g/L Tryptone, 5 g/L yeast 
extract, 10 g/L NaCl) supplemented with antibiotics of choice (see Note 1 below). Incubate the 
plates at 37oC for 18 to 24 hours. 
 Note 1: The antibiotics needed depend on the phagemid and E. coli strain used in the 
experiment. 
 
1.2) Pick a total of ninety-six single clones from selected output agar plates with sterile 
micropipette tips or inoculation loop. Inoculate into microtitre plate wells containing 200 µL of 
SB broth (10 g/L MOPS, 30 g/L Tryptone and 20 g/L yeast extract) supplemented with 
antibiotics (see Note 1 above). Grow shaking at 37oC for 6-8 hours at 200 rpm. 
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1.3) Coat a Nunc maxisorb plate (ELISA plate) with 100 µL /well of a 1-5 µg/mL antigen 
solution in phosphate buffered saline, pH 7.4 (PBS containing 0.15 M NaCl, 10 mM Na2HPO4, 
18 mM KH2PO4, 2.5 mM KCl) for 1 hour at 37
oC. Remove the antigen solution by inversion and 
block with 200 µL /well of 3% (w/v) BSA in PBS for 1 hour at 37oC. 
 
1.4) Remove 20 µL of culture from step 1.1 and transfer to a sterile tube/microtitre plate well. 
This is a master stock and can be used to re-culture the clone at a later stage. Add 20 µL of 10 
mM IPTG to the remaining 180 µL of culture (the final concentration of IPTG should be 1mM). 
Remove the blocking solution from the ELISA plate by inversion (as in step 1.3) and 
immediately transfer the induced culture to the ELISA plate using a multichannel micropipette 
and sterile tips. 
Note 2: IPTG is used for expression of genes cloned under the control of a lac promoter system 
and should be used at a concentration of 0.5 to 1 mM [9]. 
 
1.5) Incubate the culture-induced ELISA plate overnight (12-18 hours) at 30oC with agitation at 
220 rpm. 
 
1.6) Remove the cells and culture media after overnight ‘on-plate’ expression by inversion and 
wash four times with 200µL /well PBST pH 7.4 (0.05% (v/v) Tween 20, 0.15 M NaCl, 10 mM 
Na2HPO4, 18 mM KH2PO4 and 2.5 mM KCl). 
Note 3: At this step cells could be removed and stored as a back-up culture before washing if 
required.  
 
1.7) Add 100 µL/well of a 25 ng/mL enzyme-labelled secondary antibody diluted in PBST pH 
7.4  containing 0.5% (w/v) BSA to each well and incubate stationary for 1 hour at 37oC. 
Note 4: The specificity of the secondary antibody used will depend on the affinity tag 
incorporated into the plasmid or antibody gene. Horse radish peroxidase (HRP) and alkaline 
phosphatase (AP)-labeled antibodies are commonly used as secondary antibodies for detection of 
bound antibody. 
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1.8) Wash the wells five times with 200 µL/well PBST, pH 7.4, and add 100 µL/well of enzyme 
substrate (see Note 5 below) to each well for detection of bound antibody. Incubate for 30 
minutes at 37 oC and stop the reaction with the addition of  50 µL/well of 1M HCl.   
Note 5: Tetramethylbenzidine (TMB) and p-nitrophenyl phosphate, disodium salt (PNPP) 
substrates are commonly used for HRP and AP-labeled antibodies, respectively.  
 
1.9) Read the absorbance of the solutions in the wells of the ELISA plate using a microtitre plate 
reader and record the results. Identify well positions with signals 3 or more times background 
(the stringency of selection ‘cutoff’ will depend on one’s individual requirements).  Inoculate 5 
L of the master clone stock (step 1.4), corresponding to each positive well, into a fresh 
microtitre plate or tube and grow as required for further testing or cell banking.  
 
2 Optional: Protocol for the comparison with ‘off-plate’ analysis 
The same antibody cultures used for ‘on-plate’ analysis, described above, can also be cultured 
‘off-plate’ in tubes overnight for a direct comparison between the methods, if required. 
2.1) Inoculate 5 µL of antibody-containing cultures (the number of clones will depend on the 
number of positive clones from 1.9 above) from the stock plate into a 20 mL tube containing 2 
mL of SB broth supplemented with antibiotics. Grow overnight at 37oC with agitation at 200 
rpm.   
2.2) Transfer 200 µL of  the overnight culture into a 250 mL flask containing 40 mL of SB broth 
supplemented with antibiotics and grow shaking at 200 rpm until an O.D.600 of 0.8 is reached. At 
this point add IPTG to a final concentration of 1 mM and grow at 30oC shaking overnight at 200 
rpm. 
2.3) Aliquot 10 mL of the overnight cultures into separate tubes prior to the extraction of 
antibody by either Tris-EDTA sucrose (TES) buffer  addition, sonication or freeze-thaw cycles. 
2.4) For TES samples, centrifuge the 10 mL of overnight culture at 3,300 g for 10 minutes and 
resuspend the pellet in 2 mL of TES buffer (0.2 M Tris-HCl, pH 8.0, 0.5 mM EDTA, 0.5 M 
sucrose) for 30 minutes. Centrifuge the solution at 6,000 g for 5 minutes to remove the cell 
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debris. Add 200 µL of the supernatant to the desired number of wells of the antigen-coated 
ELISA plate (as described in step 1.3 above). 
2.5) For extraction by sonication, centrifuge the 10 mL overnight culture at 3,300 g for 10 
minutes and resuspend the pellet in 2 mL PBST. Sonicate for 50 seconds (40 amps for three 10 
second pulses with a 10 second interval between pulses) and centrifuge at 6,000 g for 5 minutes 
to remove cell debris. Finally, add 200 µL of supernatant to wells of the antigen-coated ELISA 
plate. 
2.6) For the freeze-thaw samples, freeze 2 mL of culture at -70oC and thaw at 37oC. Repeat this 
process three times. Remove cell debris by centrifugation at 6,000 g and add 200 µL of 
supernatant to wells of the antigen-coated ELISA plate. 
2.7) Incubate all samples at 37oC for 1 hour and detect, as described in steps 1.6 -1.9 above, for 
the ‘on-plate’ analysis.   
 
Results: 
The simple ‘on-plate’ screening method was applied to scFv and Fab clones selected by phage 
display against cardiac troponin T (cTnT). The ‘on-plate’ approach was performed on forty-eight 
anti-cTnT scFv clones from selected rounds of biopanning.  It was shown that a wide range of 
binding signals (signals > 3.0 to < 0. 1) were detected (Fig. 2). As expected, binding signals and  
number of positive clones increased from rounds four to five of biopanning This was due to the 
increased stringency during biopanning process and subsequent enrichment of target specific 
clones. Although cell growth was observed in every well, no binding signals were detected in a 
number of wells, which indicates that no non-specific binding phenomena were caused by 
overnight cell growth on ELISA plate. High binding signals were generated (signal > 3.0) due to 
long interaction time between antibodies and antigen.  In addition, low binding signals (signal < 
0.4) were also detected, which were not detected using freeze-thaw methods (data not shown). 
During the screening process, antibodies were produced by bacterial cells and released from the 
periplasm of aging and dying cells by natural leakage into culture media [10]. The natural 
leakage eliminated the requirement for cloning specific antibody secretion signal sequences and, 
therefore, the ‘on-plate’ method could be used for any cell and plasmid combination.    
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Comparison of the ‘on-plate’ screening method described here with commonly used ELISA-
based screening approaches requiring an antibody extraction step showed that the ‘on-plate’ 
method yielded the highest responses. This indicated that the increased antibody/antigen 
incubation time of the ‘on-plate’ method allowed the interaction to reach equilibrium which was 
not the case for the 1 hour incubation with the same clones (Fig. 3). For the smaller and more 
easily expressed scFv clones, high binding signals were observed irrespective of the method 
used. Lower signals were observed with the Fab clones. The TES and freeze-thaw methods 
generated the lowest signals for both Fab antibody fragments and the ‘off-plate’ method for one 
of the Fab antibody fragments. 
 
Discussion:  
The screening of two scFv and two Fab antibodies using the ‘on-plate’ approach reveals a 
number of advantages in comparison with conventional ELISA-based methods (that require cell 
lysis). Firstly, the ‘on-plate’ approach yielded higher signals due to longer interaction time 
antibody and antigen (Fig. 3). Secondly, this ‘on-plate’ approach reduced experimental time with 
less manipulative steps due to the elimination of cell lysis process. In addition, the preparation of 
backup stocks is also simplified by plating the overnight expressed culture on appropriate agar 
plates. Finally, by eliminating the need for centrifugation and the need for pipetting highly 
viscous cell extract solutions (which can interfere with accuracy of automated robotic pipetting), 
the ‘on-plate’ approach can improve the efficiency of automated robotic antibody screening 
systems.  
 
Even though incubating cells with antigen could possibly lead to antigen degradation, the 
consistent high binding signals obtained indicates that the purified cardiac troponin T remains 
stable (no signs of degradation) throughout the screening process. Similarly, we have observed 
no loss of antibody binding signals when screening antibody fragments against a number of 
analytes such as hapten-protein conjugates, peptides and biomarkers of cancer.  
 
This protocol describes the analysis of cardiac troponin T antibodies using a simple ‘on-plate’ 
screening method. As an alternative to conventional ELISA-based screening, the ‘on-plate’ 
screening approach saves valuable experimental time and cost during sample analysis; in 
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addition, this approach may be incorporated in to automated robotic system, therefore, 
facilitating high throughput analysis with reduced overall complexity. 
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Tables and Figures:   
Figure 1: Schematic of the ‘on-plate’ screening method with diagrammatic insert showing 
secreted scFv antibodies binding to immobilised analyte during overnight cell culture. Colonies 
from the output panning plates are inoculated into 96 well culture plates containing sterile media 
and grown for 3-4 hours at 37oC. Meanwhile, a microtitre plate is coated with the analyte of 
interest and blocked with an appropriate blocking solution. After addition of the induction agent 
the cultures are transferred to the analyte-coated plate and grown overnight with shaking. The 
following day the cells are simply removed by centrifuging (kept if required) and bound antibody 
fragments detected with an enzyme-labelled tag-specific secondary antibody. 
 
Figure 2: Representative monoclonal ELISA plate result after 4 and 5 rounds of biopanning of 
an anti-cTnT scFv library using the ‘on-plate’ method. Even though cell growth (as characterised 
by turbid culture media) was observed in each well of the ELISA plate, the antibody binding 
signals ranged from less than 0.1 to greater than 3.0 absorbance units indicating that the growth 
of cells in the ELISA plates caused no increase in non-specific binding.  
 
Figure 3: Comparison of ‘on-plate’ expression with commonly used antibody extraction 
methods performed prior to monoclonal ELISA. Two scFv (left panel) and two Fab (right panel) 
fragments specific to cTnT were prepared using different methodologies and analysed by ELISA 
(values are the average of 4 replicates for each antibody).  The ‘on-plate’ data are derived from 
growing cultures in antigen-coated microtitre plate wells. The ‘off-plate’ data are derived from 
growing the cells in tubes overnight and adding the cultures to the ELISA plate wells for 1 hour 
without any cell removal. The TES data are derived from the supernatant of cell lysis in Tris-
EDTA sucrose (TES) buffer for 30 minutes prior to addition to the ELISA plate wells for 1 hour. 
The sonication data are derived from the supernatant of sonicated cell pellets incubated for 1 
 12 
hour on the ELISA plate and the freeze-thaw data are derived from incubating media 
supernatants on the ELISA plate for 1 hour after three freeze-thaw cycles. The ‘on-plate’ 
negative control data are derived from growing cultures in blocked microtitre plate wells lacking 
antigen so that the difference in signal from the ‘on-plate’ data is due to specific antigen binding. 
 
 
